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Abstract 
Crohn’s Disease (CD) is an incurable form of inflammatory bowel disease (IBD) of 
complex etiology that is associated with gut dysbiosis that frequently includes 
colonisation by adherent-invasive E. coli (AIEC). AIEC are adept at forming 
biofilms and are able to invade host cells and stimulate the production of pro-
inflammatory cytokines. A number of antibiotics have been tested in the treatment 
of CD but at best show limited efficacy. Additionally, broad spectrum antibiotics are 
themselves strong drivers of dysbiosis and a number of studies have linked the 
administration of antibiotics with an increased risk of the development of CD. An 
alternative approach to the eradication of pathogenic bacteria in a complex 
community is to use species-specific antibiotics such as the colicin-like 
bacteriocins. Alongside their narrow spectrum killing, colicins also demonstrate 
extreme potency, are active against bacterial biofilms and can be readily isolated 
from clinical isolates. The aim of this work was to investigate the efficacy of these 
E. coli targeted antibiotics against AIEC. To achieve this, colicin activity against 
ileal CD-mucosa associated AIEC strain LF82, was tested in vitro and also in vivo 
using a murine model of persistent AIEC colonisation. Colicins showed good 
efficacy against LF82 associated with intestinal epithelial cells and growing 
intracellularly within macrophages. In addition, colicins do not show toxicity 
towards a macrophage cell line or stimulate the production of pro-inflammatory 
cytokines. To test the efficacy of colicins in an in vivo model of AIEC colonisation, 
methods were developed to formulate purified protein for delivery to the GI tract. 
However, this formulation showed only minimal efficacy in a mouse model of AIEC 
colonisation. In addition to investigating the efficacy of colicins, this thesis also 
attempts to further elucidate the role of the target pathogen, AIEC in the 
development of intestinal inflammation. Interestingly, we show here that AIEC 
associated phenotypes can be detected in commensal E. coli strains, undermining 
the current definition and classification of the AIEC pathotype.  
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1 Introduction 
“We are fast approaching a post-antibiotic era.”                            
(World Health Organisation, 2014) 
 
1.1 The emerging problem of antibiotic resistance 
The beginning of the antibiotic era was marked by the discovery of penicillin by 
Alexander Fleming in 1928. This was followed by the discovery of streptomycin in 
1943 and the ‘golden era’ of antibiotic discovery (1950-1960) during which 
approximately one half of the antibiotics commonly used today were produced 
(Aminov 2010).  This ‘golden era’ however, lasted less than half a century and we 
have now returned to an era where novel antibiotics are urgently required and 
bacterial infections are once again recognised as a major threat (Figure 1.1). 
One reason for this is that antibiotics are losing their effectiveness at an alarming 
rate. This is mainly due to the emergence of resistant bacteria as a result of the 
misuse and overuse of antibiotic therapies in human health and agriculture (Figure 
1.1). The WHO have expressed great concern on the problem of antibiotic 
resistance and last year published a detailed report on its incidence and 
significance worldwide (World Health Organisation 2014). This report showed that: 
1) antibiotic resistance is a global problem and is detected in every surveyed 
country and 2) there are high rates of resistance for many bacteria that cause 
important health care associated and community acquired infections (World Health 
Organisation 2014). Furthermore, a subsequent report on the global response to 
antimicrobial resistance showed that very few countries (34 /133 participating in 
the survey) have a comprehensive national plan to fight resistance to antibiotics 
(World Health Organisation 2015). Additionally, public awareness of the issue is 
low in all regions, with many people still believing that antibiotics are effective 
against viral infections (World Health Organisation 2015). 
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Figure 1-1: Antibiotic resistance is a major health concern. 
Figure shows timeline of antibiotic discovery and the development of antibiotic resistance (1930-
2000s). Timeline on top shows discovery and timeline on bottom shows emergence of resistance. 
ESBL; Extended-spectrum beta-lactamases, VRE; Vancomycin-resistant Enterococci, VISA; 
Vancomycin-intermediate Staphylococcus aureus, VRSA; Vancomycin-resistant Staphylococcus 
aureus. Image adapted from Lumibyte (LumiByte 2015).  
Bacteria employ a wide range of strategies to resist antibiotics and we now face 
sophisticated, highly resistant and often multi-resistant pathogens including 
Pseudomonas aeruginosa, Escherichia coli (E. coli) and Klebsiella pneumonia.  
The almost absent production of new classes of antibiotics also contributes 
significantly to this problem. Due to the high costs and risk associated with 
antibiotic discovery and development, only one new class of antibiotics, the 
oxazolidinones (2000), has progressed to therapeutic use since the 1960s (Chien 
et al. 2000). The lipopeptides represent an old class of antibiotics, discovered over 
50 years ago that include the polymyxins (Figure 1.1) (Pirri et al. 2009). In 
addition, the number of Food and Drug Administration (FDA) approved antibiotics 
has reduced in recent years, with only 3 antibiotics being approved between 2008 
and 2012 (Figure 1.2). However, recent work has identified a novel antibiotic that 
kills by inhibiting cell wall synthesis, via binding to lipid II and III, suggesting that 
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new and effective classes of antibiotics can still be isolated from currently 
unculturable bacteria (Ling et al. 2015). 
 
Figure 1-2: The number of new antibiotic agents approved for clinical use by FDA (1983-
2012). 
Data shown in figure is adapted from (Shlaes et al. 2013). 
1.1.1 The requirement for potent and narrow spectrum antibiotics 
Alongside the emerging problem of resistance, additional and unrelated factors 
also contribute significantly to the requirement for novel antimicrobials. For 
example, some bacteria cause chronic biofilm mediated infections that are highly 
resistant to antibiotic treatment (Costerton 1999). Key examples of this include 
chronic, biofilm-mediated Pseudomonas aeruginosa infection in the lungs of cystic 
fibrosis patients and recurrent UTI infections mediated by biofilm growth of 
uropathogenic E. coli (UPEC) on the urinary bladder wall (Tapiainen et al. 2014). 
Many of the antibiotics currently used in clinical practice show poor efficacy 
against bacterial biofilms and the mechanisms of increased tolerance to antibiotics 
displayed in the biofilm state are poorly understood (Høiby et al. 2010, Li Zhang et 
al. 2013).  
Increased knowledge on the significance of the gut microbiota in health also 
highlights potential concerns in the use of broad spectrum antimicrobials. Several 
independent studies have reported prolonged antibiotic induced changes in the 
composition of gut bacterial populations (Jakobsson et al. 2010, Jernberg et al. 
2007, Löfmark et al. 2006). Furthermore, antibiotic exposure in early childhood is 
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now being linked to an increased risk of developing chronic immune related 
disorders including asthma, inflammatory bowel disease (IBD), autism and obesity. 
This is thought to be mediated by dysfunctional immune responses induced by 
altered microbiota populations (Bailey et al. 2014, Mueller et al. 2015, Murk et al. 
2011, Shannon L Russell et al. 2012, Ungaro et al. 2014). It has been suggested 
that increased use of antibiotics may be a contributing factor to the large increase 
in the incidence of immune related disorders that has occurred since the 1950s   
(Figure 1.3).  
 
Figure 1-3: Increase in incidence of autoimmune diseases from 1950—2000. 
Figure shows increase in prevalence of chronic immune disorders between 1950 and 2000 that 
coincides with introduction of antibiotics and increased clinical use of antibiotics. Reproduced with 
permission from (Bach 2002). Copyright Massachusetts Medical Society. 
 
Alternatives to traditional antibiotics include bacteriophage, phage lysins, 
probiotics and antimicrobial peptides (Parisien et al. 2008). The ideal properties of 
novel antibiotics include good efficacy and potency against persistent and biofilm 
mediated infections. Additionally, in order to overcome the problem of resistance, 
novel therapeutics would employ distinct and diverse killing mechanisms so that 
‘combinational therapy or ‘antibiotic cocktails’ could be utilised. Finally, 
preservation of the gut microbiota composition should be recognised as a crucial 
component for the development of novel antimicrobials. The significance of this 
‘microbial organ’ in human health will now be discussed.  
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1.2 The gut microbiota in health and disease 
“No man is an island, entire of itself’’ — John Donne (1572–1631) 
 
1.2.1 Stability of the gut microbiota 
The human gastrointestinal tract is a multi-functional system that exhibits structural 
sectioning to facilitate its diverse functions. Sectioning of the gastrointestinal (GI) 
tract allows the digestive functions (proximal) to be separate from the vast 
microbial populations that inhabit and thrive within the intestinal regions (distal) 
(Underwood 2014).m The gut microbial community termed the microbiota includes 
a diverse range of microbial species (Figure 1.4). The microbiota is comprised of 
bacteria, viruses, fungi and archaea with 99% of total microbial gene number 
being bacterial (Avila et al. 2009, Qin et al. 2010). Although bacteria are 
recognised as the most abundant members of the gut microbiome, in some 
individuals bacteriophage particles are present in potentially greater numbers than 
bacterial cells (Reyes et al. 2012). The size of the bacterial population of the GI 
tract, that is currently estimated at 100 trillion, greatly exceeds the size of any 
other microbial community found in the human body (Qin et al. 2010). This 
microbial community possesses many genes that provide us with an array of 
additional metabolic and genetic functions (Fredrik Karlsson et al. 2013). Studies 
on germ-free (GF) animals have demonstrated the intestinal bacterial population 
as a multi-functional community; providing the host with nutritive, metabolic, 
protective and immunogenic functions (Falk et al. 1998, Macpherson and Uhr 
2004). These include improved digestion of complex dietary polysaccharides 
(Martens et al. 2008) and through competitive colonisation of the intestinal lumen, 
protection of the host from invasion by pathogens (Sekirov et al. 2010). This 
protective role is further facilitated by direct interactions of the microbiota with 
components of the host immune system.   
Analysis of 16S rRNA sequences has shown that over 1000 bacterial species are 
capable of inhabiting the human gut (Human Microbiome Project Consortium 
2012) with at least 160 species in each individual (Qin et al. 2010). Bacterial gene 
numbers present in the gut are proposed to outnumber the count of host genes by 
approximately 150-fold (Qin et al. 2010). 
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Mammals become colonised by microbes during and after birth, and in humans 
colonisation is from mother to infant (Palmer et al. 2007). The delivery mode used 
for birth has been shown to shape the initial intestinal microbiota composition in 
new-borns. 16S rRNA pyrosequencing demonstrated that vaginally delivered 
babies acquired bacterial communities resembling their mother’s vaginal 
microbiota, dominated by Lactobacillus, Prevotella, or Sneathia spp (Dominguez-
Bello et al. 2010). However, infants delivered by C-section possessed bacterial gut 
communities resembling the mother’s skin microbiota that included 
Staphylococcus, Corynebacterium, and Propionibacterium spp (Dominguez-Bello 
et al. 2010). By the age of 2-5 years, the gut microbiota profile of infants will 
resemble that of a healthy adults in both composition and diversity (Koenig et al. 
2011, Palmer et al. 2007). Although there is a considerable level of variation 
between individuals, the adult gut microbiota is dominated by 4 major bacterial 
phyla. These are the Firmicutes and Bacteroidetes, which constitute approximately 
90% of the microbiota population, and Proteobacteria and Actinobacteria.    
(Dominguez-Bello et al. 2010). Additionally, it was proposed that the human gut 
can be classified into one of three distinct gut types, termed enterotypes. The 
three enterotypes are characterised by the enrichment of a single microbial genus: 
Bacteroides (enterotype 1), Prevotella (enterotype 2), or Ruminococcus 
(enterotype 3) (Arumugam et al. 2011). The existence of distinct enterotypes is still 
highly controversial with recent work suggesting that enterotypes exist as 
gradients involving additional species including Methanobrevibacter.  
 
1.2.2 Individual variations in the gut microbiota 
Individual variations in the gut microbiome are driven by a range of complex 
processes. Diet is one of the most important factors shaping microbial diversity in 
the gut. As different members of the gut microbiota have unique preferences for 
dietary substrates, there is a high level of competition for resources. Therefore, 
alterations in diet can result in significant changes in microbiota composition and 
metabolic functions. It was demonstrated that individuals on long-term diets 
enriched in protein and animal fat possessed a gut enterotype dominated by 
Bacteroides and carbohydrate enriched diets were associated with a Prevotella 
dominated enterotype (Wu et al. 2011). Similar trends were reported in European 
and African children, who have diets rich in protein/animal fat and carbohydrates 
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respectively (De Filippo et al. 2010). Children from rural Africa showed a gut 
microbiota population dominated by Bacteroidetes and EU children showed an 
increased abundance of Firmicutes, that were present in low numbers in African 
children (De Filippo et al. 2010). Higher microbial richness and diversity was also 
detected in rural African faecal samples.  
Obesity is also associated with distinctions in microbiome composition. 16S rRNA 
sequencing of faecal microbial communities of monozygotic and dizygotic obese / 
lean twin pairs showed obesity to be associated with reduced bacterial diversity 
and reduced representation of the Bacteroidetes (Turnbaugh et al. 2009).  
Additionally, recent work has also highlighted an association between exercise 
and variations in gut microbiota composition. Clarke and colleagues reported 
specific alterations in the microbiota composition of professional athletes 
compared to non-athlete controls (Clarke et al. 2014). Alongside increased 
microbial gut diversity, athlete microbiota showed a significant increase in the 
abundance of Akkermansia muciniphila, that has been shown to inversely 
correlate with obesity and metabolic disorders (Clarke et al. 2014).  
Work carried out over the last decade has demonstrated the significant impact of 
antibiotic exposure on the gut microbiota. It is now known that administration of 
broad spectrum antibiotics has the capacity to induce drastic and long-term shifts 
in the microbiota structure (Cotter et al. 2012). Exposure of healthy adults to a 
short dosage of ciprofloxacin impacted on the relative abundance of 30% of 
bacterial taxa in the gut decreasing the taxonomic richness and diversity of the 
community (Dethlefsen et al. 2008). Additionally, repeated exposure to 
ciprofloxacin resulted in incomplete recovery of the distal gut microbiota 
composition with subjects showing a distinct gut profile post-treatment compared 
to pre-treatment profile (Dethlefsen and Relman 2011). 
Enteric infection can also influence the bacterial community structure of the gut. 
Clostridium difficile infection (CDI) was shown to decrease gut microbial diversity, 
evenness, and species richness that involved a lowered abundance of Firmicutes 
sequences and enriched Lactobacillus and Enterococcus sequences (Antharam et 
al. 2013). Sequences from Gammaproteobacteria were also enriched in CDI 
patients compared to healthy controls. Furthermore, in CDI patients, a depletion of 
butyrate-producing bacteria including members of Clostridium cluster XIVa was 
detected (Antharam et al. 2013).   
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Chronic intestinal inflammation, experienced by inflammatory bowel disease (IBD) 
patients induces marked alterations in microbial composition. IBD patients 
consistently demonstrate reduced microbial stability and diversity in the gut 
microbiota compared to healthy individuals (Manichanh et al. 2006, Ott et al. 
2004). A decrease in Bacteroidetes and Firmicutes frequencies and an increase in 
Proteobacteria and Actinobacteria frequencies has been detected in several 
studies using high throughput sequencing of 16S rRNA genes (Frank et al. 2007, 
Manichanh et al. 2006). Additionally, patients with sporadic colorectal cancer 
(CRC) show perturbed gut microbiota composition involving overrepresentation of 
Bacteroides and Fusobacterium (Kostic et al. 2012, Toprak et al. 2006). 
Furthermore, an increased abundance of mucosa-associated and internalised E. 
coli is detected in the gut mucosa of inflammation-associated CRC patients 
compared to healthy controls (Bonnet et al. 2014, Martin et al. 2004).  
Indeed, a wide range of processes are capable of influencing the structure and 
composition of the gut microbiome. However, a key factor in the development and 
stability of the intestinal microbiota population is the host immune system. The gut 
microbiota and host mucosal immune system co-exist as mutualistic partners 
creating an environment in which stability is dependent on a complex array of fine-
tuned processes. This is known as intestinal homeostasis.  
 
 
 
 
30 
 
 
 
Figure 1-4: The gut microbiota is comprised of bacteria, archaea, viruses and eukaryotic 
microbial species.  
Bacterial genes comprise 99% of total microbial genes, with the remainder being archaea and viral 
and eukaryotic genes (Qin et al. 2010). Figure shows dominant microbial species for each 
microbial component.  
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1.2.3 Intestinal homeostasis 
 
1.2.3.1 Regulation of the intestinal microbiota by the host immune system 
The intestinal microbiota is recognised or ‘sensed’ by the host through pattern 
recognition receptors (PRRs). PRRs are expressed by immune and non-immune 
cells and include Toll-like receptors (TLRs) and nucleotide-binding oligomerization 
domains (NODs) (Benoit Chassaing, Kumar, et al. 2014). NODs are the main 
receptors involved in recognition of conserved bacterial motifs termed microbe 
associated molecular patterns (MAMPs) (Kawai and Akira 2011).  Due to the high 
antigenic burden present in the gut an ongoing challenge exists for the host 
immune system. It must ensure that resident microbiota communities remain intact 
without pro-inflammatory responses being induced. However, it must also remain 
equipped to eradicate and clear invading pathogens entering via the intestine 
(Benoit Chassaing, Kumar, et al. 2014). 
To maintain intestinal homeostasis the host mucosal immune system regulates 
both the composition and localisation of the resident gut microbiota (Sekirov et al 
2010) (Figure 1.5).  These two functions are carried out by a wide range of 
immune cells that function in both the innate and adaptive immune system. Cross-
talk between the intestinal epithelial cells and gut microbiota mediated by PRRs 
leads to the expression of gene products that enhance epithelial barrier function 
and innate immunity (Takeuchi and Akira 2010). The physical separation of 
microbiota and gut mucosa is mediated by myeloid differentiation primary 
response gene 88 (MyD88) signalling in intestinal epithelial cells (Benoit 
Chassaing, Kumar, et al. 2014). Cytoplasmic adaptor protein MyD88 transduces 
signals from TLRs that recognise bacterial products (Jobin 2010). MyD88 
activation triggers a cascade of signalling events leading to nuclear localisation of 
NF-κB along with other inflammatory responses. MyD88 signalling also controls 
the production of the mucus layer and antimicrobial peptides (AMPs) in the 
intestine (Frantz et al. 2012). 
Intestinal goblet cells secrete mucin glycoproteins that form a thick mucus layer at 
the epithelial cell surface. In the colon, this is comprised of two distinct layers with 
the inner layer being resistant to bacterial penetration (Vaishnava et al. 2011). 
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Mucus in both the small and large intestine is comprised of the same mucin 
protein, mucin 2 (MUC2). MUC2 plays a crucial role in the organisation of the 
intestinal mucus layers at the epithelial surface of the colon (Hansson and 
Johansson 2014). The inner mucus layer of the distal colon is formed from sheets 
of MUC2 organised into stacked layers in a stratified way that prevents bacteria to 
penetrate (Johansson et al. 2014). Mice deficient in the Muc2 gene lack secreted 
mucus layers that results in contact between gut bacteria and the epithelium 
(Hansson and Johansson 2014). The significance of mucin production by goblet 
cells for intestinal homeostasis was demonstrated in Muc2-deficient mice that 
spontaneously develop colitis and show predisposition to colitis-induced colorectal 
cancer (Sluis and Koning 2006, Velcich et al. 2002).  
Furthermore, in murine models of experimental colitis and in patients with active 
ulcerative colitis (UC) increased bacterial penetration of inner mucus layer is 
mediated by reduced MUC2 density in the inner mucus layer (Johansson et al. 
2014). 
In the small intestine, a less robust mucus layer is found and therefore secretion of 
AMPs limits penetration of bacteria (Vaishnava et al. 2011).  Paneth cells, 
secretory cells in the epithelium of the small intestine, are an important source 
of antimicrobial peptides including α-defensins (Bevins and Salzman 2011). The 
significance of AMPs in the regulation of microbial composition has recently been 
demonstrated (Cullen et al. 2015). In this work, it was shown that commensal 
bacteria were largely resistant to inflammation associated AMPs but pathogenic 
species were highly susceptible (Cullen et al. 2015). Susceptibility to AMPs is 
mediated by the expression of specific lipopolysaccharide (LPS) types on the 
bacterial surface (Cullen et al. 2015). Additionally, production of secretory 
immunoglobulin A (IgA) in the small intestine maintains barrier function of the 
epithelium (Frantz et al. 2012) (Figure 1.5). 
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Figure 1-5: Components of the gut mucosal immune system. 
 In healthy individuals, PRR-microbiota interactions result in the secretion of antimicrobial peptides 
(AMPs) and development of gut-associated lymphoid tissue (GALT). Crosstalk between microbiota 
and intestinal immune system results in intestinal homeostasis that includes sIgA and defensins 
that maintain microbiota homeostasis and epithelial barrier integrity. Adapted from figure shown in 
(Benoit Chassaing, Kumar, et al. 2014) 
 
1.2.3.2 Functional input of the intestinal microbiota 
Maintenance of intestinal homeostasis requires a high level of functional input from 
the intestinal microbiota. Studies using GF animals have given us great insights 
into the mechanisms involved in this partnership. GF animals show defects in the 
structure and function of many intestinal immune components. This includes 
impaired development of gut associated lymphoid tissues (GALTs), reduced 
antibody production, fewer and defective Peyer’s patches and reduced numbers of 
mesenteric lymph nodes (Falk et al. 1998, Macpherson and Uhr 2004). The rate of 
production of crypt cells is also reduced in the colon of rats bred in GF 
environments (Alam et al. 1994). Additionally, sensing of the commensal 
microbiota through TLR-MyD88 triggers several functions involved in intestinal 
homeostasis. Innate signals mediated by myeloid cells are required to enhance 
epithelial cell proliferation and induce repair of damaged intestinal epithelium via a 
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MyD88-dependent mechanism (Pull et al. 2005, Rakoff-Nahoum and Medzhitov 
2007). MyD88- dependent bacteria signalling is also required for production of 
epithelial cell AMPs such as RegIIIγ (Vaishnava et al. 2011). 
Commensal microbiota are also involved in the shaping of T-cell subsets. Luminal 
resident bacteria have been shown to upregulate the anti-inflammatory branch of 
the adaptive immune system by inducing differentiation of regulatory T-cells or 
interleukin-10 (IL-10) expression (Hooper et al. 2012). For example, 
polysaccharide A (PSA) of Bacteriodes fragillis was shown to induce IL-10 
responses in T-cells that prevented expansion of Th17 cells and hence damage to 
the intestinal epithelial barrier. However, mutant B. fragillis that lacked PSA was 
shown to induce pro-inflammatory responses in the host (Round et al. 2011).  
Evidently, alterations in gut microbiota composition, termed dysbiosis, has the 
potential to significantly impact on host immune responses. Intestinal dysbiosis is 
linked to a diverse range of diseases that exhibit unique triggers, symptoms and 
localisations.  
 
1.3 Dysbiosis of the gut microbiota in disease 
The gut microbiota has been implicated in several distinct forms of chronic disease 
including disorders encompassing metabolic syndrome (obesity, type 2 diabetes), 
gastrointestinal disease (inflammatory bowel disease (IBD), colorectal cancer 
(CRC), irritable bowel syndrome (IBS)), allergic disease (allergic asthma) and 
neuronal disease (autism spectrum disorders (ASD)).  Although these disorders 
exhibit distinct symptoms and localisations, most share the common characteristic 
of possessing a complex etiology that lacks a single causative agent. Recent 
evidence now indicates that specific alterations in individual microbiota profiles 
may provide the missing link (Table 1.1). Key examples of these will now be 
discussed. 
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Table 1-1: Dysbiosis of the gut microbiota in disease. 
Disease Evidence of dysbiosis Microorganisms identified 
 
Inflammatory 
bowel disease 
(IBD) 
 
 IBD does not occur under germ-
free conditions in animal model 
studies.(Kennedy et al. 2000, 
Madsen et al. 1999). 
 Colitis occurs in IL-2 deficient 
germ free mice with a non-
pathogenic strain of E. coli but 
not with Bacteroides vulgatus 
(Waidmann et al. 2003).  
 Reduced diversity in luminal 
bacteria populations is 
consistently detected in human 
IBD patients compared to 
healthy controls (Manichanh et 
al. 2006, Ott et al. 2004). 
 Antibiotic treatment have shown 
beneficial effect on inflammatory 
symptoms in IBD patients (Khan 
et al. 2011).  
 
 Decrease in Firmicutes and 
increased Bacteroides in IBD 
patients (Frank et al. 2007, 
Hedin et al. 2015). 
 Increase in 
Gammaproteobacteria in IBD 
patients (Li et al. 2012, Walters 
et al. 2014). 
 Presence of E. coli, specifically 
adherent invasive E. coli in IBD 
patients (A Darfeuille-Michaud 
et al. 2004). 
 Reduced Faecalbacterium and 
Roseburia  (Hedin et al. 2015, 
Sokol et al 2009, Swidsinski 
and Weber 2005). 
 
Colorectal 
cancer (CRC) 
 
 Mice genetically susceptible for 
CRC develop less tumours 
when raised in germ free 
conditions  (Uronis et al. 2009) 
 Antibiotic treatment reduces the 
development of tumours in the 
colon of mice with colitis-
induced CRC (Chen et al. 2008, 
Klimesova et al. 2013). 
 
 Increased abundance of 
Fusobacterium in colorectal 
biopsies (McCoy et al. 2013). 
 Increased Firmicutes and 
Fusobacteria; reduced 
Proteobacteria and 
Actinobacteria in CRC biopsies 
(Gao et al. 2015) 
 Distinct composition of 
mucosa-associated bacteria 
involving enriched 
Fusobacterium and 
Peptostreptococcusten (Gao et 
al. 2015). 
 Increased abundance of 
Enterotoxigenic Bacteroides 
fragillis (ETBF)  (Toprak et al. 
2006). 
 Increased mucosa-associated 
E. coli in colitis-associated 
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CRC (Prorok-Hamon et al. 
2014). 
 
Allergic 
asthma 
 
 Probiotic therapy improves 
allergic asthma symptoms (Ege 
et al. 2011, Isolauri et al. 2000, 
Murk et al. 2011) 
 Antibiotic exposure in first year 
of life increases risk of 
developing allergic asthma (Ege 
et al. 2011, Marra et al. 2009, 
Murk et al. 2011).  
 Reduced microbiota diversity in 
early infancy precedes asthma 
development at school age 
(Abrahamsson et al. 2014). 
 
 Increased Clostridium genus 
(Atarashi et al. 2011). 
 Increased Lactobacillus spp, 
Reduced Bacteroides  
(Shannon L Russell et al. 
2013). 
 
Autism 
spectrum 
disorder 
 
 Subset of patients show 
gastrointestinal symptoms 
(McElhanon et al. 2014). 
 Antibiotic treatment shown to 
temporarily alleviate ASD 
neuronal symptoms (Sandler et 
al. 2000). 
 GI symptoms in patients 
strongly correlated with severity 
of autism (Adams et al. 2011). 
 
 Reduced Bifidobacteria spp 
and increased Lactobacillus 
spp (Adams et al. 2011).   
 Bacteroides fragilis treatment 
reduced neurological defects in 
mouse model of ASD (Hsiao et 
al. 2013). 
 
Rheumatoid 
arthritis 
 
 Animal models of 
spondyloarthropathy raised in a 
germ free environment do not 
develop peripheral joint disease. 
(J D Taurog et al. 1994) 
 Severe joint inflammation 
reported in adjuvant induced 
arthritis animal model when rats 
were raised in germ free 
conditions (Kohashi et al. 1979). 
 
 Increased abundance of 
Prevotella copri in of patients 
with new-onset rheumatoid 
arthritis (NORA) (Scher et al. 
2013). 
 
 
 
 
 
 
Obesity  Conventionally raised mice 
show 40% higher body fat 
 Increased abundance of 
Actinobacteria in obese 
37 
 
content compared to germ free 
mice, independent of diet 
(Bäckhed et al. 2007). 
 Germ-free mice fed high-sugar, 
high-fat Western diet do not 
develop obesity (Bäckhed et al. 
2007). 
 Increased antibiotic exposure in 
childhood is associated with 
increased weight gain in 
adolescence (B S Schwartz et 
al. 2015). 
 Distinct microbiota composition 
detected in lean and obese 
human twins (Turnbaugh et al. 
2009). 
 
individuals compared to lean 
individuals in human twin study 
(Turnbaugh et al. 2009). 
 Reduced abundance of 
Bacteroideted in obese 
individuals compared to lean 
individuals in human twin study 
(Turnbaugh et al. 2009). 
 In overweight children, 
decreased beneficial bacteria 
such as Bifidobacteria that is 
associated with increased 
Gram-negative bacteria such 
as Enterobacteriecea 
(Kalliomäki et al. 2008).   
Type 2 
diabetes 
mellitus 
 Antibiotic treatment reduced 
metabolic endotoxemia and  
cecal LPS in both high-fat-fed 
and ob/ob mice and caused 
improvement of insulin 
sensitivity (Cani et al. 2008).   
 Altered microbiota composition 
detected in diabetic subjects 
compared to healthy controls 
(Fredrik H Karlsson et al. 2013, 
Qin et al. 2012). 
 
 TDM2 subjects show reduced 
number of Clostridiales bacteria 
(Roseburia species and 
Faecalibacterium prausnitzii), 
that produce the SCFA butyrate 
(Fredrik H Karlsson et al. 2013, 
Qin et al. 2012). 
IBS  Human IBS develops following 
recovery from enteric infections 
(Spiller and Garsed 2009).  
 Probiotic bacteria treatment 
alleviates IBS symptoms in 
animal models of post-infectious 
IBS  (Lutgendorff et al. 2008)  
 Increased Bacteroidetes and 
reduced Clostridials correlate 
with impaired barrier function in 
IBS patients (Jalanka-Tuovinen 
et al. 2014). 
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1.3.1 The role of the gut microbiota in the development of    
immune related disorders 
1.3.1.1 Rheumatoid arthritis 
A striking example of the role of the microbiota in immune related disorders is in 
the development of rheumatoid arthritis (RA). RA is a highly prevalent, systemic 
autoimmune disease with predilection for the joints (McInnes and Schett 2011). If 
left untreated, RA can lead to chronic joint deformity, disability, and increased 
mortality. The first report of a possible role for the gut microbiota in the pathology 
of arthritis was in the late seventies in GF rats. In an adjuvant induced arthritis 
model, severe joint inflammation and 100% penetrance was reported when rats 
were raised in germ free conditions (Kohashi et al. 1979). Furthermore, human 
leukocyte antigen (HLA) B27 transgenic rats (spontaneous model of 
spondyloarthropathy) raised in a GF environment do not develop peripheral joint 
disease or intestinal inflammation (J D Taurog et al. 1994).  Recent work has shed 
light on a potential causative microbial agent for RA in at least a portion of 
patients. Littman and colleagues reported increased abundance of the bacterial 
species Prevotella copri in the faeces of patients with new-onset rheumatoid 
arthritis (NORA) compared with patients with established rheumatoid arthritis, 
patients with psoriasis or healthy controls (Scher et al. 2013). P. copri was 
detected in the microbiota of 75% of patients with NORA compared to only 21.4% 
of healthy controls. It remains to be determined whether expansion of P. copri is a 
causative factor in the development of rheumatoid arthritis in these patients (Table 
1.1). 
 
1.3.1.2 Allergic asthma 
Intestinal dysbiosis is proposed to have wider implications on human health and is 
associated with allergic immune disorders. Allergic asthma affects approximately 
100 million people worldwide and its incidence is increasing in developed 
countries (Mukherjee and Zhang 2011). Although controversial, the reported ability 
of probiotic therapy to improve allergic asthma symptoms and reduce inflammatory 
markers indicates a role for the gut microbiota in this disease (Isolauri et al. 2000). 
Epidemiological data has reported distinct gut microbiota composition between 
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asthmatic and non-asthmatic infants and early life, antibiotic exposure increases 
the risk of developing allergic asthma (Ege et al. 2011, Murk et al. 2011). 
Moreover, it was recently demonstrated that children developing asthma (n = 8) 
had a lower diversity of the total gut microbiota than non-asthmatic children at one 
week and one month of age (Abrahamsson et al. 2014). The mechanisms by 
which dysbiosis is able to induce allergic inflammation was proposed by Noverr 
and colleagues who showed that mice receiving antibiotic treatments followed by 
infection of Candida albicans exhibited an altered microbiota composition and 
altered immune regulation in the airways, leading to upregulation of Th2 
responses to both mould spores and ovalbumin exposure in BALB/c mice (Noverr 
et al. 2005). Furthermore, these mice were more susceptible to developing allergic 
airways disease (Noverr et al. 2005). Evidently, these data show that functional 
input of the intestinal microbiota has far greater implications than maintaining 
intestinal homeostasis. Indeed, recent work carried out over the last decade also 
supports a role for gut microbiota in neuronal development. 
 
1.3.1.3 Autism spectrum disorder 
Autism spectrum disorders (ASD) describes a range of neurodevelopmental 
disorders including autism and Asperger’s and has an incidence of approximately 
1/1000 in the UK (Taylor et al. 2013). Autism is recognised as a multifactorial 
disorder and symptoms are associated with genetics, environmental triggers and 
also immune and neuronal dysregulation.  Interestingly, a subset of ASD patients 
also display gastrointestinal symptoms indicating a role for the gut microbiota in 
ASD (McElhanon et al. 2014) (Table 1.1). Several independent studies have 
reported altered gut microbiota composition in ASD patients compared to healthy 
controls (Adams et al. 2011, Lv Wang et al. 2013). This has involved a diverse 
range of bacterial species including increased abundance of Bifidobacterium spp, 
Sutterella spp and increased mucolytic bacterium Akkermansia mucinphila that is 
also associated with IBD (Png and Lindén 2010, L Wang and Christophersen 
2011, Lv Wang et al. 2013). Furthermore, it was demonstrated by Adams and 
colleagues that GI symptoms are strongly correlated with the severity of autism, 
indicating a causal or primary role for the gut microbiota in ASD symptom 
development (Adams et al. 2011). This is further supported by other work that 
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showed that vancomycin treatment temporarily alleviated autistic symptoms in 8 
out of 10 patients (Sandler et al. 2000).   
 
1.3.2 The role of the gut microbiota in the development of 
gastrointestinal disease 
As described in this work, the gut microbiota has a strong functional input on the 
maintenance of intestinal homeostasis. As one may predict, intestinal dysbiosis is 
associated with a diverse range of gastrointestinal disorders. Key examples of 
these that show strong associations with dysregulated gut mucosa immune 
functions will now be discussed.  
 
1.3.2.1 Colorectal cancer 
Several types of cancer are associated with infectious agents and most of these 
cancers tend to occur in tissues that have a high level of exposure to 
microorganisms. A key example of this is colorectal cancer (CRC) that is the third 
most common cancer and the fourth leading cause of cancer deaths worldwide, 
accounting for approximately 1.2 million new cases and 600,000 deaths per year 
(Brenner et al. 2014). CRC is a heterogeneous disease, including at least three 
major forms: hereditary (attributed to less than 5% of cases), sporadic, and colitis-
associated CRC (Danese et al. 2011, Jess et al. 2005).  Much evidence now 
exists to support a role for the intestinal microbiota in the aetiology of CRC not 
only via the pro-carcinogenic activities of specific pathogens, but also via the 
immunoregulatory function of the resident microbial communities (Sobhani et al. 
2013).  Animal models have shown that mutant mice genetically susceptible to 
CRC develop significantly less tumours when maintained in a GF environment 
(Uronis et al. 2009). Additionally, depletion of the intestinal microbiota by antibiotic 
treatment reduces the development of tumours in the colon of mice affected by 
colitis-associated cancer induced by azoxymethane and dextran sodium sulphate 
(Klimesova et al.. 2013).   
Pyrosequencing of sporadic CRC-associated microbiota isolated from colonic 
tumour tissue has revealed increased abundance of Firmicutes and Fusobacteria 
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and reduced numbers of Proteobacteria compared to healthy adjacent tissue (Gao 
et al 2015). Significant differences in the composition of mucosa-associated 
bacteria was also reported in CRC colonic samples that involved enriched 
Fusobacterium and Peptostreptococcusten (Gao et al. 2015). Fusobacterium 
nucleatum is recognised as a potential causative agent for CRC as it has the 
capacity to induce colonic neoplasia via the expression of the surface adhesion 
molecule FadA. FadA facilitates the attachment and invasion of Fusobacterium 
nucleatum into colonic epithelial cells (Han et al. 2005, Xu et al. 2007). FadA binds 
to E-cadherin, activates β-catenin signalling, and differentially regulates the 
inflammatory and oncogenic responses (Rubinstein et al. 2013).  Increased 
abundance of Fusobacterium in rectal biopsies of CRC patients was recently 
demonstrated and this correlated with expression of tumour necrosis factor alpha 
(TNF-α) and IL-10 (McCoy et al. 2013). 16S rRNA pyrosequencing of faecal 
samples from patients with sporadic CRC has also reported enriched Bacteroides 
fragilis operational taxonomic units (OTUs) compared with healthy controls 
(Tingting Wang et al. 2012). B. fragillis, that is shown to colonise humans 
asymptomatically, also secretes a toxin termed B. fragillis toxin (BFT). In the Min 
(multiple intestinal neoplasia) mouse model for colon cancer, enterotoxigenic B. 
fragillis (ETBF) promotes colonic tumorigenesis via the inflammatory Th17/IL-23 
pathway (Wu et al. 2009). Higher levels of the bft gene were detected in mucosal 
samples of CRC patients, especially in late onset CRC compared to samples 
obtained from routinely screened healthy patients (Boleij et al. 2015).   
Colitis-associated cancer, that develops in areas of active colonic inflammation, is 
listed as cause of death in 10%-15% of all IBD patients (Van Der Kraak et al. 
2015).  Gut dysbiosis detected in colitis-associated cancer is associated with 
specific microbiota alterations detected in IBD (Martin et al. 2004, Swidsinski et al. 
1998). Colonic adenomas, carcinomas, and the gut mucosa of colitis-associated 
CRC patients are abnormally colonized by E. coli belonging to the B2 phylogroup 
that are also associated with CD (Bonnet et al. 2014, Martin et al. 2004, Swidsinski 
et al. 1998). These mucosa-associated E. coli strains that show adherent-invasive 
properties, have been detected in increased numbers of CRC and CD biopsies 
compared to healthy controls (Prorok-Hamon et al. 2014). A high prevalence of 
genotoxin producing E. coli has been reported in colitis-associated CRC (Buc et al. 
2013, Raisch et al. 2015).  Recent studies show that E. coli possessing the 
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polyketide synthase gene complex (pks) responsible for producing the genotoxin 
colibactin, induce inflammation-associated CRC in mice and are commonly 
mucosa associated in sporadic CRC (Prorok-Hamon et al. 2014). B2 CRC-
associated E. coli are shown to invade and survive within macrophages that 
induces protumour responses including upregulated cyclooxygenase-2 (COX-2) 
expression (Raisch et al. 2015).  
 
1.3.2.2 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is comprised of Crohn’s disease (CD) and 
ulcerative colitis (UC) and is characterised by chronic and relapsing inflammation 
of the intestine. IBD is a disease of complex etiology and is proposed to occur in 
genetically susceptible hosts following periods of inflammation induced intestinal 
dysbiosis involving both the host mucosal immune system and the gut microbiota 
(Craven et al. 2012). Much evidence now exists to support an altered gut 
microbiota composition as a key characteristic of IBD. Under GF conditions, IL-10 -
/- mice and HLA-B27 transgenic rats do not develop colitis (Kennedy et al. 2000). 
Furthermore, in spontaneous models of colitis intestinal inflammation is abolished 
if mice have a deficiency in individual TLRs or MyD88 (Hoshi et al. 2012). One 
hypothesis is that the onset of IBD is due to a general dysbiosis of gut microbiota 
composition involving an imbalance of resident commensal populations. Several 
independent studies have shown, by culture independent and dependent 
techniques, that intestinal inflammation is associated with reduced bacterial 
diversity and not bacterial numbers (Joossens et al. 2011). Metagenomic analysis 
of IBD patient microbiota has also reported approximately 25% fewer genes 
compared to healthy controls, indicating reduced diversity in microbiota species 
(Qin et al. 2012). IBD-associated dysbiosis involves lower abundance and 
complexity of the Bacteriodetes and Firmicutes phyla (Frank et al. 2007, Joossens 
et al. 2011, Manichanh et al. 2006). An increased abundance of 
Gammaproteobacteria has also been reported (Li et al. 2012, Walters et al. 2014). 
Several independent studies have reported reduced numbers of the anti-
inflammatory commensal Firmicute, Faecalibacterium prausnitzii in IBD patients 
(Frank et al. 2007, Sokol et al. 2009, Swidsinski and Weber 2005). Interestingly, in 
other work, an increased abundance of F. prausnitzii was reported in paediatric 
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CD patients who had not yet been exposed to antibiotic therapies. Although highly 
controversial, this indicates a potential protective role for this bacterial species in 
IBD pathogenesis (Hansen et al. 2012). Among the Proteobacteria an overgrowth 
of Enterobacteriaceae, specifically E. coli, has been detected in IBD patients 
(Giaffer et al. 1992, Seksik et al. 2003, Sokol et al. 2006). More specific features of 
CD and UC associated dysbiosis also include reduced Roseburia and 
Phascolarctobacterium, that are involved in anti-inflammatory regulatory T-cell 
production and propionate production in the gut, respectively (Morgan et al. 2012). 
Other studies have reported decreased abundance of other short chain fatty acid 
(SCFA) producing bacteria including Ruminococcaceae (CD) and 
Leuconostocaceae (UC) (Morgan et al. 2012).  The mechanisms by which the gut 
microbiota trigger intestinal inflammation in IBD are still unknown, however, it is 
proposed that individual immune defects determine the ability of intestinal bacteria 
to trigger colitis. This has been shown in GF mice deficient in IL-10 whereby colitis 
could be triggered by infection with E. coli or Enterobacter faecalis but not with 
Bacteroides vulgatus (Kim et al. 2005). Additionally, Tlr-5-/- mice develop 
spontaneous colitis in some housing facilities but not all, indicating microbiota 
composition affects disease susceptibility (Vijay-Kumar et al. 2007). Furthermore, 
deficiency in Tlr-2, Tlr-4, Tlr-9 or Myd88 in mice is associated with increased 
susceptibility to DSS-induced colitis (Lee et al. 2006, Saha et al. 2010).   
A second hypothesis that has been gaining increased support is that IBD 
pathogenesis is associated with abnormal colonisation of the gut by a specific 
pathogenic agent. One example that has gained a great deal of attention over the 
last 2 decades is increased mucosal association of adherent-invasive E. coli 
(AIEC) in CD.  AIEC is now proposed to be a likely cause of CD associated 
pathology.  
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1.4 Adherent-invasive E. coli infection associated with 
Crohn’s disease 
1.4.1 Crohn’s disease 
Crohn’s disease was first recognised as a distinct entity of IBD approximately 80 
years ago. Unlike UC, CD is characterised by discontinuous and granulomatous 
inflammation and may affect any region of the gastrointestinal tract from mouth to 
anus (Bandzar et al. 2013). In CD, TNF-α is present in extremely high quantities 
and is thought to be the major cause of excessive inflammation (Murray et al. 
1997). Crohn's disease is debilitating and expensive to treat and affects 
approximately 150-200 /100,000 in the UK (Kalla et al. 2014).  Once recognised as 
a disease of Western regions, the incidence of CD is increasing in both developing 
and developed countries (Benchimol et al. 2011, Molodecky et al. 2012). This 
trend is most pronounced in paediatric patients, confirmed recently by a study of 
paediatric Scottish patients (Henderson et al. 2012). CD is currently recognised as 
an incurable disorder and current therapies function to induce or sustain periods of 
remission. They include antibiotics, immune system suppressors, anti-
inflammatory mediators and the last resort therapy of surgery.  
 
1.4.2 Crohn’s disease is a multifactorial disorder 
CD is recognised as a multifactorial disorder of complex aetiology. It is proposed 
that disease development is a consequence of aberrant immune responses to 
intestinal bacteria following an environmental trigger, a process intimately linked to 
host genotype. The increased concordance for CD in monozygotic twins (~36%) 
and higher risk of developing IBD if a first degree relative has CD (relative risk 5-
35) suggest a genetic determinant in disease pathogenesis (Van Limbergen et al. 
2008, R K Russell and Satsangi 2004). Genome wide association studies (GWAS) 
have identified 71 (out of 163 IBD loci identified) distinct genetic susceptibility loci 
for CD (Jostins et al. 2012). However, CD associated polymorphisms are 
associated with only a 30-40 fold increase in risk of developing disease and 
expression of all polymorphisms in single individuals account for less than 20% of 
total risk (Van Limbergen et al. 2009).  This prevents GWAS to predict disease 
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development and also emphasises that genetics alone cannot account for the 
tendency of an individual to develop CD. Many of the risk susceptibility genes 
identified have improved our understanding of the etiology of CD. The key genetic 
susceptibility loci contain genes that encode for various components that function 
in innate pattern recognition (NOD2/CARD15), differentiation of Th17 lymphocytes 
(IL-23R, JAK2, STAT3, CCR6, ICOSLG), autophagy (ATG16L1, IRGM, LRRK2) 
and intestinal epithelial barrier integrity (IBD5, DLG5, PTGER4, ITLN1, DMBT1, 
and XBP1) (Franke et al. 2010). The identified risk susceptibility genes indicate a 
strong microbial component in CD and a crucial role for bacterial recognition and 
clearance in disease pathogenesis. 
Indeed, much evidence has reported an altered or dysbiotic intestinal microbiota 
composition in CD patients (Martin Baumgart et al. 2007, Fujimoto et al. 2013, 
Joossens et al. 2011, Kang et al. 2010, Manichanh et al. 2006). Gut dysbiosis in 
CD involves increased abundance of Proteobacteria, particularly E. coli and 
decreased bacteria of the Firmicutes phylum (Manichanh et al. 2006, 
Mukhopadhya et al. 2012). It is yet to be determined if gut dysbiosis is a primary 
factor in the development of CD, or is a secondary factor induced by 
environmental triggers or specific host factors.  
A likely trigger for CD associated dysbiosis are variations in diet. Western society 
has shifted to a high-fat, high carbohydrate diet over the past-half century, and this 
has correlated with a significant increase in the incidence of disease in this region 
(Burisch et al. 2013). The mechanisms by which Western diet promotes dysbiosis 
and intestinal inflammation was demonstrated in mice whereby dietary fat, via 
changes in bile salt metabolism,  promoted bacterial dysbiosis that involved 
intestinal blooms of Bilophila wadsworthia (Devkota et al. 2012). B. wadsworthia 
blooms were associated with colitis and increased production of pro-inflammatory 
cytokines in Il-10-/- mice, indicating a role for host genotype in dietary induced 
intestinal inflammation (Devkota et al. 2012). It was also shown that high-fat diet 
accelerated the development of intestinal inflammation in a murine Crohn’s 
disease-like ileitis model, independent of weight gain (Gruber et al. 2013). In this 
case, accelerated pathogenesis was mediated by increased intestinal permeability 
via reduced occludin expression and altered immune responses involving 
increased Th17 responses (Gruber et al. 2013).   
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Furthermore, administration of emulsifiers to Il-10-/- mice was shown to induce 
perturbation of gut microbiota involving a significant reduction in microbial 
diversity, blooms of members of the Verrucomicrobia phyla and increased 
abundance of mucosa-associated pro-inflammatory Proteobacteria (Benoit 
Chassaing et al. 2015). Emulsifier exposure also increased faecal levels of 
bioactive LPS and increased the incidence of colitis in Il-10-/- mice (Benoit 
Chassaing et al. 2015).   
Inflammation is also shown to be a key driver of intestinal dysbiosis, indicating that 
disease itself is a prerequisite for pathogenic shifts in the gut microbiota. It was 
shown that severe inflammation, induced by Toxoplasma gondii infection, caused 
significant gut dysbiosis in mice, involving a shift from >95% Firmicutes to >95% 
Proteobacteria. This also involved reduced bacterial diversity and increased 
mucosal invasion by E. coli.  Administration of anti-TNF-α antibodies to mice 
alleviated gut dysbiosis and reduced bacterial mucosal invasion.    
Intestinal dysbiosis in CD extends further than a perturbed microbiota composition 
and involves dysregulated mucosal immune responses and impaired intestinal 
barrier function (Figure 1.6). Increased intestinal permeability has been 
demonstrated in a larger proportion of CD patients than healthy subjects (Jenkins 
and Rooney 1987, Wyatt et al. 1997). Furthermore, patients with active CD 
demonstrate increased intestinal permeability that decreases during disease 
remission (Sanderson et al. 1987). Moreover, anti-inflammatory therapies such as 
infliximab, an anti-TNF-α blockade, also restores intestinal permeability in CD 
patients (Suenaert et al. 2002, Zeissig et al. 2004). The adaptive immune system 
is proposed to mediate and perpetuate intestinal inflammation in CD but is not 
recognised as the primary trigger for inflammatory symptoms.  CD is characterised 
by an imbalance of inflammatory Th cells vs tolerance-maintaining Treg cells 
(Chao et al. 2014). Both human and murine studies have shown different T-cell 
subpopulations aberrantly activated in CD (Fuss et al. 1996). Initial studies 
showed that CD is predominately mediated by a T-helper Th1 immune response 
through activation of IL-12/STAT4 and interferon-gamma (IFN-γ)/STAT1 signalling 
pathways (Monteleone et al. 2005). However, there may be a partial Th1/Th2 
polarisation in CD that involves other cytokines like TNF-α, IL-1β, and IL-17A, that 
primarily activate NF-κB, IL-6, and Il-10, that activate STAT3 (Zhan-Ju Liu et al. 
2009, Sanchez-Munoz et al. 2008). Defects in processes crucial for microbial 
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sensing and eradication are also observed in CD. Impaired stimulation of the 
innate MyD88 pathway and also autophagy have been observed in CD monocytes 
(Homer et al. 2010, Kuballa et al. 2008, Lapaquette et al. 2010). Furthermore, 
reduced production of host AMPs including Paneth cell produced α-defensins has 
been observed (Wehkamp and Salzman 2005). 
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Figure 1-6: Crohn’s disease (CD) is a multifactorial disorder. 
A) CD possesses a complex etiology, associated with aberrant host immune responses to 
intestinal bacteria following an environment trigger in genetically susceptible hosts. B) The 
mechanisms involved in the pathogenesis of CD. A combination of genetic factors (incl. mutations 
in nucleotide-binding oligomerization domain 2 (Nod2), autophagy-related gene 16-like 1 (Atg16l1)) 
and environmental factors (such as infection, stress and diet) result in gut dysbiosis. Dysbiosis 
(infection or imbalance of beneficial bacteria) induces chronic inflammation involving 
hyperactivation of Th1 and Th17 cells. Adapted from (Kamada et al. 2013). 
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1.4.3 Increased abundance of E. coli in Crohn’s disease 
Intestinal overgrowth of E. coli in CD has been demonstrated by a wide range of 
culture based and molecular based studies (Martin Baumgart et al. 2007, Lopez-
Siles and Martinez-Medina 2014, Neut et al. 2002, Willing and Halfvarson 2009).  
In the cohort of Martinez-Medina et al. E. coli 16S rRNA gene copies comprised 
14% and 33% of total bacterial 16S rRNA in healthy and ileal CD patients, 
respectively (Martinez-Medina, Aldeguer, et al 2009). Furthermore, increased 
levels of E. coli have been shown in active CD patients compared with those in 
remission (Martin Baumgart et al. 2007, Lopez-Siles and Martinez-Medina 2014, 
Schwiertz et al. 2010).  
Additionally, in a previous study utilising fluorescent in situ hybridisation (FISH), 
increased E. coli numbers were detected in the epithelium and lamina propria of 
patients with active CD compared to inactive CD (Mylonaki and Rayment 2005). 
Increased E. coli numbers have also been shown to correlate with reduced time 
before disease relapse (Lopez-Siles and Martinez-Medina 2014). This correlates 
with work showing that high levels of antibodies against E. coli outer membrane 
protein C (OmpC) are associated with disease progression, longer duration and 
need for surgery in CD patients (Beaven and Abreu 2004, Landers et al. 2002, 
Mow et al. 2004). E. coli DNA is also more frequently detected in granulomas of 
CD patients (80%) compared with non-Crohn’s control granulomas (10%) (Ryan et 
al. 2004). In addition, E. coli isolated from CD patients has been detected in the 
mucus layer, close to intestinal epithelial cells (Swidsinski and Weber 2005, 
Walmsley et al. 1998). Increased mucosa-associated E. coli are detected in CD 
patients relative to healthy controls and some genotypes appear to be associated 
with the disease. Further investigation of these mucosa-associated E. coli strains 
has demonstrated their strong adhesive and invasive properties . This phenotype 
has grouped these mucosa-associated strains as a novel E. coli pathovar 
associated with CD, designated AIEC for adherent-invasive E. coli (Arlette 
Darfeuille-Michaud 2002).    
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1.4.4 AIEC definition 
The AIEC pathotype is defined as E. coli strains that (1) adhere and invade to 
intestinal epithelial cells; (2) involve host cell actin polymerization and microtubule 
recruitment in bacterial uptake; (3) survive and replicate within macrophages 
inducing pro-inflammatory cytokine production (Arlette Darfeuille-Michaud 2002). 
Since its definition, invasive determinants characteristic from ExPEC have been 
detected in diverse AIEC strains (Martinez-Medina, Mora, et al. 2009). These 
virulent phenotypes designate AIEC as a putative CD-associated pathogen that 
overlap significantly with other pathogenic E. coli (UPEC, APEC, DAEC, and 
APEC) (Nash et al. 2010). 
  
1.4.5 Genetic classification of AIEC 
AIEC strains that have been isolated from CD patients are clonally diverse and 
belong to different serogroups. No specific clone has been associated with 
disease pathogenesis (Martin Baumgart et al. 2007, Kleessen and Kroesen 2002, 
Sepehri et al. 2011). On the most part, AIEC belong to the B2 and D phylogroups 
as is the case for extra intestinal pathogenic E .coli (ExPEC) (Kotlowski et al. 
2007). Furthermore, AIEC carry distinct sets of virulence genes that are 
characteristic of ExPEC (Elliott et al. 2013, Gombošová et al. 2011). Additionally 
virulence genes not associated with commensal E. coli, such as afaC, pks, malX 
or lpf, have been detected frequently in AIEC strains (Dreux et al. 2013, Rolhion et 
al. 2010). Moreover, analysis of sequenced AIEC genomes has failed to identify a 
unique genetic characteristic for this group (Miquel et al. 2010, Nash et al. 2010). 
  
1.4.6 AIEC is associated with ileal and colonic Crohn’s disease 
AIEC can be described as a specialised pathogen in CD as it is also isolated from 
the gut mucosa of healthy individuals (Baumgart et al. 2007, Martinez-Medina et 
al. 2011).  AIEC comprise approximately 3.58% and 0.9% of ileal and colonic E. 
coli in healthy subjects, however in this setting it is not shown to translocate across 
the intestinal mucosa barrier (Martinez-Medina, Mora, et al. 2009, Mylonaki and 
Rayment 2005).   
The association of AIEC with CD was suggested over 2 decades ago in the first 
study by Darfeuille-Michaud (A Darfeuille-Michaud et al. 2004). In this early study, 
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it was shown by culture dependent techniques that AIEC could be more frequently 
isolated from patients with ileal CD (36%) compared to colonic CD (3.7%). This 
work was highly suggestive of a dominant role for AIEC in ileal disease. Indeed, 
many independent studies have reported a high prevalence of AIEC in ileal CD 
patients compared to healthy controls (Martin Baumgart et al. 2007, A Darfeuille-
Michaud et al. 2004, Martinez-Medina, Aldeguer, et al. 2009, Sasaki et al. 2007). 
Additionally, recent work reported a prevalence of approximately 25% for AIEC in 
ileal CD patients compared to healthy controls (Dogan et al. 2013).  
Other work has demonstrated a high prevalence of AIEC in colonic CD, 
suggesting a role for this E. coli pathotype in both colonic and ileal disease. A high 
number of mucosa-associated E. coli that displayed the AIEC phenotype were 
detected in mucosa preparations isolated from CD colonic biopsy samples (Martin 
et al. 2004). It was shown that mucosa-associated bacteria were isolated from 
71% cases with ileal or ileocolonic Crohn’s disease and from 86% of cases with 
colonic CD (Martin et al. 2004).  
In other work, Baumgart and colleagues detected AIEC strains in the ileum of 
38.5% of CD patients with ileal involvement but also in the colon of 37.5% of 
patients with colonic CD (Martin Baumgart et al. 2007). Furthermore, in other work 
that utilised a collection of 95 - 150 E. coli colonies per patient, AIEC strains were 
reported in the ileum of 54.5% of CD patients and in the colon of 50% of CD 
patients (Martinez-Medina, Aldeguer, et al. 2009).   FISH analysis also reported 
the presence of mucosa-associated E. coli in 42% of colonic biopsy samples 
obtained from CD patients (Mylonaki and Rayment 2005). 
The mechanisms by which expansion of AIEC in CD gut mucosa triggers intestinal 
inflammation have been described in both in vitro and in vivo studies of infection 
and will now be discussed. 
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1.4.7 AIEC and CD pathogenesis 
 
1.4.7.1 Colonisation of intestinal mucosa 
Much of the work that has aimed to identify the pathogenic mechanisms of AIEC in 
CD has utilised the AIEC reference strain LF82 (A Darfeuille-Michaud et al. 2004). 
AIEC LF82 was isolated from a CD chronic ileal lesion in 1999 and has been 
subsequently utilised by a number of groups as the model organism for AIEC 
associated CD infection (Boudeau et al. 1999). LF82 is an excellent biofilm 
forming bacteria and has been shown to form robust biofilms on the intestinal 
epithelial cell surface in several in vitro and in vivo studies (B Chassaing and 
Darfeuille-Michaud 2013). Biofilm formation is a common phenotype of AIEC 
strains. In one study, 17/27 AIEC strains were classified as biofilm producers 
compared with only 9/38 non-AIEC strains, with all being intestinal isolates (Weiss-
Muszkat et al. 2010).  
In ileal CD, LF82 colonises the intestinal mucosa by adhering to intestinal 
epithelial cells. LF82 adheres to intestinal epithelial cells via a common type I pili 
adhesin FimH variant that recognises and interacts with host intestinal receptor 
carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in a 
mannose dependent manner (Barnich et al. 2003, 2007). Interestingly, CEACAM6 
expression is upregulated in ileal CD patients and this may increase susceptibility 
to AIEC colonisation (Barnich and Darfeuille-Michaud 2007).  This highlights an 
intimate link between genetic susceptibility, inflammation and intestinal dysbiosis 
in disease pathogenesis. Recent work has shown that AIEC express FimH 
variants that facilitate more efficient binding to intestinal epithelial cells (Dreux et 
al. 2013). AIEC flagella have also been shown to facilitate colonisation of the 
intestinal mucosa in a process related to active motility (Barnich et al. 2003). 
Flagella also play a role in the perpetuation of intestinal inflammation and induce 
secretion of pro-inflammatory cytokines from polarised intestinal epithelial cells 
causing recruitment of macrophages and dendritic cells (DCs) at the localised area 
(Eaves-Pyles et al. 2008, Subramanian, Rhodes, et al. 2008). Pro-inflammatory 
cytokines produced by these immune cells including TNF-α and IFN-y, induce 
expression of CEACAM6 receptors, hence promoting AIEC colonisation (Barnich 
and Darfeuille-Michaud 2007). 
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Colonisation of the colonic mucosa by AIEC is likely to occur via alternative 
adhesins to FimH namely the afimbrial adhesin Afa-1. Increased prevalence of 
afimbrial adhesion afa-1 operon was detected in mucosal E. coli isolates from CD 
patients compared to healthy controls (Prorok-Hamon et al. 2014). Furthermore 
expression of Afa-1 correlated with the ability of E. coli to adhere and invade to 
intestinal epithelial cells (Prorok-Hamon et al. 2014).  
 
1.4.7.2 Invasion of intestinal epithelial cells 
AIEC are proposed to invade intestinal epithelial cells (IECs) via a macro-
pinocytosis like process (Boudeau et al. 1999). Outer membrane vesicles (OMVs) 
also play a key role in AIEC invasion of intestinal epithelial cells (IECs). Rolhion 
and colleagues showed that outer membrane vesicles (OMVs) rich in OmpA fused 
to the membrane of host IECs via binding of LF82 OmpA to endoplasmic stress 
response chaperone glycoprotein 96 (Gp96) (Rolhion et al. 2010). This is 
predicted to facilitate release of bacterial effector proteins that induce actin 
polymerisation and microtubule rearrangement of the epithelium and hence 
bacterial translocation. Furthermore, Gp96 is also shown to be overexpressed in 
the ileum of CD patients that increases their susceptibility to AIEC infection and 
again demonstrates the multifactorial and complex etiology of this disease 
(Rolhion et al. 2010). It has been recently demonstrated for another AIEC 
prototype strain, NRG857c, that deletion of the gene encoding invasive protein 
IbeA, caused reduced invasion of, but not adhesion to intestinal epithelial cells in 
vitro (Cieza et al. 2015). Deletion of ibeA however did not affect AIEC persistence 
in the murine gastrointestinal tract, indicating that AIEC possess additional 
adhesins and invasins that facilitate interaction with the host. 
Following bacterial invasion, LF82 are detected within intracellular compartments 
within intestinal epithelial cells including LC-3 positive autophagosomes 
(Lapaquette et al. 2010). It was recently demonstrated that LF82 reduces the level 
of autophagy in intestinal epithelial cells through activation of NF-κB that causes 
increased expression of microRNAs, MIR30C and MIR130A, and consequently 
reduced expression of key autophagy genes ATG16L1 and ATG5 (Nguyen et al. 
2014). Ileal samples from patients with CD had increased levels of these 
microRNAs and reduced levels of ATG5 and ATG16L1 (Nguyen et al. 2014). 
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1.4.7.3 AIEC translocation of intestinal mucosa  
Along with the ability to invade intestinal epithelial cells, other studies have also 
reported the ability of AIEC to translocate across the intestinal mucosa (Benoit 
Chassaing et al. 2011). AIEC translocate the gut mucosa via M cells of Peyer’s 
patches (PPs). M cells, that cover approximately 10% of follicle-associated 
epithelia (FAE), are highly specialized cells for the phagocytosis and transcytosis 
of intestinal lumen macromolecules, antigens, and microorganisms. AIEC target M 
cells via type I pili and long polar fimbriae (LPF) (Benoit Chassaing et al. 2011).  M 
cell specific cell surface protein, glycoprotein2 (Gp2) is reported to recognise the 
FimH component of bacterial type I pili that promotes bacterial uptake (Hase et al. 
2009). The M cell specific receptor for AIEC LPF during bacterial translocation is 
currently unknown. Recent work has demonstrated a role for GipA factor in the 
colonisation and translocation of PP’s by AIEC (Vazeille et al. 2016).  Vazeille and 
colleagues reported that AIEC gipA deletion mutants showed impaired 
translocation of M cells in ex vivo murine models of infection (Vazeille et al. 2016). 
GipA was also reported to positively regulate expression of the lpf operon under 
bile-salt enriched conditions (Vazeille et al. 2016).  
Furthermore, LF82 induce expression of pore-forming protein, claudin-2, and 
displace ZO-1 and E-cadherin from apical tight junctions, resulting in increased 
intestinal permeability (Denizot et al. 2012, Wine et al. 2009) 
 
1.4.7.4 AIEC survival and persistence within host macrophages 
Once AIEC has gained entry to the lamina propria it then invades and survives 
within macrophages inducing production of pro-inflammatory cytokines. (Bringer et 
al. 2006, Glasser et al. 2001). Extensive replication of LF82 within macrophages 
has been reported in several independent studies (Bringer et al.. (Mpofu et al. 
2007, Subramanian, Roberts, et al. 2008); Martin et al. 2004). Within 
macrophages, intracellular LF82 survive within phagolysosome-like compartments 
indicating an ability to survive and persist in environments that contain acidic pH, 
oxidative stress and proteolytic enzymes (Bringer et al. 2006). Indeed, Bringer and 
colleagues showed that an acidic environment within the phagolysosome is 
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essential for AIEC intracellular replication (Bringer et al. 2006). The specific 
mechanisms involved in this process have yet to be determined.  The stress 
protein HtrA and thiol-disulphide oxidoreductase DsbA have been reported to be 
important for survival and replication within macrophages (Bringer et al. 2005, 
2007). LF82 htrA deletion mutants showed increased sensitivity to oxidative stress 
induced by hydrogen peroxide (H2O2) and demonstrated reduced growth in 
environments reproductive of the phagolysosome (Bringer et al. 2005). 
Additionally, Hfq, a RNA-binding protein that functions as a global 
posttranscriptional regulator of gene expression, is proposed to function in LF82 
survival and replication within macrophage (Simonsen et al. 2011). Vazeille and 
colleagues have reported a crucial role for GipA in AIEC intramacrophagic 
persistence. It was shown that LF82 gipA mutants showed significantly reduced 
survival in macrophages at 7 h post infection compared to the wild-type strain. 
Reduced survival of isogenic mutant within macrophages was explained by the 
ability of GipA to increase tolerance of LF82 to oxidative stress and acidic pH 
(Vazeille et al. 2016). A role for ibeA in AIEC persistence within macrophages has 
also been demonstrated whereby mutant AIEC that lack ibeA show significantly 
reduced intramacrophagic survival up to 24 h post-infection (Cieza et al. 2015).  
AIEC persistence in macrophages causes increased secretion of pro-inflammatory 
cytokines including IL-6 and TNF-α, without inducing host cell death (Glasser et al. 
2001). This has been linked to granuloma formation, the hallmark of CD 
associated inflammation, and has been demonstrated in vitro (Meconi et al. 2007). 
Prolonged survival of AIEC infected macrophages has been explained by the 
direct role of LF82 in delaying apoptosis. It was recently demonstrated that LF82 
infection of macrophages increased proteosomal degradation of caspsase-3, a key 
regulator of apoptosis, hence promoting LF82 intracellular persistence (Dunne et 
al. 2013).  
These data obtained from a multitude of in vitro studies show AIEC expansion in 
CD is a multifactorial process involving host genetic determinants, environmental 
triggers and also the presence of specific E. coli with enhanced capacity to interact 
with the host mucosa. Animal models for AIEC intestinal infection, that have been 
recently established, have given greater insights into the mechanisms involved in 
AIEC induced gut inflammation. 
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1.4.8 Insights from AIEC animal models 
The current animal models for AIEC colonisation further highlight the multifactorial 
and complex mechanisms involved in the role of this E. coli pathotype in CD 
pathogenesis. 
In the first model of LF82 colonisation of the murine intestine, Carvalho and 
colleagues demonstrated that intestinal persistence of AIEC was dependent on 
expression of human CEACAMs (Frédéric a Carvalho et al. 2009). In CEABAC10 
mice (Chan et al. 2007), that express human CEA, CEACAM3, 6 and 7, LF82 
persistence induced severe intestinal colitis involving bloody diarrhoea, weight 
loss, epithelial damage and immune cell infiltration of colonic mucosa.  Wild-type 
mice that lacked CEACAM receptors, infected with LF82, did not exhibit any 
clinical or histological symptoms of colitis (Frédéric a Carvalho et al. 2009). It was 
recently demonstrated by Small and colleagues that persistent colonisation of the 
intestine of conventional mice with AIEC strain NRG 875c required depletion of gut 
microbiota. Chronic infection with AIEC was established following streptomycin 
treatment of mice and infection induced intestinal inflammation involving 
heightened Th17 responses, increased secretion of pro-inflammatory cytokines 
and transmural fibrosis and inflammation (Small et al. 2013). In a different model, 
where intestinal inflammation was induced in mice via Toxoplasma gondii infection 
or administration of indomethacin, inflammation was shown to drive severe 
dysbiosis that primarily involved proliferation of AIEC and increased bacterial 
invasion of intestinal mucosa (Craven et al. 2012). Furthermore, administration of 
anti-TNF-α antibodies was shown to limit inflammation induced dysbiosis and also 
bacterial invasion. Compelling work by Chassaing and colleagues has given great 
insight into the triggers and mechanisms involved in AIEC colonisation. Mice 
engineered to lack the flagellin receptor,TLR5, are prone to developing 
spontaneous intestinal inflammation(B M Carvalho et al. 2012, Vijay-Kumar et al. 
2007). The work of Chassaing and colleagues demonstrated that mice lacking 
TLR5 (T5K0), raised in a GF environment, were more susceptible to LF82 
infection (Frederic A Carvalho et al. 2012). Furthermore, LF82 infection of T5KO 
mice induced chronic colitis that was not detected in wild-type mice (Frederic A 
Carvalho et al. 2012).  
Interestingly, LF82 induced colitis was shown to be greater in T5KO mice that 
were exposed to LF82 and then placed in specific pathogen-free (SPF) housing 
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after LF82 bacterial load was cleared from intestine (Benoit Chassaing, Koren, et 
al. 2014). This indicates that exposure of T5KO mice to AIEC alters the intestinal 
immune responses to other microbiota, highlighting its potential as a pro-
inflammatory/ immunoregulatory bacterium. Moreover, LF82 induced colitis in 
T5KO mice was linked to dramatic shifts in microbiota composition, involving 
reduced species diversity and also increased gut LPS and flagellin, activating 
TLR4 and NLRC4 dependent pathways. Remarkably, altered microbiota 
components and increased levels of bioactive LPS and flagellin persisted beyond 
clearance of LF82(Benoit Chassaing, Koren, et al. 2014). Wild-type mice that 
possessed TLR-5, colonised by AIEC did not exhibit altered inflammatory markers, 
bacterial loads, microbiota composition or pro-inflammatory immune responses to 
intestinal microbiota.  
This evidence further highlights the requirement for multiple triggers for the onset 
of CD associated pathology. This factor may in part explain the poor efficacy of 
current therapies for CD that frequently target one or few components of disease 
pathogenesis. Key examples of CD therapies will now be discussed. 
 
1.5 CD therapies currently used in clinical practice 
1.5.1 Anti-inflammatory therapies 
CD is currently recognised as an incurable disease and displays a range of 
therapeutic challenges. Therapies aim to induce or sustain periods of remission 
and those currently in clinical use include broad spectrum antibiotics, immune 
system suppressors, anti-inflammatory agents and also resection surgery. The 
most common treatments for CD are the use of synthetic antibodies against TNF-α 
or use of an alpha-4 integrin subunit. Alpha-4 integrin is expressed on leukocytes 
and controls cell migration to inflammation site. Key examples of anti-TNF-α 
antibodies include infliximab (REMICADE) and adalimumab (HUMIRA) (Bandzar 
et al 2013). The currently used alpha-4 integrin inhibitor in clinical practice is 
natalizumab (Bandzar et al. 2013). This class of CD therapies effectively control 
symptoms in some patients but fail to alleviate growth impairment shown in 
paediatric patients or induce complete remission. Moreover, recipients often 
become resistant to these therapies and use of anti-TNF-α antibodies is 
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associated with a range of adverse side effects including opportunistic infections, 
malignancy, hematologic disorders and formation of autoantibodies (Antoni and 
Braun). Corticosteroids (CS) are a well-established treatment for active CD and 
have been used widely in clinical practice for decades. Common systemic CS 
include hydrocortisone, budesonide and prednisolone (Yang and Lichtenstein 
2002). Corticosteroids down regulate production of inflammatory cytokines such as 
IL-1, IL-6, and TNF-α (Ho et al. 2006). If used correctly this class of therapy is 
cheap, safe and effective in a proportion of patients.  However CS use is linked to 
serious toxic side effects and approximately 50% of recipients fail to respond to 
CS or become steroid resistant after only one year (Tung et al. 2006, Yang and 
Lichtenstein 2002).    
 
1.5.2 Antimicrobial therapies 
A recent addition to the group of CD therapies are broad spectrum antibiotics. The 
use of antibiotics for the treatment of this complex disorder however, is highly 
controversial as their role is not clearly defined. However, recent meta-analysis 
data has indicated use of broad spectrum antibiotics as a potential primary 
treatment for CD (Khan et al. 2011). In the large cohort study (n=402) of Prantera 
et al. 62% of CD patients who received rifaximin (61 of 98) were in remission, 
compared with 43% of patients who received placebo (43 of 101). However, in this 
work disease remission required prolonged courses and high doses (800 mg for 
12 weeks) of antibiotic treatment that is associated with a range of adverse effects 
including secondary Clostridium difficile infections that is associated with disease 
relapse in a portion of patients (Huebner and Surawicz 2007).  Furthermore, 
important work carried out over the last decade, now demonstrates a strong 
association between CD development and exposure to broad spectrum antibiotics 
in early childhood (Hildebrand et al. 2008, Ungaro et al. 2014). Indeed, increased 
antibiotic exposure in childhood has been shown to increase the risk of being 
newly diagnosed with CD(Hildebrand et al. 2008). Furthermore, additional work 
that demonstrates both short-term and long-term intestinal dysbiosis induced by 
antibiotic treatment highlights a potential limitation for this class of therapy in 
patients that exhibit altered microbiota composition (Dethlefsen and Relman 2011, 
Jernberg et al. 2007).  
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Recent studies also suggest a potential role for therapies able to specifically 
manipulate the microbiota in CD patients. These include faecal transplant therapy, 
probiotics and prebiotics (Fujimori et al. 2007, Gordon and Harbord 2014). 
However, due to the lack of long-term and large cohort studies, it is difficult to 
assess the in vivo efficacy of these types of therapies. Indeed, a therapy that 
employed such a technique would be highly desirable for the treatment of 
disorders such as CD, in which targeting of a specific species of the microbiota is 
required.  
 
1.6 Bacteriocins 
1.6.1 Bacteriocins as alternative antimicrobials 
The production of antimicrobial peptides is not confined to multicellular organisms. 
Bacteriocins are ribosomally synthesised antimicrobial peptides produced by one 
bacterium that are active against other bacteria either of the same species (narrow 
spectrum) or across genera (broad spectrum) (Figure 1.7). It has been suggested 
that 30-99% of bacteria and archaea make at least one bacteriocin, however, 
advances in genome analysis will provide a more definite figure (Margaret a Riley 
and Wertz 2002). Bacteriocins show potential as novel antibiotics to specifically 
target a narrow spectrum of the bacterial population. This specificity combined with 
their unmatched potency may enable their use to treat conditions where currently 
available antibiotics are inadequate. Furthermore, genomic data can be used to 
identify large numbers of bacteriocin encoding genes in the human microbiota 
(Zheng et al. 2015). Limitations associated with the use of bacteriocins as 
antimicrobials include instability of a protein therapeutic, antigenic stimulation of 
the host immune response and also generation of resistance in target species. 
Despite this, a number of studies have demonstrated good efficacy of bacteriocins 
in vivo for the treatment of a range of bacterial infections. Bacteriocin treatments 
have been utilised as both bacteriocin producing probiotics and also as purified 
peptides. Key examples of both will now be discussed.  
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Figure 1-7: Bacteriocin production by E. coli human faecal bacterial isolate. 
Faecal E. coli isolate was spotted on eosin methylene blue (EMB) agar containing mitomycin C and 
tested against AIEC LF82 indicator strain. Zones of inhibition are shown as clearing around faecal 
E. coli spots where growth of LF82 has been inhibited.  
  
 
1.6.1.1 Bacteriocin producing probiotic strains 
A number of studies have demonstrated bacteriocins as important colonisation 
peptides that provide a competitive advantage in high cell density environments 
such as the human gut (Figure 1.9).  Important work of Hillman and colleagues 
(Hillman 1987) showed a strong correlation between the ability of Streptococcus 
mutans to colonise the human oral cavity and the production of a bacteriocin, 
mutacin 1140. It was demonstrated that a mutacin producing strain was stably 
maintained in a human subject, persisting for 14 years following a single 
administration (Hillman 1987, 2002, Hillman et al. 1998). In other work, Gillor and 
colleagues reported persistence of commensal colicin-producing E. coli in the 
mouse gastrointestinal tract (Osnat Gillor et al. 2009). Colicin producing E. coli 
were shown to produce sufficient levels of colicin to outcompete the isogenic non 
colicin-producing E. coli strain and higher numbers of colicin- producing E. coli 
were detected in the mouse GI tract at day 120 (~105  CFUs/g faeces)  compared 
to the non-producing isogenic strain (<101 CFUs/g faeces) (Osnat Gillor et al. 
2009).   
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Figure 1-8: The ecological role of bacteriocins in highly populated microbial communities. 
Figure shows the role of bacteriocins as colonising peptides (left) that are produced by probiotic 
bacteria for killing of competing microbiota to facilitate colonisation of probiotic producing bacteria. 
Right panel shows the role of bacteriocins as killing peptides; when produced by probiotic bacteria 
elicit killing against pathogenic bacteria. Adapted from Dobson et al.(Dobson et al. 2012). 
  
Other work also demonstrated the anti-infective ability of probiotic bacteriocin 
producing Lactobacillus salivarius strain UCC118 against the food-borne pathogen 
Listeria monocytogenes in the murine GI tract (Corr et al. 2007). In this work, mice 
were infected with L. monocytogenes and then orally treated with probiotic L. 
salivarius that produces bacteriocin Abp118. Oral administration of the bacteriocin 
producing probiotic significantly reduced infection by L. monocytogenes that was 
represented by reduced counts detected in the liver and spleen (Corr et al. 2007). 
This protective effect was abolished when mice received a stable mutant of L. 
salivarius UCC118 that was unable to produce bacteriocin. In a later study, oral 
administration of L. salivarius UCC118 to mice had no significant effect on the 
major phyla with comprised the microbiota, but increased numbers of Firmicutes 
were detected (Riboulet-Bisson et al. 2012). Other work reported the ability of 
colicin-producing commensal E. coli to inhibit growth of UPEC biofilms on an 
abiotic catheter surface (Trautner et al. 2005). The presence of colicin-producing 
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E. coli K-12 on the catheter surface prevented catheter colonization by colicin-
susceptible E. coli but not by colicin resistant E. coli. One possible method for the 
treatment of bacterial infections in humans, is use of probiotic species isolated 
from the healthy gut environment that produce bacteriocins active against 
pathogenic bacteria. The ability to engineer specific colicin-producing probiotic 
bacteria was recently assessed (Trivedi et al. 2014). Colicin E2 isolated from a 
bacteriocin producing vaginal Lactobacilli strain was overexpressed in the probiotic 
strain Lactobacillus brevis DT24. This strain showed superior activity against 
UPEC E. coli in vitro compared to wild-type producer strain in overlay spot plate 
assays (Trivedi et al. 2014). 
 
1.6.1.2 Activity of isolated bacteriocins 
The ability of bacteriocin producing strains to inhibit pathogenic strains in vitro has 
been extensively investigated. However, there are limited studies demonstrating a 
correlation between in vitro activity and in vivo efficacy. This represents a key 
challenge in the development of bacteriocins as an antimicrobial therapy. 
However, good activity of a purified lantibiotic bacteriocin, mersacidin, was 
demonstrated against methicillin-resistant Staphylcoccus aureus (MRSA) strain 
99308, colonising the mouse nasal epithelium (Kruszewska et al. 2004). Intranasal 
administration of mersacidin reduced S. aureus 99308 bacterial counts below the 
detection limit and also reduced production of pro-inflammatory cytokines 
(Kruszewska et al. 2004).  Additionally, bacteriocins isolated from Paenibacillus 
polymyxa and Lactobacillus salvairius showed good efficacy against 
Campylobacter jejuni infection in chickens when microencapsulated and 
incorporated into chicken feed (N J Stern et al. 2006, Norman J Stern et al. 2005).  
In this case, the use of the equivalent bacteriocin producing strains was 
unsuccessful with no detectable reduction in bacterial counts (N J Stern et al. 
2006, Norman J Stern et al. 2005).   
The treatment of antibiotic resistant bacterial infections represents a great clinical 
challenge and is one that current antibiotics frequently fail to overcome. One 
example of this is ‘superbug’ infection or hospital-acquired Clostridium difficile 
infection (CDI). CDI frequently displays resistance to multiple antibiotics, is very 
difficult to treat and hence is associated with relapse and increased risk of 
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mortality. Interestingly, a novel narrow spectrum bacteriocin, thuricin CD, isolated 
from Bacillus thuringiensis showed good activity against CDI in an ex vivo human 
distal colon model (Rea et al. 2011). Thuricin CD showed superior killing activity 
against CDI compared to the commonly used broad spectrum antibiotics 
vancomycin and metronidazole. Furthermore, unlike both of these broad spectrum 
antibiotics, thuricin CD did not significantly alter the composition of the wider 
microbiota (Rea et al. 2011). Additionally, work by Smith and colleagues reported 
activity of purified pyocins against Pseudomonas aeruginosa (Smith et al. 2012). 
P. aeruginosa forms biofilms that are highly tolerant to antibiotics and is 
associated with high mortality rates in cystic fibrosis and burns patients. In this 
work, pyocin S2 displayed superior killing activity against P. aeruginosa biofilms 
compared to the commonly used antibiotics tobramycin and azetronam (Smith et 
al. 2012). Additionally, using the waxmoth larvae model of infection, pyocin S2 
also showed good efficacy against P. aeruginosa in vivo (Smith et al. 2012). 
 
The main conclusions derived from these data are 1) bacteriocins specifically 
target pathogens and may not significantly alter other populations present in the 
environment (Rea et al. 2014) ; 2) bacteriocin producing strains produce sufficient 
levels of bacteriocin in vivo to eradicate susceptible target strains (Osnat Gillor et 
al. 2009); 3) the presence of bacteriocin producers in the environment can induce 
desirable alterations in microbial communities (Trautner et al 2005); and 4) in 
some cases bacteriocins show superior killing activity against bacterial infections 
compared to broad spectrum antibiotics currently used in clinical practice (Rea et 
al. 2011, Smith et al. 2012). Together these properties demonstrate bacteriocins 
as a putative novel, targeted therapy with highly potent activity.  
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1.6.2 Bacteriocins of Gram-negative bacteria 
The first description of bacteriocin mediated inhibition was reported approximately 
90 years ago and showed antagonism between E. coli strains (Gratia 1925). Since 
this original discovery, bacteriocin production has been reported in many bacterial 
species and is associated with both clinical and environmental isolates. Within a 
species, tens and even hundreds of bacteriocins are often produced (Margaret a 
Riley and Wertz 2002). The bacteriocin family includes a vast diversity of proteins 
in terms of size, targets, modes of action and immunity mechanisms. In general, 
the Gram-negative bacteriocins are named after the bacterial genus (klebicins of 
Klebsiella pneumonia) or after species (colicins of E. coli; cloacins of Enterobacter 
cloacae; marcescins of Serratia marcesens) (Cascales et al. 2007, Margaret a 
Riley and Wertz 2002). The bacteriocins produced by Pseudomonas aeruginosa 
are generally termed pyocins (Michel-Briand and Baysse 2002). The diversity of 
Gram-negative bacteriocins is divided into three groups: 1) large colicin-like 
bacteriocins (25-80 kDa); 2) smaller sized microcins ( <10 kDa); 3) phage tail-like 
bacteriocins that are large, multimeric peptide assemblies (Margaret a Riley and 
Wertz 2002).  The remainder of this section will focus on the colicin-like 
bacteriocins, specifically the colicins and pyocins that are the best characterised.  
 
1.6.3 Colicin-like bacteriocins 
Colicins that are produced by E. coli are the best characterised type of the colicin-
like bacteriocins (CLBs). They are described as high molecular weight (30-80 kDa) 
bactericidal proteins and are produced by a wide range of E. coli. Colicins are 
produced by E. coli strains that harbour a colicinogenic plasmid (pCol) (Cascales 
et al. 2007). These strains, termed colcinogenic strains, are widely distributed in 
nature and are detected in the human gut (Micenková et al. 2014). Over 30 
bacteriocins from E. coli have now been identified and are shown to employ 
diverse killing activities. Colicins target cells by 1) pore formation that depolarises 
the inner membrane (e.g colicin A, B, K, N, E1); 2) an endonuclease activity that 
non-specifically degrades chromosomal DNA (e.g colicin E2, E7, E8, E9); a 
ribonuclease activity that specifically cleaves 16S rRNA (e.g colicins E3, E4, E6) 
or specific tRNAs (e.g colicin D and E5) and 4) inhibition of peptidoglycan 
synthesis (colicin M) through cleavage of lipid II (El Ghachi et al. 2006). Pyocin 
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genes are chromosomally encoded and are ubiquitous among Pseudomonas spp. 
Three types of pyocins have been classified; F-type, R-type and S-type.  In a 
previous study,  R- and F-type pyocins were produced in over 90% of 
Pseudomonas aeruginosa strains and S-type, that are colicin-like bacteriocins, in 
approximately 70% of tested strains (Michel-Briand and Baysse 2002). S-type 
pyocins have been shown to kill by DNase activity (pyocin S1, S2, S3, AP41), 
tRNase activity (S4) or pore-forming activity (S5)  (Michel-Briand and Baysse 
2002, Nakayama et al. 2000, Sano et al. 1993). Other examples of colicin-like 
bacteriocins such as klebicins (Klebsiella), alveicins (Hafnia alvei) and marcesens 
(Serratia marcesens) are not as well characterised. 
 
1.6.3.1 Colicin-like bacteriocin gene organisation 
Colicin-encoding operons are comprised of three tightly linked genes (Cascales et 
al. 2007). The genetic organisation of many known colicin operons has been 
reviewed elsewhere (MA Riley 1993). Colicin gene operons are comprised of:  i) a 
colicin gene that encodes the toxin; ii) an immunity gene that encodes a protein 
conferring specific immunity to the producer cell by inactivating the toxin protein 
and iii) the lysis gene that encodes a protein (known as the lysis protein or 
bacteriocin release protein) involved in release of colicin i.e lysis of producing cell 
(Figure 1.9). Nuclease-type colicins are released as heterodimers with their 
cognate immunity protein and all other colicins are released as monomers 
(Cascales et al. 2007). In nuclease-type colicins, expression of the immunity gene 
is regulated by the promoter that controls colicin expression and also by its own 
constitutive promoter that ensures a constant level of immunity protein production 
that prevents death of the producing cell. This promoter is located within the 
structural gene for the nuclease-type colicin (Figure 1.9). In pore forming colicins, 
the immunity protein is located on the opposite DNA strand of the intergenic space 
between colicin and lysis genes and is transcribed from its own constitutive 
promoter. Some nuclease colicins (e.g E3) have additional genes within the cluster 
that provide immunity to other colicins (e.g E8) (Toba et al. 1988).   
Gene clusters of other pore forming and nuclease colicin-like bacteriocins show a 
similar organisation to pore forming and nuclease colicin gene clusters (M A Riley 
et al. 2001, Wertz and Riley 2004). For S-type pyocins, genes are also organised 
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on a single operon, however, only two open reading frames (ORFs) are present. 
The first encodes the bactericidal or toxin protein and the second encodes the 
immunity protein. Immunity genes and toxin genes of S-type pyocins are 
expressed from the same strand similar to the nuclease-type colicins. However, for 
pyocin S5 a pore forming pyocin, the immunity gene is encoded on the opposite 
strand to the pore forming colicins. Interestingly, no lysis gene has been identified 
in pyocin gene clusters (Margaret a Riley and Wertz 2002).   
 
 
Figure 1-9: Genetic organization of i) nuclease and ii) pore-forming colicins. 
The orientation of genes encoding for killing activity, immunity and lysis proteins is depicted with 
large coloured arrows. The transcriptional starts are indicated by curved arrows. The LexA-binding 
region is indicated by bolt symbol. 
 
1.6.3.2 Colicin-like bacteriocin expression 
Colicin expression is regulated by the SOS induction system mediated by the 
LexA repressor that binds to the inverted repeat sequence between the promoter 
and the ribosome binding site (Varley and Boulnois 1984). Briefly, upon DNA 
damage, the nucleoprotein filament formed by RecA binding to single stranded 
DNA, stimulates autocleavage of LexA and derepression of LexA regulatory genes 
(i.e on accessory plasmids such as colcinogenic plasmids) (Kreuzer 2013). The 
SOS response in Pseudomonas aeruginosa is more complex and is coordinated 
by LexA and two related regulators, PrtR and PtrN.  Pyocin operons do not 
possess a LexA binding box (Margaret a Riley and Wertz 2002). Pyocin production 
is initiated during the SOS response when autocleavage of PrtR derepresses PrtN. 
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PrtN then binds to the P-box in the promoter region of pyocin genes to activate 
their expression (Nakayama et al. 2000, Sano et al. 1993). The SOS response is 
triggered in cells during times of stress, more specifically bacteriocin gene 
expression is swiftly induced leading to very high levels of protein being produced 
upon DNA damage. Colicin production at the population level was investigated in 
the early study of Ozeki (1959) (Ozeki et al. 1959). This study reported that 
approximately 0.1% of colcinogenic cells produced colicin under normal conditions 
and this increased to 50% of the total population after induction by DNA damaging 
agents (Ozeki et al. 1959). A later study showed that 3% of cells in a population 
produced colicin when induced by nutrient starvation (Mulec et al. 2003).  
 
1.6.3.3 Functional domains of colicin-like bacteriocins 
Colicins are composed of three domains with each encoding a separate function. 
These are 1) the receptor binding (R) domain that is involved in binding to a 
specific surface receptor on the target cell; 2) the translocation (T) domain that 
mediates transport across the outer membrane by binding to either the Tol or Ton 
protein complexes); 3)  the cytotoxic (C) domain that possesses a specific killing 
function (Figure 1.10). The S-type pyocins also possess 3 functional domains, 
however they show different organisation and include an additional domain of 
unknown function. Organisation of domains for the majority of S-type pyocins from 
N to C- terminus is; receptor-binding domain, domain of unknown function, 
translocation domain and the cytotoxic domain (Figure 1.10). Pyocin S1 lacks the 
second domain of unknown function indicating that it is not essential for the 
cytotoxic function for this pyocin. 
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Figure 1-10: Colicin-like bacteriocins show similar organisation of functional domains. 
Colicin like bacteriocin (CLB) protein domain organization for A) colicins and B) S-type pyocins. 
Functional domains are translocation domain (T), receptor-binding domain (R), cytotoxic domain 
(C) and pyocin-specific domain (U), of as yet unknown function.  
 
 
1.6.4 Receptor binding and translocation of colicin-like 
bacteriocins 
 
1.6.4.1 Colicins translocate the outer membrane via the Tol- or TonB system 
The N-terminal translocation and central receptor binding domains of nuclease-
type colicins are highly conserved. This reflects the existence of a common 
delivery apparatus for structurally diverse cytotoxic domains.  Colicin N-terminal 
domains parasitize two distinct and conserved complexes that are essential for the 
development of the bacterial cell; Tol and TonB systems.  Group A colicins (e.g 
colicin A, E1 to E9, K, N, S4, U and Y) are translocated via the Tol-system and 
Group B colicins (colicin B, D, H, Ia, Ib, M, 5 and 10) are translocated via the TonB 
system (JK Davies and Reeves 1975).  The Tol and TonB systems are coupled to 
the proton motive force across the inner membrane and act as energy transducers 
for outer membrane (OM) stability and active transport, respectively. Colicin 
translocation is initiated by binding of the colicin to a specific outer membrane 
receptor on the cell surface.  
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1.6.4.2 Receptor binding 
Group A and group B colicins target E. coli cells by interacting with specific outer 
membrane proteins that are frequently nutrient acquisition proteins. Group A 
colicins, colicin A and E1- E9 target the TonB-dependent vitamin B12 transporter, 
BtuB (Cascales et al. 2007). Colicin K binds the nucleoside transporter Tsx and 
colicin U binds OmpA. For translocation of these colicins a second OM protein is 
required (i.e OmpF or TolC for colicin E1). For pore-forming colicins from group A, 
Cavard showed that target cells lacking BtuB could be killed if incubated in low 
osmotic strength buffers (Cavard 1976). In this case, OmpF functioned as the sole 
receptor for pore forming colicins. For group A colicins it is thought that the primary 
receptor does not function in the process of colicin translocation across the OM. 
Group B colicins also target TonB dependent transporters in the OM. These 
include ferric enterobactin receptor, FepA, (colicin B and D) and also ferrichrome 
receptor FhuA (colicin M). Additionally, colicin Ia and Ib recognise the colicin I 
receptor, Cir. In these systems only one OM protein is required for both reception 
and translocation (Jakes and Finkelstein 2010). 
 
1.6.4.3 Tol-dependent colicin translocation 
For group A colicins, all but colicin N require two OM proteins for colicin 
translocation. These proteins are the TonB dependent cell surface receptor as 
described and either OmpF or TolC. The Tol-system is comprised of 5 proteins 
that form a multiprotein complex in the cell envelope of most Gram-negative 
bacteria. The five tol genes are tolQ, tolR, tolA, tolB and pal.  Different group A 
colicins utilise distinct subsets of Tol proteins for translocation. Colicin A, E2-E9 
and K require TolABQR and colicin E1 requires the TolAQ proteins.  Structural 
data for colicin E2 and E3 bound to BtuB suggest a mechanism for colicin 
translocation across the OM (Kurisu et al. 2003, Sharma et al. 2007) (Figure 1.11). 
These data  indicate that these colicins do not utilise the central channel of BtuB 
for outer membrane translocation(Kurisu et al. 2003, Sharma et al. 2007). Instead, 
the E-type colicins are proposed to form a complex known as the translocon that is 
comprised of the outer membrane receptor, BtuB, and OmpF and TolB (Housden 
et al. 2005, Jakes and Finkelstein 2010, Zakharov et al. 2008). Translocon 
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assembly is facilitated by the unstructured region of the translocation domain, 
termed the intrinsically unstructured translocation domain (IUTD). The IUTD 
recruits the OM translocator OmpF and delivers an epitope to the periplasm in 
order to interact with TolB. Group A colicins recruit Tol proteins to the translocon 
through one or more Tol binding sites in the IUTD (Cascales et al. 2007). Tol 
proteins that are commonly required for group A colicin killing are the IM 
components of the Tol system; TolQRA. Indeed, the main target is TolA that 
makes contact with IUTD directly or indirectly via TolB (Bonsor et al. 2009).  
 
Figure 1-11: Colicin E3 and Ia binding to outer membrane receptor proteins on target cells. 
The receptor-bound colicins ColE3 (part a) and ColIa (part b) use their amino-terminal intrinsically 
unstructured translocation domains (IUTDs) to recruit the outer-membrane translocators outer-
membrane protein F (OmpF) and colicin I receptor (Cir) respectively. The signalling epitope in 
ColE3, that is shown bound to its immunity protein Im3, is the TolB-binding epitope, whereas for 
ColIa the signalling epitope is the TonB box. Reprinted by permission from Macmillan Publishers 
Ltd: Nature Reviews Microbiology, (Colin Kleanthous 2010), Copyright 2010.  
  
1.6.4.4 TonB dependent colicin translocation. 
OM translocation of group B colicins is less defined with the mechanism still 
unknown (Figure 1.11). The TonB system is comprised of an OM transporter and 3 
known inner membrane (IM) proteins; TonB, ExbB, ExbD (Lazdunski et al. 1998). 
The three IM proteins show amino acid and functional similarity to the Tol system; 
TolA, Q and R. E. coli strains that lack functional TonB show tolerance to all group 
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B colicins. In this system colicins are able to bind OM transporters but are unable 
to translocate into the periplasm (JK Davies and Reeves 1975). Structural data for 
colicin IA bound to its receptor Cir, suggests a mechanism for group B colicin 
translocation (Buchanan et al. 2007).  Following receptor binding colicin Ia recruits 
another copy of its receptor to capture TonB. For translocation, a short sequence 
located in the nutrient transporter termed the TonB box is also detected in the 
IUTC domain. Under normal conditions, binding of the TonB box by the specific 
nutrient leads to TonB recruitment from the periplasm and therefore opening of 
central pore in transporter. The presence of the TonB box in both the transporter 
(Cir) and colicin IA IUTD is required for translocation of colicin Ia (Buchanan et al. 
2007, Jakes and Finkelstein 2010).    
 
1.6.5 Immunity proteins of colicin-like bacteriocins 
Colicin-like bacteriocins are targeted against species closely related to the 
producing strain. Due to this, both the target cells and producing cells possess the 
import apparatus required for binding and translocation of the bacteriocin. 
Therefore, in order to prevent killing of the producing cell, an effective mode of 
immunity is utilised to prevent cell suicide. This mode of immunity occurs in the 
form of a small (~10 kDa) protein, termed the immunity protein (Espesset et al. 
1994). The immunity protein is highly specific for each type of colicin (Cascales et 
al. 2007).  Two distinct types of immunity proteins are detected for nuclease and 
pore-forming colicins that function by unique mechanisms. This section will briefly 
summarise the function of immunity proteins for both nuclease and pore forming 
colicins. 
1.6.5.1 Nuclease colicins 
The target of nuclease colicins is located in the cytoplasm of target cells. In this 
case, the immunity protein forms an high affinity complex with the cognate colicin 
in the producing cell that neutralises its catalytic activity (Cascales et al. 2007). 
The affinity of colicin E9 binding to its immunity protein, Im9, has been found to be 
in the femtomolar range.  This is recognised as one of the strongest associations 
observed for a complex of two proteins (Wallis et al. 1995). Immunity proteins of 
nuclease colicins bind at the cytotoxic domain of colicin but at a site distinct from 
72 
 
the active site (C Kleanthous and Walker 2001). The immunity protein binding 
region of the cytotoxic domain is the most sequence variable region of this 
functional domain that is thought to permit the evolution of novel binding 
specificities in conjunction with the maintenance of the catalytic activity of the toxin 
(C Kleanthous and Walker 2001). The interaction of enzymatic colicin E3 with its 
cognate immunity protein was revealed in previous work that proposed that 
bipartite recognition of the immunity protein by colicin facilitates disassociation of 
immunity protein from the toxin on binding to a target cell (Walker et al. 2003).  It 
was shown that binding of colE3 to BtuB, via the receptor binding domain triggered 
translocation of the T-domain into the periplasm where it forms a complex with 
TolB. The affinity of the toxin for the immunity protein is now reduced allowing it to 
dissociate from the toxin. This triggers translocation of the cytotoxic domain into 
the periplasm and ultimately the cytoplasm (Walker et al. 2003). The colicin E9 
immunity protein, Im9, binds with very high affinity and specificity to E9 DNase 
domain (Kd - 2.4x10-14 M). Energy input in the form of the cytoplasmic membrane 
proton motive force has been shown to promote Im9 release from the colicin 
E9/Im9 complex and initiate OM translocation of DNase domain (Bonsor et al. 
2009). Recent work has indicated that this cellular energy is used for unfolding and 
structural rearrangement required for membrane translocation (Vankemmelbeke et 
al. 2013). 
1.6.5.2 Pore-forming colicins  
The immunity proteins of pore forming colicins are integral membrane proteins 
with several transmembrane spanning regions (Mankovich et al. 1986). The 
cytotoxic function of pore-forming colicins is inhibited through direct interaction in 
the inner membrane. Little is known about the immunity protein residues involved 
in recognition of the lethal domains of pore-forming colicins (Cascales et al. 2007, 
YL Zhang and Cramer 1993).  Immunity proteins of pore forming colicins are 
classified into two distinct groups respective of their sequence homologies: type A) 
immunity proteins for colicins A, B, N, and U;  type E1) (immunity proteins for 
colicins E1, 5, K, 10, Ia, and Ib (Cascales et al. 2007, Espesset et al. 1994, Song 
et al. 1991). Data obtained in several independent studies over the last two 
decades has suggested that prior to formation of pore, the A-type immunity 
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proteins diffuse laterally in the membrane and interact with their cognate 
hydrophobic helical hairpins (Espesset et al. 1994, Pilsl and Braun 1995, Pilsl et 
al. 1998). For  E1-type immunity proteins, a similar mechanism is proposed but 
they are thought to interact with the voltage responsive segment of the E1-type 
colicin instead of the hydrophobic helical hairpin (Lindeberg and Cramer 2001, 
Pilsl and Braun 1995). 
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1.7 Aims and Hypothesis 
1.7.1 Hypothesis 
The hypothesis for this work is that colicins would show good activity against AIEC 
strains associated with CD. We hypothesised that these potent and narrow-
spectrum antibiotics would display good efficacy against AIEC infection in vitro and 
in vivo and hence may represent a potential antimicrobial therapy for CD patients 
that display gut dysbiosis involving enriched mucosa-associated E. coli.  
 
1.7.2 Aims 
The aim of this work is to demonstrate the potential of colicins as novel 
antimicrobial therapeutics for the treatment of CD-associated AIEC infection. This 
aim will be achieved by: 
1) Assessing the efficacy of colicins against AIEC in vitro. 
 AIEC adhere to and invade intestinal epithelial cells and survive within 
macrophages, inducing production of pro-inflammatory cytokines. Investigation of 
colicin activity against AIEC associated with mammalian cells will provide good 
insight into the efficacy of colicins against this distinct E. coli pathotype.  
2) Assessing the efficacy of colicins against AIEC in vivo. 
 AIEC abnormally colonise the gut mucosa of a portion of CD patients and this is 
associated with disease pathogenesis. Investigating colicin activity against AIEC 
growing in the murine gastrointestinal tract will demonstrate the efficacy of colicins 
as a future antimicrobial therapy against intestinal infection.  
3)        Assess the prevalence of AIEC-associated phenotypes in E. coli 
isolated from HLA-B27 (+) juvenile idiopathic arthritis (JIA) patients 
 JIA is a juvenile spondyloarthropathy (SpA). SpAs, associated with HLA-B27 
genotype, demonstrate clinical overlap with CD. Gut dysbiosis involving increased 
E. coli is associated with the HLA-B27 genotype. To ascertain the association of 
AIEC with HLA-B27 genotype, the prevalence of AIEC in HLA-B27 (+) patients will 
be investigated. This work will demonstrate the wider applicability of colicins 
against AIEC overgrowth in other inflammatory gut-associated disorders.  
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2 Materials and methods 
2.1 Chemicals, growth media and strains 
2.1.1 Chemicals 
All chemicals used in this study were of analytical grade and were purchased from 
Sigma-Aldrich, Thermo Scientific, Invitrogen or Melford unless otherwise stated. 
 
2.1.2 Strains  
The bacterial strains used in this study are described in Table 2.1 
Table 2-1: Strains used in this study 
Strain Genotype or description Reference or source 
LF82 AIEC reference strain. Isolated from ileal biopsy 
of CD patient. 
Kindly donated by 
Arlette Darfeuille-
Michaud (A Darfeuille-
Michaud et al. 2004) 
LF82-GFP WT LF82 strain harbouring pDM15 plasmid that 
encodes gfpmut2 gene 
Constructed by Karen 
Smith, Walker lab 
LF82::StrpR Streptomycin resistant WT LF82 strain that 
harbours a K42T mutation in rpsL that confers 
streptomycin resistance. Strain also harbours 
chromosomal integration vector containing a 
synthetic lux operon at 16S rRNA region that 
confers erythromycin resistance.  
 
Kindly donated by 
Marjenberg and Douce 
(University of Glasgow) 
HM95 Colonic mucosally-associated AIEC strain 
isolated from ileal CD patient 
University of Liverpool 
(Martin et al. 2004) 
HM154 Colonic mucosally-associated AIEC strain 
isolated from colonic CD patient. 
University of Liverpool 
(Martin et al. 2004) 
HM419 Colonic mucosally-associated AIEC strain 
isolated from ileo-colonic CD patient. 
University of Liverpool 
(Martin et al. 2004) 
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HM580 Colonic mucosally-associated AIEC strain 
isolated from colonic CD patient 
University of Liverpool 
(Martin et al. 2004) 
 
HM605 Colonic mucosally-associated AIEC strain 
isolated from colonic CD patient 
University of Liverpool 
(Martin et al. 2004) 
HM615 Colonic mucosally-associated AIEC strain 
isolated from colonic CD patient 
 
University of Liverpool 
(Martin et al. 2004) 
DH5α F-, φ80dlacZΔM15, Δ (lacZYA-argF) 
U169, deoR, recA1, endA1, hsdR17(rk-, 
mk+), phoA, supE44, λ thi-1, gyrA96, relA1 
 
Invitrogen 
BL21(DE3)pLysS F- ompT hsdSB (rB-mB-) gal dcm (DE3) pLysS 
(CamR) 
Invitrogen 
K-12 W3110 F- lambda- IN(rrnD-rrnE)1 rph-1 (Bachmann 1972) 
F18 Commensal E. coli strain isolated from human 
intestine 
Kindly donated by Donal 
Wall (University of 
Glasgow) (Wall et al. 
2007) 
BZB2101 E. coli K12 W3110 (Wild type) gyrA, pColA-
CA31 
(Pugsley 1985) 
BZB2102 E. coli K12 W3110, pColB-K260 (Pugsley 1985) 
BZB2104 E.coli K12 W3110, pColE1-K53, Tra- Mob+ (Pugsley 1985) 
BZB2108 E. coli K12 W3110, pColE5-099 Tra-, Mob+ (Pugsley 1985) 
BZB2103 E. coli K12 W3110, pColD-CA23 (Pugsley 1985) 
BZB2123 E. coli K12 W3110 gyrA, pColN-284, Tra- Mob+ (Pugsley 1985) 
BZB2114 E. coli K12 W3110 gyrA, pColIa-CA53, Tra (Pugsley 1985) 
BZB2115 E. coli K12 W3110 gyr, pCollb-P9drd (Pugsley 1985) 
BZB2125 E. coli K12 W3110 gyrA, pColE2-P9 (Pugsley 1985) 
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2.1.3 Growth media 
Lysogeny broth (LB) was prepared in dH2O using the recipe shown and was 
adjusted to pH 7.5 and sterilised by autoclaving (Table 2.2). MacConkey agar and 
EMB agar were purchased and were prepared as per manufacturer’s instructions 
(Sigma-Aldrich).  
 
Table 2-2: Growth media used for cultivation of bacterial strains and mammalian cell lines in 
this study. 
 
Media 
 
 
Composition / Source 
 
Sterilisation 
Lysogeny broth (LB)  
 
10 g Tryptone, 10 g NaCl, 5 g 
yeast extract, 1 L dH2O 
Autoclave at 121ºC for 
15 min  
 
LB agar 10 g Tryptone, 10 g NaCl, 5 g 
yeast extract, 15 g nutrient 
agar, 1 L dH2O 
Autoclave at 121ºC for 
15 min  
 
Eosin methylene blue 
agar 
Sigma Autoclave at 121ºC for 
15 min  
 
MacConkey agar Sigma Autoclave at 121ºC for 
15 min  
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2.2 Bacteria cultivation techniques 
2.2.1 Storage of bacteria 
One millilitre aliquots of frozen bacterial stocks were made by adding 500 µl of 
glycerol to 500 µl of an overnight LB culture and storing in cryo tubes at -80C. 
 
2.2.2 Growth of bacteria 
All strains were inoculated into LB or onto agar plates with the appropriate 
antibiotics. When required, ampicillin was added at 100 µg ml-1, kanamycin was 
added at 50 µg ml-1, streptomycin added at 100 µg ml-1 and erythromycin at 500 
µg ml-1. Cultures were propagated from a single colony and grown at 37C with 
shaking. 
 
2.3 Molecular techniques  
2.3.1 Extraction of genomic DNA 
Bacterial cells were pelleted from 1 ml of overnight LB cultures grown at 37C. 
Genomic DNA (gDNA) was extracted using the Qiagen QIAamp DNA Mini kit 
(Qiagen, UK), as per the manufacturer’s instructions. DNA was resuspended in 
200 µl of distilled water and stored at -20C until required. DNA was quantified 
using a Nanodrop spectrophotometer 
 
2.3.2 Preparation of plasmid DNA 
Bacterial cells were pelleted from 5 ml of overnight LB cultures grown at 37C. 
Plasmid DNA was extracted using the QIAprep Spin Miniprep kit (Qiagen, UK), as 
per the manufacturers instructions. DNA was resuspended in 30 µl of elution 
buffer (10 mM Tris-HCl, pH 8.5) and stored at -20C until required. 
 
2.3.3 Polymerase chain reaction 
A typical PCR used 1 µl Pfu turbo (Agilent, UK) with 0.2 µM forward and reverse 
primers, 100 ng genomic DNA and 200 µM dNTP mix in a final volume of 50 µl. 
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reaction. The standard PCR protocol used in this study is shown in Table 2.3. If 
initial conditions did not yield the desired product the reaction was optimised by 
the inclusion of 5 - 10% dimethylsulfoxide (DMSO) and variation of the annealing 
temperature. 
For colony PCR a single bacterial colony was resuspended in 25 μl of distilled 
water, and incubated at 96°C for 5 min. The lysate was centrifuged and 5 μl of the 
supernatant was added to 95 µl of water and 1 µl was used as DNA template in 
the PCR reaction described above. 
 
Table 2-3: Standard PCR protocol 
Step Temp (°C) Time (s) Cycles 
Initial denaturation 95 120 1  
Denaturation 95 30  
18-30* Annealing 58 30 
Extension 72 60 / kb 
Final extension 72 600 1 
Hold 4 -  
 
*30 cycles used for standard PCR and 18 cycles used for PCR mutagenesis. 
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2.3.4 Primers 
All primers used in this study were synthesised by Eurofins MWG Operon. Primers 
listed in Table 2.4 were used to amplify DNA. Appendix A shows DNA sequence 
for colicin E9H575A mutant.  
Table 2-4: Primers used in this study 
Name 
Restriction 
enzyme site 
Sequence 5’ to 3’ 
 
Colicin 
E9H575AF 
(mutagenesis) 
 
NcoI  
ACT ACA CCT AAG CGA GCT ATC GAT ATT CAC CGA 
GGT AAG  
Colicin 
E9H575AR 
(mutagenesis) 
XhoI 
CTT ACC TCG GTG AAT ATC GAT AGC TCG CTT AGG 
TGT AGT 
Colicin E9-RFPF NcoI  
GTT GAC GTC CAT GGC CTC CAC CGA GGA CGT 
CAT CAC CGA) 
Colicin E9-RFP XhoI 
CCA CTG TGC TCG AGC AGG AAC AGG TGG TGG 
CGG CCC TCG 
88F -  AYTGGGYDTAAAGNG 
91R  - CCCGTCAATTYYTTTRAGTTT 
Y, C/T; N, A/T; R, A/G  
 
2.3.5 PCR mutagenesis 
Constructs to express the colicin E9 mutant H575A were created using the 
QuikChange Site Directed Mutagenesis kit (Stratagene) as per manufacturer’s 
instructions, utilising pCS4 as template and E9H575AF and E9H575AR 
mutagenesis primers (See Appendix A for peptide sequence) (Garinot-Schneider 
et al. 1996). 
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2.3.6  Agarose gel electrophoresis 
For a 0.8% (w/v) agarose gel, 0.8 g of agarose was added to 100 ml 100mM Tris-
Hydrochloride, pH 8.2 / 7.7 mM Borate/ 2.5 mM ethylenediaminetetraacetic acid 
(EDTA) (TBE) buffer. This was heated until the agarose dissolved and allowed to 
cool to approximately 42ºC. GelRED gel stain (Cambridge Biosciences, UK) was 
added 1:10,000 and the gel poured into the gel tray to set. The appropriate volume 
of 6x loading buffer (10 mM Tris-HCl pH 7.6 0.03% bromophenol blue, 
60% glycerol, 60 mM EDTA was added to DNA samples prior to loading and the 
gel was run at 200 mA for 45 min. The 100bp or 1 kb+ size marker (New England 
Biolabs Inc (NEB), UK) was used to determine the size of sample bands and gels 
were visualised using an UVIpro gold Uvitec transilluminator (Uvitec, UK). 
 
2.3.7 Restriction enzyme digest 
A typical digest reaction consisted of 1 µg of prepared DNA, restriction enzyme 
digestion buffer, 10 U restriction enzymes and distilled water to final volume of 25 
µl. The reaction was mixed and incubated at 37ºC for 1 hr. The digest products 
were subjected to agarose gel electrophoresis to visualise and purify fragments. 
 
2.3.8 DNA gel purification 
Bands of interest were excised from 0.8% agarose gels and were purified using 
the Qiagen Gel Extraction Kit (Qiagen, UK), as per the manufacturer’s instructions. 
The purified DNA was eluted into 30 µl of elution buffer (10 mM Tris-HCl, pH 8.5) 
and stored at -20°C. 
 
2.3.9 DNA sequencing and identification of bacterial strains  
DNA for sequencing was prepared using Qiagen Gel Extraction Kit (Qiagen, UK) 
as described. Sequencing reactions required 50-200 ng of DNA and were 
performed by Source Bioscience Sequencing (Glasgow; UK). For sequencing of 
16S rRNA and identification strains, nucleotide sequences were compared with 
other strains by using NCBI BLAST analysis.  
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2.3.10 Ligation reaction 
A typical ligation reaction consisted of 50 ng digested plasmid, 10x DNA ligase 
buffer and 5 U T4 DNA ligase (NEB; UK). Insert was added at a 1:1 and 1:3 molar 
ratio (plasmid: insert). The reaction was incubated at room temperature overnight 
and then used in transformation reactions. 
 
2.3.11 Transformation of E. coli  
Five microlitres of ligation reaction or 1 µl of plasmid was added to 50 µl of 
chemically competent E. coli BL21 (DE3) pLysS, Top 10 or DH5 cells and 
incubated on ice for 30 min. Cells were then heat shocked at 42°C for 45 s or 30 s 
(Top 10) and then placed on ice for 5 min. Five hundred microlitres of LB broth 
was added to the cells and incubated shaking at 37°C for 1 h. The cells were then 
plated onto LB agar plates containing appropriate antibiotic and incubated 
overnight at 37°C. 
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2.3.12 Plasmids 
The plasmids used in this study are described in Table 2.5.  
Table 2-5: Plasmids used in this study. 
Plasmids Description Reference or source 
PCs4 
Colicin E9-Im9 expression plasmid, 
AmpR, IPTG-inducible T7 promoter 
(Garinot-Schneider et al. 
1996) 
pDM15 
KanR expression vector, Cp25 
promoter, encodes gfpmut2 gene 
Kindly donated by John 
Butcher, University of 
Glasgow 
pAR5 
Encodes RFP-tagged colicin 
constructed by amplification of the 
RFP gene using primers RFPF and 
RFPR 
Kindly donated by Angela 
Rinaldi, Walker lab, 
Univeristy of Glasgow  
 
2.4 Microbiology 
2.4.1 Overlay spot plate method 
Soft agar overlay spot plates were performed using the method of Fyfe et al. (Fyfe 
et al. 1984). One hundred and fifty microlitres of log phase test strain culture 
(OD600= 0.6) was added to 6 ml of 0.8% soft agar and overlayed on LB agar plate. 
Five microlitres of purified colicin, at varying concentrations, was spotted onto 
overlay plates and incubated for 18 h at 37°C. Clear zones indicate killing. 
Colicin production of E. coli strains was assessed via adapted overlay spot plate 
method. Five µl of log phase test strain culture (OD600 = 0.6) was spotted onto an 
LB agar plate containing mitomycin C (0.75 µM) and incubated overnight at 37°C. 
The cells were lysed using chloroform and the chloroform allowed to evaporate 
before 50 µl of the required indicator strain culture (adjusted to OD600 = 0.6) was 
added to 5 ml of soft agar (0.8% agar in distilled water) and poured over the LB 
agar plate (containing the lysed cells). Plates were incubated overnight at 37°C 
and diameter of inhibition zones was measured. 
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2.4.2 Minimum inhibitory concentration assay 
MIC assay with serial broth microdilution was used to determine antimicrobial 
susceptibility, in sterile 96-well plates (Corning). In the first column, a starting 
concentration of test compound was prepared in LB (180 µl) in triplicate. Serial 2-
fold dilutions were performed for each test compound in subsequent columns. 
Overnight cultures were diluted in sterile PBS to OD600= 0.6. The bacterial cultures 
were then diluted 1000-fold in LB and 20 μl of the final solution was added to each 
well of the 96-well plate within 30 min of inoculum preparation. The microtitre 
plates were then wrapped in parafilm and incubated at 37°C for 18 – 24h. The 
lowest concentration at which there was no visible growth (the first clear well), was 
taken as the MIC of the test compound.  
 
2.5 SDS-PAGE and silver staining 
Samples were mixed 4:1 in sample buffer (62.5 mM Tris-HCl pH 6.8, 2.5% sodium 
dodecyl sulphate (SDS), 0.002% bromophenol blue, 0.7135 M (5%) β-
mercaptoethanol, 10% glycerol), boiled at 95°C for 10 min and 15 µl loaded onto a 
sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE) of the appropriate size 
(typically 12% or 18% gels). Broad range protein markers (2 - 212 kDa, NEB, UK) 
or broad range ColourPlus Prestained protein markers (10 - 230 kDa, NEB, UK) 
were used throughout. SDS-PAGE gels were stained using Coomassie stain (500 
ml dH2O, 400 ml methanol, 100 ml acetic acid, 0.5 g Coomassie blue R250) and 
destained with destain solution (500 ml dH2O, 400 ml methanol, 100 ml acetic 
acid).  
 
2.6 Western blotting 
For preparation of protein samples, log phase cultures (OD600 = 0.6) were 
centrifuged at 1700 g for 10 min and cell pellets were resuspended in PBS and 
heated at 65°C to liberate cell surface Ag43α domain. Following SDS PAGE (10% 
polyacrylamide) proteins were transferred from the gel onto nitrocellulose 
membranes using an ECL semi dry transfer unit at 30 mA for 1 h. After the transfer 
the membrane was blocked in blocking buffer consisting of 20 mM Tris HCl, 200 
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mM NaCl, 0.01% (v/v) Tween, 5% (w/v) skimmed milk (Marvel; UK) for 2 hours at 
room temperature. A polyclonal rabbit antiserum raised against the α-domain of 
Ag43 (1:2000) was applied to the nitrocellulose membrane for 1 h at room 
temperature and agitated. Excess unbound antibody was washed from membrane 
using 20 mM Tris HCl, 200 mM NaCl, 0.01% (v/v) Tween. The membrane was 
then incubated with a goat anti rabbit secondary antibody (1:10,000) coupled with 
horseradish peroxidase (HRP) for 1 h shaking at room temperature and washed 
as described above. The blot was developed using enzyme-linked 
chemiluminescence (ECL) with SuperSignal West Pico chemiluminescent 
substrate (Thermo Scientific, UK). 
 
2.7 Protein purification 
2.7.1 Overexpression and purification of recombinant colicin 
protein E9 
Tandom overexpression of colicin E9 in complex with it’s His6-tagged immunity 
protein (Im9) was performed as previously described (Garinot-Schneider et al. 
1996). Colicin E9-Im9His6 was overexpressed from E.coli BL21 (DE3) cells 
carrying the plasmid pCS4. 5 L of LB broth was inoculated (1:100) and overnight 
culture and cells were grown at 37°C in shaking incubator to an OD600 =0.6. 
Protein production was induced by addition of 1 mM IPTG and cells were grown 
for further 4 h and harvested by centrifugation. The cell pellet was re-suspended in 
200 mM Tris-HCl and 500 mM NaCl containing 10 mM imidazole pH 7.5. Cells 
were lysed using MSE Soniprep 150 (Wolf laboratories, UK) and cell debris 
separated by centrifugation. The cell-free lysate was applied to a 5 ml His trap™ 
HP column (GE healthcare, USA) and the protein eluted over a 0-350 mM 
imidazole gradient. E9-Im9 (His6) containing fractions were dialysed overnight into 
50 mM Tris-HCl, 200 mM NaCl and the protein was further purified by gel filtration 
chromatography on a Superdex S75 26/60 column (GE Healthcare) equilibrated in 
50 mM Tris-HCl, 200 mM NaCl pH 7.5. The protein was stored at -20°C in this 
buffer until required. E9H575-Im9 (His6) was purified as described above. 
Purification of E9-RFP was performed by Angela Rinaldi (Walker lab; Appendix B).  
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2.7.2 Purification of colicin E1  
Purification of colicin E1 was performed as previously described (SA Schwartz and 
Helinski 1971). E. coli BZB2104 (pColE1-K53) was sub-cultured overnight in LB 
broth at 37°C. The culture was used to inoculate 6 x 625 mL LB culture that was 
grown to log-phase (OD600=0.6) and then induced with mitomycin C (0.4 µM) and 
incubated at 37°C for 18 h. The cultures were collected by centrifugation at 6360 g 
for 30 min and supernatant was retained. The supernatant was re-suspended in 
ammonium sulphate (404 g/L) for 45 min at 4°C and centrifuged as described 
previously. The pellet was re-suspended in 50 mM Tris 200 mM NaCl buffer pH 
7.5. The sample was collected in a porous membrane and dialysed for 18 h in 5 L 
of 50 mM Tris pH 8.0 at 4oC. The next morning the sample was dialyzed in fresh 
buffer for 3h and cell debris was removed by centrifugation for 20 min at 6360 g 
and 4°C. The protein was purified using anion exchange column constructed 
following manufacturers guidelines (DE52 preswollen microgranular DEAE 
cellulose, Whatman) and eluted on a 0-1 M NaCl gradient using an Akta-purifier 
chromatography system (GE Healthcare, USA) The protein was detected in elution 
flow through that was concentrated by centrifugation using Vivaspin® centrifugal 
concentrator (GE Healthcare Life Sciences) and further purified by gel filtration 
chromatography on a Superdex S75 26/60 column (GE Healthcare) equilibrated in 
50 mM Tris-HCl, 200 mM NaCl pH 7.5. The protein was stored at -20°C in this 
buffer until required. The total protein was evaluated by SDS-PAGE (12% 
polyacrylamide) (Appendix C).  
 
2.7.3 Lipopolysaccharide removal from purified proteins 
Removal of lipopolysaccharide (LPS) from colicin protein was performed using 
polymyxin B-agarose columns (Detoxi Gel, Pierce) according to manufacturer’s 
recommendation. One ml of purified colicin E9 (3 mg ml-1) was loaded onto each 
0.5 ml Detoxi column and incubated at room temperature for 60 min. The protein 
was then eluted with endotoxin free water in 1 ml fractions. Fractions were pooled 
and stored at -20°C. 
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2.8 Tissue culture 
2.8.1 T84 cells 
The T84 colon carcinogen cell line obtained from the American Type Culture 
Collection (ATCC #CCL-248) was maintained in a 50:50 mixture of Dulbecco’s 
Modified Eagle’s Medium (DMEM) and Hams F-12 Medium (both Sigma) 
supplemented with 10% FBS, 2 mM L-glutamine, 15 mM HEPES buffer (pH 7.5), 
14 mM sodium bicarbonate and 2% penicillin (200 U/ml) /streptomycin (200 µg ml-
1) (Sigma-Aldrich). Media was changed every 2 days and cells were grown for 6-9 
days before being used in assays. Confluent T84 monolayers were subcultured by 
0.25% trypsin + EDTA (Invitrogen) treatment. Experiments that required infection 
of T84 cells were performed using antibiotic-free medium. T84 cells were 
passaged after reaching 70% confluency.  
 
2.8.2 RAW 264.7 cells 
RAW 264.7 macrophages obtained from the European Collection of Authenticated 
Cell Cultures (ECACC # 91062702) were cultured in RPMI-1640 media (Sigma) 
supplemented with 10% FBS, 2 mM L-glutamine and 2% penicillin (200 U/ml) 
/streptomycin (200 µg ml-1) (all Sigma). RAW 264.7 cells were maintained at 37°C 
at 5% CO2. The media was replaced daily. When cells reached 90% confluency, 
old media was replaced and cells were split using cell scrapers (Invitrogen) that 
were used to dislodge cells from the bottom of the flask. The cells were counted 
using a haemocytometer and then seeded at the appropriate density into a new 
flask. The cell line was used between 3-30 passages. 
 
2.8.3 J774.1 cells 
J774A.1 mouse BALB/c macrophages (ECACC # 91051511) were grown in RPMI-
1640 media supplemented with 10% FBS, 2% penicillin (200 U/ml) /streptomycin 
(200 µg ml-1) and 2 mM L-glutamine (all Sigma). Cells were kept in a humidified 
incubator at 37°C with 5% CO2. Media was replaced daily. When cells reached 
90% confluency, old media was replaced and cells were split using cell scrapers 
(Invitrogen) that were used to dislodge cells from the bottom of the flask. The cells 
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were counted using a haemocytometer and then seeded at the appropriate density 
into a new flask. The cell line was used between 3-30 passages. 
 
2.9 Colicin treatment of mammalian cells 
2.9.1 Intracellular colicin killing assay 
Investigation of colicin activity against intramacrophagic LF82 was measured by 
the gentamicin protection assay (Falkow et al. 1987). RAW 264.7 macrophages (2 
x 105 /well) were seeded on to 24-well plates (Corning) and were grown for 18 h to 
confluency. Prior to infection of cells, bacteria were washed and re-suspended in 
antibiotic-free RPMI-1640 media and added to cells at a multiplicity of infection 
(MOI) of 50. After 2 h infected macrophages were washed with PBS and exposed 
to RPMI media containing gentamicin (100 µg ml-1) to kill extracellular bacteria that 
had failed to invade macrophages. After 1 h, the media was removed and 
macrophages were then treated with culture media containing antimicrobial 
treatments in the presence of gentamicin (20 µg ml-1) at 37°C, 5% CO2. For LF82 
growth curves, media was free from antimicrobial treatments and was replaced 
every 24 h. Antimicrobial treatments used were colicin E9, colicin E1 and the 
antibiotic ciprofloxacin (100 µg ml-1). After incubation with antibiotic for desired 
time point, RAW264.7 cells were washed three times with sterile PBS. If colicin 
was added, macrophages were also treated with trypsin (0.25%) in EDTA for 5 
min at 37°C. This was to ensure all macrophage bound colicin protein was 
inactivated. The macrophages were then scraped from the surface of the plate and 
lysed with 2% Triton X-100 for 5 min.  Recovered intracellular bacteria were 
quantified by plating serial dilutions on LB agar containing ampicillin (50 µg ml-1). 
The plates were incubated overnight at 37°C and CFU counts were performed. 
Bacterial survival in RAW 264.7 cells (% survival) were calculated as a % of viable 
internalised bacteria relative to the number recovered from untreated cells infected 
with LF82, considered as 100%.  
 
2.9.2 Colicin killing of cell-associated E. coli 
To assess efficacy of colicin against LF82 associated with T84 monolayers, 
adhesion assays were performed. T84 cells were grown in 24 well plates for 3-5 
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days at 37°C in 5% CO2 until an epithelial monolayer was formed. Prior to 
adhesion assays T84 cell monolayers were washed with sterile PBS.  LF82 were 
grown to OD600 = 0.6 in LB broth and resuspended in DMEM culture and added to 
cells at a multiplicity of infection (MOI) of 10 for 3 h at 37°C, 5% CO2. To assess 
antimicrobial killing of adherent bacteria, colicin E9 and the antibiotic ciprofloxacin 
were diluted in DMEM culture media to concentrations of 100 µg ml-1 and added to 
separate wells at 15, 30, 45 and 60 min post infection. After 3 h, monolayers were 
washed three times with sterile PBS to remove non-adherent bacteria and treated 
with trypsin (0.25%) in EDTA for 10 min at 37°C. The cell suspension was 
removed by aspiration and homogenised by passing through a 22-gauge needle. 
Cells were lysed by sonication and cell-associated LF82 were serially diluted and 
plated on LB agar plates containing ampicillin (50 µg ml-1). Plates were incubated 
overnight at 37°C and CFU counts were performed. All adhesion assays were 
repeated in triplicate.  
To assess inhibition of LF82 adhesion by colicin producing commensal E. coli, co-
culture adhesion assays were performed using LF82 and E. coli BZB2104 
(pColE1-K53). For co-culture assays, bacteria were added in equal volumes at a 
MOI of 10 for 3 h and number of cell-associated LF82 were determined as stated 
before. 
 
2.9.3 Photomicroscopical analysis of T84 cell morphology 
For photomicroscopy T84 cell monolayers were grown on glass coverslips in 6 
well plates (Corning) for 5-7 days. Cells were infected with LF82 (MOI of 10) and 
when required were treated with colicin E9 (100 µg ml-1) 15 min post infection. 
After 3 h monolayers were washed three times with sterile PBS and fixed with 10% 
methanol in PBS for 10 min. Cells were washed again in sterile PBS as above and 
then Giemsa stained (20% (v/v) Giemsa in dH2O) for 20 min at room temperature. 
Cover slips were washed and mounted on slides using clear nail varnish solution. 
Images were captured using Zeiss Axioskop attached to QImaging Micropublisher 
3.3 RTB camera at 40 x magnification.  
 
2.9.4 Confocal microscopy 
 In order to visualise colicin and bacteria associated with cells, RAW 264.7 
macrophages were seeded (2 x 105/well) on glass cover slips in 6 well plates 
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(Corning) and grown to confluency for 18 h at 37°C. Culture media used for 
infection contained 50 µg ml-1 kanamycin to select for growth of the GFP-
expressing LF82 strain. Where required, macrophages were infected with LF82-
GFP (MOI of 50) for 2 h and exposed to culture medium (RPMI-1640, FBS, L-
glutamine and kanamycin) containing gentamicin (100 µg ml-1) for 1 h to ensure 
killing of extracellular bacteria. Cells were treated with culture media containing 
colicin E9-RFP (100 µg ml-1) and gentamicin (20 µg ml-1) for the required time. 
Infected cells were washed three times in sterile PBS and treated with 0.25% 
trypsin in EDTA for 5 min at 37°C to inactive extracellular colicin E9-RFP. RAW 
264.7 macrophages were washed as above to remove macrophage bound protein 
and fixed with 2% paraformaldehyde (PFA) in PBS and 0.5 M sucrose for 10 min 
at room temperature. Fixed cells were permeabilised with 0.5% Triton X-100 for 3-
5 min at room temperature. Actin cytoskeleton was stained using Alexa-647 
labelled phalloidin (Life Technologies) and nuclear DNA was stained with 4',6-
diamidino-2-phenylindole (DAPI) (Life Technologies). Cover slips were air dried 
and mounted on slides with Dako Mounting Medium (Dako UK). Slides were 
examined using a Zeiss LSM410 Laserscan Microscope equipped with periphera 
argon-UV laser. Image processing was performed using the LSM Image Browser 
software (Zeiss).  
 
2.9.5 Drug treatment of macrophages 
The following drugs were purchased from Sigma Aldrich and used as described 
previously (Marina-García et al. 2009). Cytochalasin B, that blocks phagocytosis, 
was used at 10 µg ml-1; polyinosinic acid, that blocks scavenger receptor mediated 
endocytosis was used at 50 µg ml-1; dynasore that blocks clathrin mediated 
endocytosis was used at 80 µM; dimethylamyloride (DMA) that blocks pinocytosis 
was used at 500 µM and mannan that blocks mannose receptors was used at 1 
mg ml-1. RAW 264.7 cells were treated with specific drug for 30 mins and then 
treated with colicin E9-RFP for 4 h and visualised by confocal microscopy as 
stated.  
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2.9.6 Enzyme linked immunosorbent assay (ELISA) for detection 
of tumour necrosis factor-α 
RAW 264.7 macrophages were infected and treated as described. At various time 
points, post-infection supernatants were collected and assayed for TNF-α by 
cytokine ELISA kits (BioLegend). Optical density was determined at wavelength 
450nm and cytokine concentration was determined as by manufacturer’s 
instructions.  
 
2.9.7 Lactate dehydrogenase hydrogenase cytotoxicity assay 
 For RAW 264.7 macrophages cytotoxicity was determined by LDH release. 
Lactate dehydrogenase (LDH) activity as a measure of cytoxicity was measured in 
cell supernatants according the manufacturer’s protocol (LDH Cytotoxicity Assay 
Kit, Abcam). LDH release was measured colormetrically according to 
manufacturer’s protocol. % Cytotoxicity = (Compound treated LDH activity – 
Spontaneous LDH activity) / (Maximum LDH activity – Spontaneous LDH activity) 
x 100. 
 
 
2.10   Isolation of clinical E. coli isolates 
2.10.1 Ethics statement 
Stored stool samples were provided from ongoing and past studies exploring the 
role of gut microbiota in health and disease. All participants and their legal carers 
provided written informed consent for their stored samples to be used in future 
studies that explore the role of gut microbiota in health and disease. The studies 
were approved by the West of Scotland Research Ethics committee and the local 
health board Research and Development office and participants were recruited 
according to the Good Clinical Practice standards for research. R&D reference 
number: GN11KH060. 
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2.10.2 Stool samples 
Patients were recruited in a pilot study of Dr Konstantinos Gerasimidis 
investigating gut microbiota composition of juvenile idiopathic arthritis (JIA) 
patients (Yorkhill Children’s foundation; University of Glasgow). Patient recruitment 
and stool collection was performed between April 2011 and October 2012. The 
age range of patients was 3 -14 years old. Stool samples from 25 HLA-B27 
negative JIA patients and 10 HLA-B27 positive JIA patients were kindly donated 
(Table 2.6). Stool samples of 35 healthy patients were also also kindly donated. All 
samples were age and sex matched and samples were labelled blind for all 
assays.  Stool samples were stored at -80ºC.  
 
Table 2-6: Table showing JIA and healthy patient stool samples used in this work. 
Healthy control samples JIA patient samples 
Patient HLA-B27 
Study sample 
no 
Patient HLA-B27 
Study sample 
no 
   
  
  
PWS029 Negative 1 JIA017 Negative 21 
PWS035 Negative 2 JIA024 Negative 22 
PWS070 Negative 3 JIA029 Negative 23 
PWS082 Negative 4 JIA034 Positive 24 
PWS116 Negative 5 JIA042 Positive 25 
PWS118 Negative 6 JIA049 Negative 26 
PWS126 Negative 7 JIA006 Positive 29 
PWS139 Negative 8 JIA021 Negative 30 
PWS073 Negative 10 JIA031 Negative 31 
PWS030 Negative 11 JIA036 Positive 32 
PWS032 Negative 12 JIA041 Negative 33 
CHIC449 Negative 13 JIA046 Negative 34 
CHIC443 Negative 14 JIA052 Negative 35 
CHIC439 Negative 15 JIA058 Negative 36 
CHIC441 Negative 16 JIA008 Positive 37 
CHIC428 Negative 17 JIA023 Negative 38 
CHIC419 Negative 18 JIA032 Positive 39 
PWS085 Negative 19 JIA038 Positive 40 
PWS092 Negative 20 JIA039 Negative 61 
CHIC451 Negative 41 JIA045 Negative 62 
CHIC459 Negative 42 JIA051 Positive 63 
CHIC462 Negative 43 JIA062 Negative 64 
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PWS105 Negative 44 JIA009 Negative 65 
CHIC429 Negative 45 JIA022 Negative 66 
CHIC461 Negative 47 JIA027 Negative 67 
CHIC458 Negative 48 JIA035 Negative 68 
PWS142 Negative 49 JIA040 Negative 69 
CHIC446 Negative 50 JIA050 Negative 70 
CHIC467 Negative 51 JIA059 Negative 72 
CHIC427 Negative 52 JIA019 Positive 73 
CHIC457 Negative 53 JIA026 Negative 74 
CHIC463 Negative 54 JIA030 Negative 75 
CHIC435 Negative 57 JIA033 Negative 76 
CHIC465 Negative 59 JIA043 Negative 77 
 JIA053 Negative 78 
JIA048 Negative 80 
JIA061 Negative 81 
JIA063 Negative 82 
JIA064 Negative 83 
JIA065 Negative 84 
 
 
2.10.3 Isolation of faecal E. coli 
0.1 g of stool sample was mixed in one hundred microliters of sterile PBS and 
vortexed thoroughly until a faecal slurry was produced.  Stool slurry was then 
serially diluted in PBS and 101, 10-1, 10-2 and 10-3 dilutions were plated on to 
triplicate plates of Gram-negative selective MacConkey agar (Sigma, UK). These 
plates were incubated for 24-48 hr at 37 °C. Colonies that showed E. coli 
phenotype (pink / purple colouration) were counted and an average CFU count 
was determined for each patient stool sample.  3 - 5 E. coli colonies were picked 
from each stool sample and restreaked on LB agar plates and eosin methylene 
blue (EMB) agar plates for 24 h at 37°C to screen for E. coli species.  Colonies 
that showed metallic green phenotype on EMB agar were stored as previously 
described.  
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2.11   Determination of AIEC phenotype 
2.11.1 Invasion of intestinal epithelial cells 
T84 cells were grown in 24 well plates (Corning) for 3-5 days at 37°C in 5% CO2 
until an epithelial monolayer was formed. E. coli strains were grown shaking in 
overnight culture at 37°C and then subcultured in fresh media to OD600 = 0.6           
E. coli were diluted in antibiotic-free DMEM media and added to T84 monolayers 
at a MOI of 10 for 2 h at 37°C, 5% CO2.  Infected T84 cells were then treated with 
gentamicin or kanamycin (100 µg ml-1) for 1 h to kill extracellular bacteria that had 
not invaded T84 epithelial monolayer. Cells were then washed and were removed 
from wells by treatment with trypsin (0.25%) in EDTA for 5 min.  Cell suspension 
was removed by aspiration and homogenised by passing through a 22-gauge 
needle. Cells were lysed by sonication and were serially diluted and plated on LB 
agar plates. Plates were incubated overnight at 37°C and CFU counts were 
performed. All invasion assays were repeated in triplicate. LF82 was used in every 
assay as a positive control for invasion. Commensal strain F18 was used as a 
negative control. Invasion of T84 cells was expressed as an invasion index (I_INV) 
calculated by: (number of intracellular bacteria / number of bacteria in original 
inoculum) * 100. Assays were performed in triplicate for all E. coli isolates.  
 
2.11.2 Intramacrophagic proliferation 
The ability of E. coli strains to proliferate within macrophages was determined by 
the gentamicin protection assay as previously described (Falkow et al. 1987). 
J774.1 macrophages were seeded (2 x 105 cells/ well) onto 24 well plates and 
were infected with E. coli strains at a MOI of 50 for 2 h. Cells were then treated 
with gentamicin or kanamycin (100 µg ml-1) for 1 h and then fresh media 
containing antibiotic was added for 3 h, 24 h or 48 h. For time points exceeding 24 
h, media was removed and replaced. Macrophages were then washed extensively 
with PBS and were then scraped from the surface of the plate and lysed with 2% 
Triton X-100 for 5 min.  Recovered intracellular bacteria were quantified by plating 
serial dilutions of cell suspension on LB agar. The plates were incubated overnight 
at 37°C and CFU counts were performed.  LF82 was used in all assays as a 
positive control for intramacrophagic replication and F18 was used as a negative 
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control. Replication within J774 cells was expressed as a replication index (I_REP) 
that was calculated by: (number of intracellular bacteria at 4 h / number of 
intracellular bacteria at 1 h) * 100. Persistence within macrophages was expressed 
as a persistence index (I_PERS) that was calculated by: (number of intracellular 
bacteria at 48 h / no of intracellular bacteria at 1 h)* 100.  Assays were performed 
in triplicate for all E. coli isolates.  
 
2.11.3 Detection of AIEC-associated virulence genes 
The presence of potential virulence determinants was confirmed by PCR 
amplification of two AIEC associated virulence genes, lpfA that encodes long polar 
fimbriae and malX, pathogenicity island marker. The PCR reaction conditions were 
the same as described previously and 1.0% agarose gel was run for qualitative 
analysis. The primers used for amplification of virulence determinants genes are 
listed in Table 2.7. Multiplex PCR for detection of 10 virulence factor gene regions 
associated with extraintestinal E. coli was performed at the Gastrointestinal 
Bacteria Reference Unit, Public Health, Colindale. Investigated genes were pap 
(pyelonephritis associated pili), fimH (type 1 fimbriae), ibeA (invasion protein), fyuA 
(yersiniabactin siderophore), iutA (aerobactin siderophore), ompT (unknown 
virulence function), traT (associated with serum resistance), k1 (capsule synthesis) 
and uidA, a molecular marker for E. coli (Johnson and Stell 2000). 
 
Table 2-7: Primers used for detection of AIEC-associated virulence genes, lpfA and malX. 
Target 
gene 
Primer 
name 
Sequence (5’ to 3’) Product 
size (bp) 
Genbank Accession 
number 
lpfA lpfAF GAAGCGTAATATTATAGGCGG 570bp CU651637.1 
lpfAR TTCGACAGTAAATTGTGAATC 
malX 
 
malXF GGACATCCTGTTACAGCGCGCA 1593bp U00096 
malXR TCGCCRCCAATCACAGCCGAAC 
 
2.11.4 Serotyping of faecal E.coli isolates 
Serotyping was performed elsewhere by agglutination of somatic antigens by the 
use of anti-E. coli polyclonal antiserum (Gastrointestinal Bacteria Reference Unit, 
Public Health, Colindale).  
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2.12   In vivo colicin treatment 
2.12.1 Ethics statement 
All animal experiments were performed in accordance with the UK Animals 
Scientific Procedures Act, authorised under a UK Home Office License and 
approved by the animal ethical review committee of the University of Glasgow. 
Animal studies were not randomised and blinding was not used in this study. 
Project licence number: 60/4128 
 
2.12.2 Mice 
For all experiments six week-old, female, murine specific pathogen-free CF-1 mice 
were used (Harlan, UK). All mice received food and water ad libitum and were 
housed in groups (n =5) during the experiments.  
 
2.12.3 Pectin Zein beads preparation 
Pectin zein complex hydrogel beads were prepared as described previously 
(LinShu Liu, Fishman, Hicks, et al. 2006). Pectin solution prepared from pectin 
(poly-D-galacturonic acid methyl ester; ≥74% esterfied) from citrus peel was 
utilised (Sigma). Beads were prepared by dropping pectin solution, 6% (w/v) into 
an ethanol solution (85%) containing zein, 1% (w/v) and calcium chloride 0.5% 
(w/v) at room temperature using a 30 gauge needle. The droplets (~50 µl/drop) 
were left to cure in reception phase for 15 min and were then washed with distilled 
water and then dried in a drying oven at ambient temperature and then stored at 
4ºC until required. To prepare colicin loaded hydrogel beads, colicin E1 protein 
was predissolved in dH2O (10 mg ml-1) and then mixed with 6% pectin solution 
prior to droplet formation. To determine colicin content in hydrogel beads, air dried 
beads were dissolved in 85% ethanol containing 0.5% NaOH and 20% Tween20 
and diluted in SDS running buffer and run on SDS-PAGE (12% polyacrylamide). 
Beads were run on SDS-PAGE with standard concentrations of recombinant E1 
and band intensities were used to approximate amount of loaded colicin in 
hydrogel beads. Encapsulation efficiency was calculated by: (amount E1 
encapsulated /total amount E1 added) * 100.  
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2.12.4 Murine model of LF82 infection 
Female CF-1 mice received streptomycin (100 mg ml-1) supplemented drinking 
water 72 h prior to infection and 0.1 M sodium bicarbonate by oral gavage 30 min 
prior to infection with 1 x 109 CFU of LF82::StrR in 0.1 ml PBS also by oral gavage.  
Following infection, the number of bacteria was monitored in faecal output. Faecal 
pellets were collected every 18 h and were homogenised in sterile PBS. Serial 
dilutions of faecal homogenates were plated on LB agar containing 100 μg ml-1 
streptomycin and 500 µg ml-1 erythromycin and incubated at 37°C overnight to 
determine bacterial load. Bacterial load was expressed as CFUs/g of faecal 
material. Streptomycin (100 mg ml-1) supplemented drinking water was used 
throughout experiment.   
 
 
2.12.5 Colicin treatment of LF82 intestinal infection 
Female CF-1 mice (n=5) were streptomycin treated and infected with LF82::StrR as 
described. 18 h post infection, mice received selected colicin bead treatment in 
100 µl distilled water by oral gavage. After 18 h faecal pellets were collected and 
plated to monitor bacterial load as described. Where required mice received colicin 
bead treatments daily for 7 days and faecal pellets were collected every 18 h. 
Control group received colicin empty pectin zein beads in dH2O (Table 2.7).  
 
For infections that involved treatment by colicin E1 solution, 18 h post infection, 
mice were treated with 0.1 sodium bicarbonate and then received purified colicin 
diluted in 100 µl dH2O (Table 2.7). Mice received colicin E1 solution every 22 h for 
8 days. Control group for this colicin treatment received dH2O. 
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Table 2-8: Delivery and dosing for colicin treatment of LF82 murine intestinal infection. 
 
 
2.12.6 Colicin stability assay 
To assess colicin stability and activity in the murine intestine, CF-1 mice that had 
not been exposed to LF82 received colicin E1 (10 mg ml-1) diluted in 100 µl dH2O 
by oral gavage for 30, 60 or 120 min. Mice were then culled by cervical dislocation 
and intestinal organs (stomach; small intestine; caecum; colon) were aseptically 
extracted and placed in sterile PBS. Organs and liquid content were then 
homogenised for 5 - 10 min using Stomacher Lab blender 80 (Steward). To test 
colicin activity, one hundred and fifty microliters of LF82::StrpR culture at OD600 = 
0.6 was added to 6 ml of 0.8% soft agar and poured over an LB agar plate before 
10 µl of intestinal organ homogenate was spotted onto the plates and incubated 
for 24 h at 37°C. Clear zones indicate cell death. 
 
2.13 Statistical analysis  
Non-parametric analyses were selected when a small sample size was present in 
data. For macrophage assays one way ANOVA followed by post-hoc analysis with 
Bonferroni correction was used to compare bacterial numbers. For in vitro 
adhesion assays unpaired student’s t-test was used to compare bacterial 
numbers. Bacteria counts in co-culture assays were compared using non-
parametric Mann-Whitney U test. One way ANOVA followed by post-hoc analysis 
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with Bonferroni correction was used to compare amount of cytokines and LDH 
present in cell supernatants. For all tests P < 0.05 was regarded as statistically 
significant.  For faecal bacterial count data, comparison of CFUs were performed 
using the nonparametric Mann–Whitney U test. For assays investigating AIEC 
phenotypes, comparison of invasion, replication and persistence index values 
between groups were performed using the nonparametric Mann–Whitney U test. 
Differences were considered statistically significant at P < 0.05.  For murine 
infection assays, non-parametric Mann–Whitney U-test was carried out at all time 
points to compare bacteria counts. All mice, including outliers were included in the 
statistical analysis. For all tests p <0.05 was regarded as statistically significant. 
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3 Colicins show activity against Crohn’s disease 
associated adherent-invasive E. coli 
 
3.1 Introduction 
3.1.1 Colicin antibiotics; Fighting bugs with their own weaponry 
Antibiotic treatments are currently used to kill or inhibit the growth of pathogenic or 
unwanted bacterial species and are utilised for this purpose in numerous sectors 
including health care, food production and veterinary medicine. The wide spread 
application of antibiotics is thought to be a major contributing factor to antibiotic 
resistance. This is in part due to the broad spectrum nature of antibiotics used for 
these purposes, that results in a build-up of resistant determinants in the wider 
bacterial population (Julian Davies and Davies 2010).  
However, inhibition of bacteria by highly targeted, narrow spectrum antibiotics is 
also observed widely in bacterial communities in the form of bacteriocins; protein 
antibiotics produced by bacteria during intraspecies competition (O Gillor et al. 
2008). Although the specific ecological role of bacteriocins is still unknown, it is 
proposed that they function as anti-competitors, by enabling the invasion of a 
producer strain into an established microbial community or by limiting the advance 
of neighbouring cells in an occupied niche (Margaret a Riley and Wertz 2002). 
Overall, the detection of bacteriocins in all surveyed prokaryotic lineages, 
highlights the significance of these products for bacterial survival and competition, 
making them ideal candidates for further investigation as therapeutics (Cascales et 
al. 2007).  
In order to function as an antimicrobial therapy in human health, bacteriocins must 
show good efficacy against target strains that demonstrate abnormal colonisation 
of the host (i.e are present in increased numbers and interact with host cells); be 
active against a range of isolates; be non-cytotoxic to host cells and also be 
successfully delivered to the site of infection. In this work, the efficacy of colicins 
was tested against AIEC infection associated with Crohn’s disease. 
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3.1.2 CD associated adherent-invasive E. coli as a target for 
colicin treatment 
AIEC bacteria are more frequently isolated from ileal and colorectal biopsies of 
Crohn’s disease patients compared to healthy controls (Conte et al. 2014, Martin 
et al. 2004, Mylonaki and Rayment 2005). It is currently unknown if abnormal 
colonisation of AIEC detected in CD patients is a primary cause of inflammatory 
symptoms or is a secondary event facilitated by host genetic factors, impaired 
epithelial barrier function and dysregulated mucosal immune responses 
associated with disease. CD patients demonstrate intestinal dysbiosis relative to 
healthy individuals and in a proportion of patients, AIEC expansion can be 
recognised as a component of this dysbiosis. In this case, it would be preferential 
to use targeted antibiotics to prevent further dysbiosis of resident microbial 
communities. This represents a complex challenge for broad spectrum 
antimicrobial therapies as they are unable to target specific members of the 
intestinal microbiota. Colicins are species-specific antibiotics that show activity 
against E. coli and closely related species and as such may make a useful 
potential treatment for AIEC infection associated with CD. 
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3.2 Aims 
The aim of the work described in this chapter was to test the efficacy of colicins 
against CD associated AIEC in in vitro models (Figure 3.1).  To achieve this, 
colicin killing was investigated against: 
1) A range of colonic and ileal AIEC clinical isolates growing in planktonic 
culture; 
2) AIEC associated with T84 intestinal epithelial cells; 
3) AIEC growing within RAW 264.7 macrophages.  
 
Figure 3-1: Hypothetical target sites for colicin treatment of AIEC. 
Figure shows model for AIEC infection in CD (left) and the investigated sites for colicin treatment of 
AIEC (right). In this work, we hypothesise that targeted killing of AIEC by colicins would preserve 
gut microbiota populations, reduce the number of AIEC interacting with intestinal epithelial cells at 
gut mucosa and therefore decrease the number of AIEC gaining entry to lamina propria and host 
macrophages. Reduced AIEC infection of macrophages may result in decreased production of pro-
inflammatory cytokines and therefore inflammatory symptoms associated with CD. 
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3.3 Results 
3.3.1 Colicins show activity against planktonic AIEC 
In order to investigate the activity of colicins against AIEC, overlay assays were 
performed. A range of indicator AIEC strains were tested. This included the AIEC 
reference strain LF82 (ileal CD) that was kindly gifted by Darfeuille-Michaud 
(Clermont-Ferrand, France) and colonic mucosally associated AIEC clinical 
isolates HM95 (ileal CD), HM419 (ileo-colonic CD) and HM154, HM580, HM605 
and HM615 (colonic CD) that were kindly gifted by Barry Campbell (University of 
Liverpool). E.coli W3110 strains that possessed colicinogenic plasmids encoding 
colicin A, B, N, E1, Ia, Ib (pore-formers); E2, E9 (DNase) and D (tRNase) were 
used.  These data showed that AIEC reference strain LF82 was susceptible to all 
tested colicins (Figure 3.2). Similarly, AIEC clinical isolates HM419 and HM95 
showed high level of susceptibility to all tested colicins tested when grown in 
planktonic culture (Table 3.1). AIEC clinical isolate HM615 showed sensitivity to 
colicins E1- E9, A, D and N but was tolerant to colicins B, Ia and Ib. By this 
method, AIEC clinical isolates HM154, HM580 and HM605 were tolerant to all 
tested colicins (Table 3.1).  
 
 
Figure 3-2: AIEC isolates show different susceptibility profiles to colicins. 
A) AIEC reference strain LF82 is susceptible to a wide range of colicins. Colcinogenic E. coli 
W3110 strains were spotted on LB agar containing mitomycin C for induction of colicin production 
and an AIEC soft agar lawn was grown on top. Colicin killing is shown by a zone of clearing around 
colicin producer strains. B) AIEC clinical isolate HM580 is tolerant to all colicins investigated in 
overlay assay. Image shown is a representative example of three independent overlay spot plate 
assays. 
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Table 3-1: Killing spectrum of colicins against AIEC reference strain LF82 and AIEC clinical 
isolates HM95-HM615. 
 
Colicin producing strains were grown on LB agar containing mitomycin C, chloroform killed and 
then overlain with soft agar suspension of AIEC indicator strain.  For results; + denotes killing and 
zone of inhibition, ~ denotes small diffuse zone and - denotes no zone of inhibition detected.  
 
 
3.3.2 Potent activity of colicins against AIEC 
To produce purified colicin E9, the plasmid pCS4, encoding full length colicin E9 
and its cognate immunity protein Im9, was transformed into E. coli BL21 (DE3) 
cells. Colicin E9 was overexpressed as previously described (Garinot-Schneider et 
al. 1996). Colicin E1 was produced in mitomycin C induced E. coli BZB2104 
(pColE1-K53) that carries the colicin E1 encoding plasmid. Purification of colicin 
E1 was performed by ammonium sulphate fractionation and ion exchange 
chromatography as previously described (SA Schwartz and Helinski 1971).  
Chromatograms and SDS-PAGE gels showing the final purified products for colicin 
E1 and E9 are shown in Appendices B and C (Figure B-1, C-1). Following 
purification colicins were filter sterilised and stored at -20°C until required.  To test 
the activity of purified colicins E1 and E9, 5-fold serial dilutions (1 mg ml-1 – 0.32 
µg ml-1) were spotted on soft agar overlays of AIEC indicator strains. Plates were 
incubated overnight at 37°C and colicin killing was detected by zones of 
 
Indicator 
strain  
  Colicin producing strains  
 A B D N IA IB E2 E5 E1 E9 
LF82 + + + + + + + + + + 
HM95 + + + + + + + + + + 
HM154 - - - - - - - - ~ ~ 
HM419 + + + + + + + + + + 
HM580 - - - ~ - - - - ~ ~ 
HM605 - - - - - - - - - - 
HM615 + ~ + + - - + + + + 
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clearance. Colicins E1 and E9 showed potent killing activity against sensitive AIEC 
strains, killing at a concentration of 0.32 µg ml-1 for AIEC strains HM95, HM419 
and HM615 and AIEC reference strain LF82 (Figure 3.3). 
These data showed that colicin E9 poorly inhibited HM154 and HM605 at 1 mg ml-
1 that was shown by a small and diffuse zone of inhibition (Figure 3.3). HM605 was 
resistant to colicin E9 killing at a concentration of 1 mg ml-1. Colicin E9 showed 
activity against HM580 at a concentration of 0.25 mg ml-1 and against HM154 at a 
concentration of 1 mg ml-1. HM605 was resistant to colicin E1 killing at 1 mg ml-1. 
The MICs of colicins E1 and E9 against AIEC growing in liquid broth are shown in 
Appendix D.  
 
 
Figure 3-3: Colicins show highly potent activity against some AIEC isolates. 
A) AIEC reference strain LF82 (ileal CD) and colonic AIEC clinical isolates HM95 (ileal CD) HM419 
(ileo-colonic CD) and HM164, HM580, HM605 and HM615 (colonic CD) were grown in planktonic 
culture and purified colicin E9 and colicin E1 protein was serially diluted 5-fold (1 mg ml-1 - 0.32 µg 
ml-1) and spotted on molten agar overlay.  Zones of clearing show killing of AIEC bacteria by each 
colicin and dilution.  Data shown is a representative example of three independent overlay assays.  
 
3.3.3 Colicins show activity against AIEC LF82 cells adhered to 
T84 intestinal epithelial cells 
It has been proposed that one of the initial stages of AIEC infection in CD may 
involve receptor mediated bacterial adhesion to intestinal epithelial cells (IECs) 
(Barnich and Darfeuille-Michaud 2007). To determine if colicins are active against 
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AIEC that are adhered to IECs, monolayers of the T84 human intestinal epithelial 
cell line were infected with LF82 and colicin E9 (100 µg ml-1) was added 15, 30, 45 
and 60 min post-infection. T84 cells are known to express CEACAM6 receptors 
and therefore represent a suitable in vitro model for ileal AIEC adherence to IECs 
(Barnich and Darfeuille-Michaud 2007). On addition of colicin E9 at 15, 30 and 45 
min post infection, live and adhered LF82 could no longer be detected by CFU 
counts (Figure 3.4). Colicin treatment at 1 h post-infection caused a 2-log unit 
reduction in CFU counts of cell associated LF82 compared to untreated controls 
(Figure 3.4). These data show that colicin E9 can effectively kill AIEC bacteria 
adherent to human IECs that express CEACAM6 receptors. 
 
 
Figure 3-4: Colicins show activity against ileal AIEC strain LF82 associated with intestinal 
epithelial cells. 
T84 intestinal epithelial cell monolayers were infected with AIEC LF82 (MOI of 10 for 3 h) and 
when required colicin E9 (100 µg ml-1) was added in presence of AIEC bacteria at 15, 30, 45 and 
60 min post infection. Cell associated LF82 numbers were determined by CFU counts. Black circle 
is mean value for each experiment. Black line represents mean value. Error bars shown are SE of 
three independent experiments. No CFU counts were detected for E9 at 15; 30; 45 min by this 
method. Comparison of CFUs for untreated and colicin E9 treated showed a significant reduction 
on colicin treatment at 60 min. (P< 0.05, unpaired Student’s t test). 
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3.3.4 Colicin killing of cell associated AIEC preserves healthy cell 
morphology of intestinal epithelial cells 
A defining feature of the AIEC pathovar is the ability to invade IECs that is 
proposed to be mediated by actin induced alterations of the host cell cytoskeleton.  
To determine if changes in morphology of IECs were induced by AIEC infection 
and subsequent colicin treatment, T84 cells were grown on glass coverslips, 
infected with LF82 and treated at 15 min post infection with colicin E9 (100 µg ml-1) 
where required. At 3 h post infection T84 cells were washed, Giemsa stained and 
visualised by light microscopy. Light micrographs showed that LF82 infection of 
T84 cells caused alterations in cell morphology (Figure 3.5). LF82 infected cells 
displayed high levels of cell detachment and increased production of abnormal cell 
protrusions and lamellipodia. (Figure 3.5b). LF82 adhered to T84 cells were also 
observed (Figure 3.5b). Colicin E9 treatment of infected T84 cells significantly 
reduced the production of cell protrusions and a smoother cell monolayer was 
observed (Figure 3.5c). LF82 infected T84 cells treated with colicin E9 also 
showed reduced cell detachment and reduced levels of debris in the apical 
supernatant. Following colicin E9 treatment, very few cell-associated LF82 could 
be visualised. Addition of colicin E9 to uninfected T84 cells did not induce changes 
in cell morphology (Figure 3.5d).   
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Figure 3-5: Colicin killing of IEC associated AIEC reduced appearance of abnormal cell 
morphology induced by infection. 
T84 cells were grown on glass cover slips in 6 well plates and infected with AIEC LF82 (MOI of 10 
for 3 h). For colicin treated samples, colicin E9 (100 µg ml-1) was added 15 min post-infection. Cells 
were Giemsa stained and visualised with Zeiss Axioskop (40 x magnification). Light micrographs 
show: A) Untreated control B) LF82 infected T84 cells, C) LF82 infected T84 cells treated with 
colicin E9 (100 µg ml-1 for 3 h) D) Uninfected T84 monolayer treated with colicin E9 (100 µg ml-1 for 
3 h). Scale bar shown is 5 µm. Image labelling is as follows; nc; nuclei; MV; membrane 
vesiculation, white arrow; adhered bacteria, La; lamellipodia. Image is representative of two 
independent experiments.   
 
3.3.5 Co-culture with colicin producing commensal E. coli 
reduces adherence of LF82 to intestinal epithelial cells  
For disorders such as CD, that are associated with intestinal dysbiosis, the use of 
probiotic bacteria that can manipulate the microbiota composition is highly 
desirable. In order to investigate the ability of colicin-producing commensal E. coli 
strains to inhibit AIEC adherence to IECs, co-culture assays were performed. For 
this, the colicin producing commensal E. coli strain BZB2014 (W3110 pColE1-K53) 
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was co-cultured with LF82 in T84 cell adhesion assays. Equal volumes of LF82 
and BZB2014 (MOI=10) were added to T84 monolayers and incubated for 3 h at 
37°C, 5% CO2. E. coli W3110 that did not carry the ColE1 plasmid was also used 
in co-culture assays with LF82.  
Co-culture of LF82 with colicin-producing commensal E. coli significantly reduced 
CFU counts of cell associated LF82 compared to LF82 mono-culture (P= 0.0256).  
No significant difference in CFU counts of cell associated LF82 was detected 
following co-culture of LF82 with the non colicin-producing W3110 strain (P=0.136) 
(Figure 3.6). These data show that concentrations of colicin produced by 
colcinogenic E. coli strains in vitro is sufficient to inhibit cell- associated AIEC. 
 
 
Figure 3-6: Co-culture of LF82 with colicin producing commensal E. coli strain reduced 
adherence of AIEC to T84 IECs. 
T84 intestinal epithelial cell monolayers grown in 24 well plates (2 x 105 cells / well) were infected 
with E. coli (MOI of 10) for 3 h. AIEC LF82 was added as a monoculture, in co-culture with colicin 
producing E. coli BZB2014 (W3110 pColE1-K53) and in co-culture with non colicin-producing 
isogenic BZB2014 strain. Number of cell-associated LF82 were determined by CFU counts on LB 
agar containing ampicillin (50 µg ml-1). Data shown represents mean and SD (error bars) of two 
independent experiments. Comparison of LF82 CFUs following co-culture with colicin producing 
strain and non colicin producing strain showed a significant reduction on colicin treatment 
(P=0.0256). Comparison of mean CFUs were performed using the nonparametric Mann–Whitney U 
test. * denotes significant difference between groups.  
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3.3.6 Colicins show activity against AIEC bacteria residing within 
macrophages 
 
3.3.6.1   LF82 is an intramacrophagic persister 
Although previous studies have reported extensive replication of AIEC strain LF82 
within macrophages in vitro, this result was not reproduced in this work (Bringer et 
al. 2006, Subramanian, Roberts, et al. 2008). Bacterial survival in RAW 264.7 
macrophages was determined using the gentamicin protection assay (Falkow et 
al. 1987). RAW 264.7 macrophages were infected with LF82 at an MOI of 50 for 2 
h and treated with gentamicin until the required time point. Viable bacteria were 
determined by CFU counts following plating of lysed cells on LB agar. LF82 was 
shown to survive within macrophages and persist intracellularly for extended 
periods with viable bacteria being detected after 48 h (Figure 3.7a). Approximately 
2 x 104 CFUs of LF82 were detected in macrophages at 1 h. This decreased to 
approximately 1 x 104 CFUs at 4 h, 1 x 103 CFUs at 24 h with approximately 40 
CFUs of LF82 detected at 48 h.  
To visualise intramacrophagic LF82 bacteria, LF82 strain expressing GFP was 
constructed. RAW macrophages were grown to confluency on glass coverslips in 
6 well plates and LF82-GFP was used in gentamicin protection assays. At 24 h, 
cells were stained with DAPI and Alexa-647-phalloidin and visualised using 
confocal microscopy. Consistent with CFU counts LF82 bacteria were only 
detected in a small proportion of macrophages in the population. LF82 bacteria 
were detected in 0.5% of macrophage cells and formed cell aggregates within 
macrophages (Figure 3.7b).  
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Figure 3-7: AIEC LF82 shows persistence within macrophages.  
A) LF82 persists in macrophages at low numbers at 48 h. RAW 264.7 macrophages (2 x 105 cells) 
were infected with LF82 (MOI of 50; 2 h) and treated with gentamicin (100 µg ml-1 for 1 h) to kill 
extracellular bacteria.  Fresh media containing gentamicin was added and incubated for 4, 8, 24 
and 48 h. Macrophages were lysed and viable intracellular bacteria determined by CFU counts. 
Data represents mean and SE of three independent experiments. B)  LF82 persists in few 
macrophages in population at 24 h. Figure shows confocal micrographs of RAW 264.7 
macrophages infected with green LF82-GFP (left) and mock-infected control (right).  Actin is 
stained with phalloidin-Alexa 647 conjugate (purple) and nuclear DNA is stained with DAPI (blue). 
Arrow shows intracellular aggregate of LF82 bacteria in single macrophage. Scale bars shown are 
10 µm.  Confocal micrographs represent two independent experiments.  
  
3.3.6.2 Colicins kill LF82 residing within macrophages 
To investigate the ability of colicins to inhibit LF82 persistence within RAW 
macrophages gentamicin protection assays were performed that included 
treatment of intracellular bacteria with a range of antibiotics. Antimicrobial 
treatments were colicin E1, colicin E9, colicin E9-H575A, a variant protein that 
lacks antibacterial activity due to a mutation in the active site of the cytotoxic 
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DNase domain (Appendix A), or ciprofloxacin (100 µg ml-1), that has previously 
been shown to be highly active against intramacrophagic AIEC (Subramanian, 
Roberts, et al. 2008). For antibiotic free controls, the number of bacteria present in 
RAW 264.7 macrophages at 4 h and 24 h was approximately 1.6 x 104 and 800 
CFUs / well, respectively. Both colicin E9 and colicin E1 treated macrophages 
showed reduced intracellular survival of LF82 at 4 h and 24 h but to a lesser extent 
than ciprofloxacin (Figure 3.8).  In contrast, treatment with inactive colicin 
E9H575A following gentamicin treatment did not reduce survival of 
intramacrophagic LF82 that indicated that the cytotoxic function of the protein was 
directly responsible for bacterial killing (Figure 3.8).  
 
 
Figure 3-8: Colicins kill intramacrophagic AIEC.  
A) Colicins show activity against LF82 residing within RAW 264.7 macrophages. RAW 264.7 
macrophages were infected with LF82 (MOI of 50; 2 h) and treated with gentamicin (100 µg ml-1 for 
1 h) to kill extracellular bacteria. Antimicrobial treatments were performed for 24 h at 100 µg ml-1 for 
all tested. At 4 h and 24 h macrophages were lysed and viable intracellular bacteria determined by 
CFU counts. E9H575A is an active site mutant protein of colicin E9. ND; None detected.  Data 
shown represents mean and SE of three independent experiments. One way ANOVA followed by 
post-hoc analysis with Bonferroni correction showed significant differences between the inactive 
colicin H575A group and colicin E9, colicin E1 and ciprofloxacin treated groups at 4 and 24 hours 
(P < 0.05). *, P < 0.05.  
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3.3.7 Colicins enter AIEC containing compartments within 
infected RAW264.7 macrophages 
In order to demonstrate colicin entry into RAW 264.7 macrophages, RFP-tagged 
fluorescent colicin E9 (colicin E9-RFP), in which the DNase domain is replaced 
with RFP leading to a cytotoxically inactive protein, was constructed (Walker lab). 
RAW 264.7 macrophages grown on glass coverslips in 6 well plates were infected 
with LF82-GFP (green) at a MOI of 50, treated with gentamicin as described and 
treated with colicin E9-RFP (red) and incubated for 24 h. In order to selectively 
visualise intracellular colicin, macrophages were treated with trypsin to inactivate 
extracellular and cell associated colicin E9-RFP. Using confocal microscopy the 
presence of both colicin and LF82 within infected macrophages was observed 
(Figure 3.9a). Confocal micrographs showed that colicin E9-RFP was present 
within infected RAW macrophages and in some cases co-localised together with 
LF82-GFP within specific compartments (Figure 3.9a). Although co-localisation of 
colicin with LF82 was detected, colicin-RFP that was not co-localised with bacteria 
was also detected within macrophages at 4 h (Figure 3.9b). 
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Figure 3-9: Colicin adheres to macrophages, enters AIEC containing compartments and 
localises with LF82. 
A) Colicin enters AIEC containing compartment in RAW 264.7 macrophages. Figure shows 
confocal micrographs of RAW 264.7 macrophages infected with GFP expressing LF82 bacteria 
(green) and treated with colicin E9-RFP (red) for 24 h. Trypsinised macrophage cells were fixed 
and permeabilised and actin stained with phalloidin-Alexa 647 conjugate (purple) and nuclear DNA 
stained with DAPI (blue). Scale bars shown are 10µm. A total number of 50-200 macrophages 
were assessed per experiment. Confocal micrographs represent three independent experiments. 
B) Colicin E9-RFP detected in macrophages and not co-localised with AIEC. Fluorescent 
micrographs of RAW264.7 macrophages infected with GFP expressing LF82 bacteria (green) and 
treated with colicin E9-RFP (red) for 4 h. Trypsinised macrophage cells were fixed and 
permeabilised and actin stained with phalloidin-alexa 647 conjugate (blue). Labels are C: Colicin-
RFP; E: E. coli LF82. Scale bar shown is 10 µm.  
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3.3.8 Colicin uptake in macrophages involves actin mediated 
endocytosis 
AIEC are proposed to enter macrophages by phagocytosis due to their residence 
within compartments highly representative of the phagolysosome (Bringer et al. 
2006). Protein uptake by phagocytosis in macrophages is not an established entry 
mechanism, therefore it was postulated that colicin utilised distinct endocytic 
pathways to gain entry to macrophage cells. To further investigate colicin uptake, 
RAW macrophages treated with colicin E9-RFP that were not exposed to trypsin 
were visualised by fluorescent microscopy (Figure 3.10). Interestingly, in the 
absence of trypsin treatment, high levels of colicin adherence at the macrophage 
cell surface were observed (Figure 3.10). This indicated binding of colicin to cell 
surface macrophage receptors.  
 
 
Figure 3-10: Colicin adheres to RAW 264.7 macrophages. 
Figure shows fluorescent micrograph of RAW264.7 macrophages treated with colicin E9-RFP for 4 
h that were not trypsinised prior to staining and fixing. Second panel shows DIC image.  Scale bar 
shown is 10 µm. 
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 In order to determine the mechanism of colicin uptake into cells, macrophages 
were pre-treated with inhibitors of multiple endocytic pathways and then treated 
with colicin E9-RFP for 4 h and trypsin treated and washed as described. Confocal 
micrographs showed that pre-treatment of macrophage cells with cytochalasin B, 
an inhibitor of actin polymerisation significantly reduced the uptake of colicin E9-
RFP (Figure 3.11). The processes of clathrin-mediated endocytosis, pinocytosis, 
mannose receptor-mediated endocytosis and scavenger receptor-endocytosis 
inhibited by dynasore, DMA, mannan and polyinosinic acid respectively, were not 
shown to influence colicin uptake (Figure 3.11). These data indicate that an actin 
regulated endocytic pathway regulates colicin uptake into AIEC-infected 
macrophage compartments. 
 
 
Figure 3-11: Pre-treatment of RAW 264.7 macrophages with chemical inhibitor of actin 
polymerisation significantly reduced uptake of colicin E9-RFP. 
Confocal micrographs of RAW 264.7 macrophages pre-treated with inhibitors of endocytosis (30 
min) and then treated with colicin E9-RFP (red) for 4 h. Inhibitors used were mannan (mannose 
receptor-mediated endocytosis), dynasore (clathrin mediated-endocytosis), dimethylamiloride 
(pinocytosis), polyinosinic acid (scavenger receptor-mediated endocytosis) and cytochalasin B 
(actin polymerisation). Actin was stained with phalloidin-Alexa 647 conjugate (purple) and nuclear 
DNA stained with DAPI (blue). Arrows and circle highlight colicin E9-RFP inside macrophage cells. 
Scale bars shown are 10 µm. Confocal micrographs represent two independent experiments. 
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3.3.9 Effect of colicin treatment on macrophage TNF-α production 
In previous in vitro studies AIEC infected macrophages have been shown to 
produce increased amounts of the pro-inflammatory cytokine, TNF-α (Glasser et 
al. 2001). We therefore sought to investigate if colicin killing of intramacrophagic 
AIEC would cause a decrease in the production of pro-inflammatory cytokines. To 
achieve this, RAW 264.7 macrophages were infected with LF82 and treated with 
colicin E9 (100 µg ml-1). For this assay, colicin was further purified using endotoxin 
removal columns to ensure LPS was extracted from protein fractions. LPS (1 µg 
ml-1; Sigma) was used as a positive control for cytokine release. For cytokine 
detection, macrophage cell supernatants were removed at 24, 30 and 40 h post-
treatment and ELISAs (BioLegend) were performed for TNF-α. Although colicin E9 
did not reduce production of TNF-α by LF82 infected macrophages, increased 
production of TNF-α was not detected following colicin treatment (Figure 3.12a). A 
similar result was obtained for ciprofloxacin treated LF82 infected macrophages 
indicating that at least in this assay, AIEC killing is not associated with reduced 
levels of TNF-α. Colicin E9 treatment of uninfected macrophages was shown to 
produce similar levels of TNF-α as the untreated mock controls at all-time points 
tested (Figure 3.12a). Additionally, lactate dehydrogenase (LDH) assays showed 
that colicin E9 treatment was not cytotoxic to macrophages (Figure 3.12b). 
Untreated macrophages were shown to produce similar amounts of LDH 
compared to colicin treated, uninfected cells at 24 h (Figure 3.12c).   
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Figure 3-12: Colicin is non-cytotoxic to macrophage cells and fails to increase production of 
TNF-α. 
TNF-α (A) and LDH (B) production by RAW 264.7 macrophages infected with LF82 (MOI of 50; 3 
h) and treated with E9; ciprofloxacin (100 µg ml-1) for 24 h, 30 h and 40 h following gentamicin 
treatment. (-) represents mock infected negative control. LPS (1 µg ml-1) stimulation of 
macrophages was control for cytokine production. % Cytotoxicity was determined by measurement 
of LDH release relative to uninfected controls.  Data are expressed as mean +/- SE of two 
independent experiments. In (A) ANOVA followed by post-hoc analysis with Bonferroni correction 
indicated differences (P < 0.05) for both mock infected and ColE9 treated vs LF82, LF82 + ColE9, 
LF82 + Cip and LPS treated cells at  24, 30 and 48 h and no difference (P  > 0.05) between mock 
infected and ColE9 treated cells. In (B) ANOVA followed by post-hoc analysis with Bonferroni 
correction indicated differences (P < 0.05) at 24h and 40 h for mock infected vs LF82 but no other 
significant differences between groups on pairwise comparison. *, P < 0.05.  
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3.4 Discussion 
A range of chronic immune related diseases such as IBD, diabetes and 
rheumatoid arthritis are associated with intestinal dysbiosis and in a subset of 
patients associations with specific bacterial species have been determined. For 
the most part, the use of broad spectrum antibiotics for the treatment of chronic 
immune related disorders, such as CD generally show poor efficacy (Selby et al. 
2007). This itself can lead to the development of severe secondary infections 
resulting in extended hospital care and requirement for further treatments (Hickson 
et al. 2007, Meropol et al. 2008). 
A potential alternative treatment for the correction of dysbiosis is the use of 
narrow- spectrum antibiotics such as the colicin-like bacteriocins. As stated in 
section 3.1.1, to be considered as a potential therapeutic, colicins must show 
activity against target strains that demonstrate abnormal colonisation of host, be 
active against a range of isolates and also be non-cytotoxic towards mammalian 
cells. These data demonstrate clearly that colicins fulfil the majority of these 
requirements and also exhibit several unexpected but useful attributes (Figure 
3.13). 
In this work colicins were shown to kill a range of clinical AIEC isolates that 
highlights their potential as a therapeutic against diverse infections. Colicins were 
also shown to kill AIEC-associated with intestinal epithelial cells and killed AIEC 
bacteria growing intracellularly within macrophages. For the latter, colicins entered 
AIEC containing compartments within RAW 264.7 macrophages by exploiting 
actin-mediated endocytosis. The unexpected ability of colicins to inhibit 
intramacrophagic AIEC highlights their potential as a therapy for CD as AIEC 
persistence within host macrophages has been associated with inflammation and 
also granuloma formation (Meconi et al. 2007).  Indeed, good efficacy of a wide 
range of broad spectrum antibiotics has been demonstrated against 
intramacrophagic AIEC HM605 in previous work, that also reported complete 
killing with ciprofloxacin (Subramanian, Roberts, et al. 2008). However, the ability 
of a narrow spectrum and potent antimicrobial to penetrate eukaryotic cells sets 
colicins apart from traditional antibiotics.  
When considering the treatment of AIEC infections in CD patients, we envisage 
that colicin delivery would take the form of a colicin producing probiotic. Indeed in 
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this work, we demonstrated the ability of a colicin producing commensal E. coli 
strain to kill AIEC associated with intestinal epithelial cells that express CEACAM6 
receptors. This result indicates that colicin producing bacteria, that can be readily 
isolated from the healthy gut microbiome, may be effective in the treatment of 
AIEC bacteria colonising the gut mucosa of CD patients (Cursino et al. 2006). 
Additionally, this work has provided further support for the utilisation of colicin 
treatments as it showed that colicin treatment of eukaryotic cells did not induce 
cytotoxicity (Figure 3.13). Although yet to be confirmed in vivo, this highlights the 
potential applicability of colicins as antimicrobial therapies in humans. 
Due to the targeted killing mechanism shown by colicins, they represent a novel 
class of ‘personalised medicine’ i.e therapies that can be ‘matched’ to patient gut 
profiles. As a major feature of CD is intestinal dysbiosis, colicins in the form of 
personalised medicine could be administered to juvenile patients who show 
genetic susceptibility of developing CD. Indeed, a multitude of data now 
demonstrates an association between increased antibiotic exposure in early 
childhood and increased risk of developing disorders such as asthma, IBD and 
rheumatoid arthritis (Arvonen et al. 2015, Shannon L Russell et al. 2012, Ungaro 
et al. 2014). By similar concepts, colicins could function in a reverse manner to 
broad spectrum antibiotics and shift microbiota populations to a ‘non – risk’ 
composition in patients who are genetically susceptible to these disorders. Long 
term colicin treatment assays in murine models will give insights into the ability of 
colicin-like bacteriocins to permanently alter the gut microbiota composition even 
after treatment has ceased.  Animal models will also contribute to overcoming the 
current limitations of colicins. These include instability of colicins in vivo and 
stimulation of host immune response that may involve the production of anti-colicin 
antibodies. Furthermore, for treatment of intestinal infections, a key limitation is the 
method of delivery. Alternative methods of delivery aside from probiotic producing 
strains may include methods of encapsulation that protect colicin protein from the 
protease enriched intestine (see Chapter 4).  
Good efficacy of colicin-like bacteriocins will rely on extensive knowledge on the 
target strain involved. In coherence with current attempts to improve detection 
methods for pathogenic agents (Longitude prize), colicin-like bacteriocins 
represent an ideal personal medicine that will partner this strategy. Colicin-like 
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bacteriocins represent an innovative and clinically relevant form of antibiotics and 
deserve increased opportunity within the clinical setting.  
 
 
Figure 3-13: Colicins as an alternative to traditional antibiotics. 
Figure shows attractive properties of colicins for their role as antibiotics demonstrated previously 
(blue), in this work (green) and that have yet to be extensively demonstrated (yellow).  
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4 Encapsulation of purified colicin for the 
treatment of persistent LF82 intestinal infection 
in mice 
Foreword 
Probiotic colicin producing bacteria represent an ideal approach for the treatment 
of AIEC infection that is associated with CD and hence intestinal dysbiosis. 
However, limitations of this method include variations in the composition of 
patients’ gut microbiota, establishing long term colonisation of the probiotic strain 
and also the potentially low concentration of colicin produced. The use of purified 
protein is an alternative strategy for colicin treatment of AIEC infection. This 
method would facilitate the use of increased, but also known concentrations of 
colicin and would allow use of combinations of different proteins or ‘colicin 
cocktails’. The work described in this chapter investigates the use of purified 
colicin for treatment of intestinal LF82 infection in mice following its encapsulation 
into colon targeting pectin zein hydrogel beads. 
 
4.1 Introduction 
4.1.1  Colonic microbiota digestible biopolymers as carriers for 
colon specific drugs 
Protein therapeutics have increased dramatically in number and frequency of use 
since the introduction of the first recombinant protein therapeutic, human insulin, 
25 years ago (Clark et al. 1982).  At present, more than 130 different proteins or 
peptides are approved for clinical use by the FDA, and many more are in 
development (Leader et al. 2008). However, oral administration of protein 
therapeutics is very difficult due to their low bioavailability. Protein degradation 
occurs at high levels in the stomach and duodenum but less so in the ileum and 
colon (Sinha and Kumria 2003). As such, various delivery systems have been 
developed to target drug absorption from the colon and ileum.  An effective 
delivery system must protect the encapsulated drug en route to colon and 
minimise exposure to digestive enzymes. The approaches commonly used in 
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formulating oral protein delivery systems include use of specific excipients 
(absorption enhancers, enzyme inhibitors and mucoadhesive polymers) or 
protective formulations (Park et al. 2011). A key example of the latter are 
biodegradable polymers that are specifically digested by enzymes produced by 
colonic bacteria (Sinha and Kumria 2003).The ability to utilise complex dietary and 
host glycans is essential for the survival of prominent members of the gut 
microbiota (Bourquin et al. 1993, Macfarlane and Macfarlane 2012). Fruits, 
vegetables and cereals are major components of human diet and provide 
carbohydrates, digested by human intestinal enzymes and also fibrous material 
that is not readily digested in the small intestine. Members of the microbiota 
extract energy from these undigested dietary products by fermentation (El Kaoutari 
et al. 2013, Miller and Wolin 1979, Sinha and Kumria 2003). For this purpose, 
members of the colonic microbiota produce a wide range of enzymes that include 
glucosidases, xylosidases, araninosidases, galactosidases and deaminases. 
These are referred to as carbohydrate–active enzymes (CAZymes) (El Kaoutari et 
al. 2013) The main saccharolytic species in the colon are Bacteroides and 
Bifidobacterium (Sinha and Kumria 2003). As these bacterial enzymes are 
produced exclusively in the colon, the use of microbial biodegradable polymers for 
drug delivery represents a site specific approach and hence highly suitable for 
treatment of colonic disorders. 
4.1.2 Pectin / zein hydrogel beads for colon specific colicin 
delivery 
Pectin is a natural heteropolysaccharide distributed abundantly in fruits and 
vegetables (LinShu Liu, Fishman and Hicks 2006). It is comprised of 1, 4 linked 
alpha-D-galactosyluronic acid residues with a range of neutral sugars including 
rhamnose, galactose, and arabinose (Figure 4.1).   
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Figure 4-1: Chemical structure of pectin. 
Repeating segment of pectin molecule and functional groups. Image adapted from (Thakur et al. 
1997). 
  
Pectin possesses several properties that make it an ideal colon specific drug 
delivery vehicle. Pectin is gastro-resistant and is selectively digested by microflora 
in the colon as a soluble dietary fibre. Pectin has also been shown to increase 
gastric transit time that would be useful when swift drug delivery is required  
(Wong et al. 2011). Additionally, pectin undergoes 100% fermentation in the colon 
that generates the production of short chain fatty acids that perform several 
beneficial roles for bowel health. The functional model for pectin as a colon 
targeted delivery vehicle involves: 1) adsorption of colonic microbiota and 
enzymes upon pectin matrix surface; 2) degradation of matrix by bacterial 
pectinases and 3) drug release at desired site.  Pectin gels have been extensively 
tested for applications in oral drug administration. This has included amidated 
pectin hydrogel beads prepared for colon specific delivery of indomethacin and 
sulfamethoxazole (Munjeri et al. 2015).  One limitation associated with the use of 
pectin gels for colon-specific drug delivery is the pectin based matrix is prone to 
swelling as well as erosion in aqueous medium leading to premature drug release 
at the upper GI tract. Numerous approaches have been investigated to prevent 
pectin based matrix undergoing premature drug release. For example, crosslinking 
pectin with calcium ions or zinc ions and complexation with polymers (chitosan 
and Eudragit TM) has been shown to reduce solubility, swelling and erosion of the 
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polymer, whilst increasing stability (LinShu Liu, Fishman and Hicks 2006, Turkoglu 
and Ugurlu 2002).  
Recent work has investigated complexation of pectin with zein, a major storage 
protein of corn kernels (LinShu Liu, Fishman, Hicks, et al. 2006).  Zein has been 
patented for the production of protein microspheres, that are able to protect 
encapsulated drugs from stomach acid and release them in the small intestines on 
protease digestion (Mathiowitz et al. 1993). It was shown previously that inclusion 
of a small portion of zein into the pectin matrix suppressed the swelling behaviour 
of pectin and stabilised the pectin matrix (LinShu Liu, Fishman, Hicks, et al. 2006). 
In a later study, pectin / zein hydrogel beads were used to successfully deliver a 
probiotic protein, p40, to the mouse colon where it activated its target protein, 
EGFR, in colonic epithelial cells (Yan et al. 2011). These data highlight the 
potential of pectin / zein hydrogel beads as a novel type of colon specific drug 
delivery vehicle. Along with the premenitoned prebiotic properties of pectin, this 
system represents a potential method for delivery of colicin proteins to the CD 
colon, which in a portion of patients is abnormally colonised by AIEC. 
 
4.1.3 Model of LF82 intestinal infection in conventional mice 
Previous work has demonstrated that persistent AIEC LF82 intestinal infection in 
mice requires depletion of gut microbiota or expression of specific host factors 
such as human CEACAM receptors (Benoit Chassaing, Koren, et al. 2014, Small 
et al. 2013). In this work, a murine model of persistent LF82 colonisation was 
utilised, that was established by Gillian Douce and Zoe Marjenberg (University of 
Glasgow; Institute of Infection, Immunity and Inflammation). In this model, 
conventional mice were first treated with streptomycin, to eradicate gut microbiota 
populations, followed by infection with streptomycin resistant AIEC LF82 strain, 
LF82::StrpR. Persistent colonisation of murine intestine with LF82::StrpR was 
facilitated by supplementation of drinking water with streptomycin throughout the 
experiment. Typically, colonisation by LF82 occurs in the murine intestine for 9 
days with approximately 105 CFUs detected in faecal pellets on day 9 (Figure 4.2; 
Douce and Marjenbern, unpublished data). LF82 are detected in the caecum 
(approx. 106 CFUs) and colon (approx. 105 CFUs) 3 days after infection.  At 9 days 
post-infection, approximately 105 CFUs and 104 CFUs are detected in the caecum 
and colon respectively (Figure 4.2c).  
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Figure 4-2: Persistent intestinal colonisation with LF82 in conventional CF-1 mice treated 
with streptomycin. 
A) Figure shows LF82 faecal CFUs. CF-1 mice were treated with streptomycin (100 mg ml-1) and 
infected with LF82::StrpR for 18 h and faecal pellets were collected for 9 days and serially diluted in 
PBS and plated on LB agar containing streptomycin (100 µg ml-1) and erythromycin (500 µg ml-1|). 
Plotted dot represents average CFU count for group (n=5). Error bars shown are SD. B) Figure 
shows LF82 CFUs detected in intestinal tissue samples. LF82 infected mice were culled at 3 days 
and tissues were extracted and homogenised and diluted to determine CFU counts. C) LF82 
bacteria counts detected in intestinal luminal samples (3 days). Infected mice were culled and 
luminal contents were flushed from organs and plated to determine CFU counts.  Each dot 
represents one mouse. Black line shown represents mean and error bars show SD. Data shown in 
figure obtained by Zoe Marjenberg (University of Glasgow; Unpublished). 
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4.2 Aims 
The aim of the work described in this chapter was to test the ability of purified 
colicin to reduce bacterial numbers in a mouse model of AIEC intestinal 
colonisation. In order to achieve this, a delivery method was established in which 
colicin was encapsulated in pectin/ zein hydrogel beads. Encapsulated colicin was 
then delivered orally to the GI tract of AIEC colonised animals.  
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4.3 Results 
4.3.1 Preparation of pectin / zein hydrogel beads 
In order to test the suitability of pectin / zein hydrogel beads for delivery of colicin 
to the mouse colon, beads were prepared as previously described (LinShu Liu, 
Fishman, Hicks, et al. 2006). Pectin solution prepared from pectin (poly-D-
galacturonic acid methyl ester; ≥74% esterified) from citrus peel (Sigma) was 
dropped manually by syringe into zein / CaCl2 solution at room temperature.  
Beads formed immediately as droplets entered reception solution and were then 
washed and dried (Figure 4.3). Several parameters were optimised for this 
process including syringe needle diameter (23 gauge-30 gauge), pectin 
concentration (2-6%) and zein concentration (0.5-1%). Beads were stored at 4°C 
and were used within one week.  Due to manual dropping by syringe, each round 
of bead production yielded approximately 200 beads. Beads were homogenous in 
appearance, were an average diameter of 1- 2mm and were stable in deionised 
water, PBS, 0.5% NaCl and 50 mM Tris-HCl (Figure 4.3). Beads also retained 
structure and rigidity for one month at 4°C. Beads produced by this method were 
used as control beads for all mouse experiments.  
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Figure 4-3: Preparation of pectin / zein hydrogel beads. 
A) Pectin droplets in zein solution (1% zein; 85% EtOH; 0.5% CaCl2) at room temperature. Beaker 
shown represents “one batch” production method. B) Light micrographs of washed pectin / zein 
hydrogel beads. Scale bar shown is 10 mm. C) Dried pectin / zein hydrogel beads. Following 
drying at 30°C beads showed highly robust consistency.  
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4.3.2 Colicin E1 encapsulated within pectin / zein hydrogel beads 
is active against LF82 
For protein encapsulation, colicin E1 was purified as previously described and was 
diluted to 10 mg ml-1 in pectin solution and dropped into zein / CaCl2 solution to 
form colicin-containing beads. As stated before approximately 200 beads were 
yielded from each production batch. To determine the efficiency of colicin 
encapsulation into pectin / zein hydrogel beads, dried beads were run on SDS-
PAGE. A single bead (~15 mg) and five beads (~75 mg) were each dissolved in 
0.5% NaOH, 20% Tween and diluted in SDS running buffer and run on SDS-
PAGE (12% polyacrylamide). For every assay, bead samples were also run 
alongside known concentrations of colicin E1 to determine band intensities for 
standard concentrations (Figure 4.4).  
For samples consisting of one colicin loaded pectin / zein bead, a band was 
detected at the corresponding size for colicin E1 (62kDa) and resolved at a similar 
intensity to band observed for colicin E1; 625 ng (Figure 3.4). Additionally, for 5 
bead samples, a band that resolved at a similar intensity to band observed for 
colicin E1; 4 µg was detected (Figure 4.4). This indicated that approximately 700 
ng of colicin E1 was encapsulated per one hydrogel bead. The encapsulation 
efficiency was calculated by: (actual E1 encapsulated / total E1 added) * 100 and 
was calculated as 1.4%. The encapsulation efficiency was determined for every 
batch of colicin containing hydrogel beads produced and utilised for further 
investigation.  
In order to test the cytotoxic activity of colicin E1 beads, overlay spot plate assays 
were performed using both colicin E1 beads and control beads. For killing assays 
a single dried bead was placed on a growing lawn of LF82::StrpR and incubated 
overnight at 37°C.  Colicin E1 beads showed good killing of LF82 and control 
beads failed to inhibit growth of LF82 lawn (Figure 4.4).  This indicated that 
encapsulation of colicin within pectin / zein matrix does not affect the cytotoxic 
function of colicin E1.  
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Figure 4-4: Encapsulation of colicin E1 in pectin / zein hydrogel beads. 
A) Figure shows SDS-PAGE gel (12% polyacrylamide) for visualisation of colicin protein 
encapsulated in one pectin / zein hydrogel bead.  ColE1 (10 mg ml-1) was mixed with pectin CaCl2 
and dropped into zein solution to form beads. To determine concentration of colicin E1 
encapsulated, beads were dissolved in 20% Tween, 0.5% NaOH, mixed with SDS running buffer, 
boiled and run on SDS PAGE. Lanes are: i)  Protein molecular weight ladder;  ii) ColE1 bead A, iii) 
ColE1 bead B; iv) ColE1 2.5 µg ; v) ColE1 1.25 µg;  vi) ColE1 625 ng  B) Figure shows SDS-PAGE 
gel for visualisation of  colicin E1 encapsulated in five pectin / zein hydrogel beads. i) protein 
molecular weight ladder ii) protein band resolved from 5 ColE1 beads iii) E1 4 µg , iv) ColE1 2 µg, 
v) Col E1 1 µg. C) Overlay of hydrogel beads on LF82 bacterial lawn.  i) + ii) Col E1 bead, iii) 
control bead.  
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4.3.3 Encapsulated colicin treatment does not eliminate LF82 
intestinal infection  
To determine if encapsulated colicin was active in vivo against intestinal LF82, 
colicin E1 loaded beads were administered to infected mice by oral gavage. 
In an initial experiment, streptomycin treated mice (n=5) were infected with 
approximately 108  CFUs of LF82::StrpR for 18 h and then received five colicin E1 
loaded pectin/ zein beads in distilled water (100 µl) containing approximately 4 µg 
colicin E1. For the control group (n=5), mice received beads not loaded with colicin 
E1. Faecal pellets were collected after 18 h to determine bacterial load in all 
groups. Faecal pellets were homogenised, serially diluted and plated on LB agar 
containing streptomycin (100 µg ml-1) and erythromycin (500 µg ml-1) and 
incubated overnight at 37°C. Colicin-loaded bead treatment of mice showed 
significantly reduced bacterial counts relative to control bead treated mice 
(P=0.01) (Figure 4.5a).   
From these data it was postulated that increased and prolonged doses of colicin-
loaded beads would result in a larger reduction in LF82 intestinal infection. To 
investigate this, streptomycin treated mice were infected with LF82::StrpR for 18 h 
as stated but then received a double dose of ten colicin loaded beads, containing 
approximately 8 µg of colicin E1. In addition to this, 10 colicin loaded beads were 
administered to mice every day, for 7 days. Bead treatments were administered 
approximately 18-22 h apart.  Faecal pellets were collected every 18 h and were 
plated as described to determine bacterial load. LF82 was shown to colonise mice 
for 8 days and high bacterial numbers (approximately 104 – 106 CFUs) were 
detected (Figure 4.5b). In mock treated mice, peak CFU counts were observed for 
LF82 at day 4 (Figure 4.5b). These data showed that bacterial loads were not 
significantly different among colicin treated and control groups at all time points 
tested (P>0.05) (Figure 4.5b). At day 4 – day 7 a reduction in bacterial load was 
shown for colicin E1 bead treated group relative to control group but this was not 
significantly different (P> 0.05) (Figure 4.5c).  
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Figure 4-5: Treatment of persistent LF82 colonisation in conventional mice with colicin E1 
loaded pectin / zein hydrogel beads. 
A) Treatment of LF82 infection with colicin E1 encapsulated in pectin / zein hydrogel beads at 18 h 
post infection.  Mice were infected with LF82::StrpR for 18 h and treated with 5 colicin loaded beads 
(~75 mg) by oral gavage. Each bead contained approximately 700 ng purified colicin E1. For the 
control group, beads were not loaded with colicin. Faecal pellets were collected 18 h after colicin 
treatment to determine bacteria counts. Colicin bead treatment significantly reduced bacterial load 
(P=0.01). Each symbol represents one mouse. Black line and error bars shown are mean and 
SEM. * shows significant difference between groups (P < 0.05). Non-parametric Mann–Whitney U-
test was carried out for statistical significance. B) Daily treatment of LF82 infection with double and 
prolonged dose of colicin loaded beads. Streptomycin treated mice were infected with LF82::StrpR 
and received ten colicin E1 loaded beads by oral gavage 18 h after infection and then daily for 7 
days. Dot represents mean CFU counts for treatment group (n=5). Day 0= day of infection. Day 1= 
first bead treatment. No significant difference in bacterial load was observed between all groups at 
all time points.  C) Bacterial load detected at day 6 in all groups for daily treatment with colicin 
beads. Error bars shown are mean and SEM. No significant difference detected in bacterial load 
between colicin E1 and control bead treated groups (P=0.055). Non-parametric Mann–Whitney U-
test was carried out for statistical significance. 
 
134 
 
4.3.4 Treatment of LF82 colonised mice with non-encapsulated 
colicin E1  
As colicin E1 loaded beads (4-8 µg) did not show good efficacy against LF82 
colonising the murine intestine, we tested the activity of purified colicin E1 solution. 
For this, streptomycin treated mice were infected with 108 CFUs of LF82::StrpR for 
18 h as previously described. Mice were administered with sodium bicarbonate 
and then received colicin E1 (10 mg ml -1) in PBS (100 µl) by oral gavage. Mice 
received colicin E1 solution daily for 7 days. Mock-treated group received PBS 
only. Bacterial load was monitored by faecal output as stated. LF82 intestinal 
infection was significantly reduced at day 2 for colicin E1 treated mice compared to 
mock treated mice (P= 0.0195; Figure 4.6).  A reduction in bacterial load was 
detected at day 4 for colicin E1 treated group relative to mock-treated group but 
this was not significantly different (P>0.05; Figure 3.6). These data indicate that 
colicin E1, when used in the form of purified protein and encapsulated within 
hydrogels is not an effective therapy against intestinal LF82 in this specific murine 
model of infection.  
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Figure 4-6: Treatment of LF82 intestinal infection with recombinant colicin E1 solution. 
A) Mice were infected with LF82::StrR for 18 h and received colicin E1 (10 mg ml-1) by oral gavage 
(100 µl). Colicin E1 treatment was administered daily for 7 days. Bacterial loads were determined 
by plating homogenised faecal pellets on LB agar. Dot represents mean CFU count for treatment 
group (n=5). Day 0 = day of infection. Day 1= first colicin treatment.  Scale bars shown represent 
SEM.  To compare bacteria numbers non-parametric Mann–Whitney U-test was carried out at all 
time points for statistical significance. * shows significant difference between groups (P< 0.05). 
LF82 intestinal infection was significantly reduced at day 2 for colicin E1 treated mice compared to 
mock treated mice (P= 0.0195).  
 
4.3.5 Assessment of colicin E1 stability in murine gastrointestinal 
tract 
It was postulated that poor killing of colonic LF82 by colicin E1 could be explained 
by digestion or inactivation of colicin in the murine small intestine. To ascertain if 
colicin administered via the oral route remained active in the murine intestine, mice 
that had not been exposed to LF82, received 0.1 M sodium bicarbonate and were 
administered with colicin E1 in PBS (10 mg ml-1) by oral gavage (100 µl). Mice 
were culled 30, 60 and 120 min post treatment and intestinal organs were 
extracted and homogenised.  Colicin activity in organ samples was tested via 
overlay spot plate method and LF82::StrpR was used as the indicator strain. Colicin 
136 
 
activity was detected in stomach samples at all time points tested. This was shown 
in the form of a clear and large zone of killing at 30 and 60 min and as a diffuse 
zone of killing at 120 min.  No colicin activity was detected in the small intestine, 
cecum and colon tissue samples at all tested time points (Figure 4.7). This 
indicates that colicin E1 was inactivated in the small intestine.  
 
Figure 4-7: Colicin stability in murine gastrointestinal tract. 
Colicin E1 is inactivated in the small intestine. Conventional mice were treated with colicin E1 (10 
mg ml-1) and were culled at 30, 60 and 120 min post treatment. A) Plate shows spot plate results 
from organs extracted from mice culled at 60 min. Intestinal tissues were extracted and 
homogenised and suspension was spotted on agar lawn of LF82::StrpR. Zones of inhibition 
represent killing of LF82. S; stomach, SI; small intestine; Ca’ cecum; C; colon.  Image is 
representative image of three replicate spot assays from 5 intestinal tissue samples of 5 mice. B) 
Table showing colicin activity detected in intestinal organs 30, 60 and 120 min post treatment.  + 
denotes large zone detected in spot plate assay, ~ denotes small diffuse zone and – denotes no 
zone.  
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4.4 Discussion 
The use of colicins as a novel therapy for CD associated AIEC infection 
demonstrates several attractive attributes, one being the preservation of resident 
bacteria populations in a microbial community likely showing dysbiosis. Due to 
this, we were extremely interested to investigate the efficacy of colicins against 
AIEC growing in the gastrointestinal tract. For this purpose, we utilised an 
established model of persistent LF82 colonisation (Marjenberg and Douce, 
University of Glasgow) that involved infection of conventional mice following 
streptomycin depletion of gut microbiota species.  For this model, LF82 
colonisation was monitored by bacterial load in faecal pellets and infected mice did 
not display symptoms of colitis or illness. The method of encapsulation utilised in 
this work was adapted from previous work that represents the first investigation of 
pectin / zein hydrogel beads for colon specific drug targeting (LinShu Liu, 
Fishman, Hicks, et al. 2006). This specific method of encapsulation was selected 
for 2 reasons: 1) the simple encapsulation process involved and 2) beads could be 
administered orally to mice without a requirement for anaesthesia. Although data 
obtained in this chapter indicates that encapsulated colicin shows poor activity 
against intestinal AIEC, the method utilised in this pilot study prevents us from 
making valid conclusions on the prospect for using colicins against AIEC.  
Firstly, due to the poor efficiency of colicin encapsulation, very low concentrations 
of colicin E1 were administered to infected mice. Taking into account the dilution of 
colicin E1 in the murine GI tract, it is likely that the final concentration of colicin E1 
reaching the site of AIEC colonisation was extremely low. Furthermore, as drug 
release at the colon target site requires colonic microbiota pectinase activity, by 
utilising a streptomycin treated murine model, it is likely that the one component 
required for this delivery vehicle was absent or severely reduced. Indeed, the 
slight reductions in bacterial load detected in colicin treated groups indicates that 
colicin E1 may be reaching its target site. Delivery of encapsulated protein drug to 
its target site was determined by western blot detection in the pioneer study 
utilising pectin/zein hydrogel beads (Yan et al. 2011). This should be incorporated 
into future work utilising this colicin treatment model. 
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It must also be realised that for future assessment of colicin efficacy, alternative 
murine models of AIEC infection should be utilised that accurately depict the role 
of this E. coli pathovar in CD. This would ensure that both killing of intestinal AIEC 
and alleviation of AIEC-induced symptoms could be investigated. Good examples 
of such models include chronic colitis induced by AIEC infection in TLR-5 deficient 
(T5KO) mice that are raised in a GF environment (Benoit Chassaing, Koren, et al. 
2014). Additionally, in mice that express human CEACAM receptors, LF82 persists 
in the intestine and induces severe colitis relative to wild type mice (Frédéric a 
Carvalho et al. 2009). Future work that utilises a more accurate model of CD 
associated AIEC infection will give greater insights into the applicability of colicins 
as a therapy for CD patients and other intestinal E. coli infections.  
Encapsulated bacteriocins for the treatment of intestinal bacterial infections has 
been previously investigated whereby Campylobacter jejuni infection in chickens 
was reduced approximately one million fold following oral administration of 
encapsulated bacteriocins isolated from Lactobacillus salivarius and Paenibacillus 
polymyxa (Norman J Stern et al. 2005). In this work, purified bacteriocins were 
micro-encapsulated in polyvinylpyrrolidone (PVP) and added into chicken feed at 
250 mg bacteriocin/kg feed, suggesting that in this case, alternative methods of 
encapsulation that facilitated better loading of colicin, should be attempted.  
When considering long term and clinical implications, this therapy could be utilised 
as both a treatment and a prophylactic for AIEC infection in CD. CD patients could 
receive encapsulated colicin immediately after diagnosis to prevent abnormal 
colonisation by AIEC and further dysbiosis of gut microbiota.  Indeed, for such a 
treatment to be utilised effectively, further information on the role of AIEC in CD is 
required to ensure accurate targeting of drug and that treatment begins before 
inflammation. This relies on determining whether AIEC is a primary cause of CD 
associated inflammation or is in fact, a commensal E. coli that behaves 
pathogenetically in the hostile CD gut environment. Key components of this will be 
investigated in the following chapter.   
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5 The prevalence of AIEC-associated phenotypes 
in E. coli isolated from HLA-B27 positive 
juvenile idiopathic arthritis (JIA) patients  
5.1 Supporting evidence 
5.1.1 Colonic E. coli are increased in HLA-B27 positive JIA 
patients 
Juvenile idiopathic arthritis (JIA) is classified as a clinically heterogeneous group of 
chronic, inflammatory diseases characterised by arthritis that begins before the 
age of 16 (Weiss 2012). Cohort studies have demonstrated that 45% of enthetis 
related arthritis (ERA) JIA patients are HLA-B27 positive (+) (Stanevicha et al. 
2010). A pilot study, performed at Yorkhill Hospital, showed increased colonic E. 
coli in JIA patients compared to healthy controls (Gerasimidis et al., unpublished 
work) (Figure 5.1a). Additionally, following subdivision of JIA patients into HLA-
B27 (-) and HLA-B27 (+) groups, it was reported that increased E. coli numbers 
were detected in HLA-B27 (+) patients compared to HLA-B27 (-) patients (Figure 
5.1b).   Results obtained from this pilot study also showed reduced Lactobacillus 
numbers in JIA patients and increased Faecalbacterium prausnitzii relative to 
healthy controls (Figure 5.1a). Additionally, faecal calprotectin measurements 
showed normal levels of this intestinal inflammatory marker in the majority of JIA 
patients relative to healthy controls indicating that increased colonic E. coli 
numbers are not a consequence of pre-existing inflammation. 
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Figure 5-1: Intestinal dysbiosis and increased E. coli in HLA-B27 positive JIA patients. 
A) Adapted from figure obtained from Yorkhill study investigating gut microbiota composition in JIA 
(Gerasimidis et al., 2011-2012. Unpublished work). Box plots for faecal bacteria in healthy and JIA 
patients determined by quantitative polymerase chain reaction using primers targeted at 16S rDNA. 
For each set of data, the horizontal line within the box is the median, the box ends are the 
interquartile range, and the whiskers represent the absolute range. B) Box plots for faecal E. coli 
16S rDNA in JIA NULL (HLA-B27 negative) and JIA RISK (HLA-B27 positive) patients.  Results 
show increased median bacteria counts for faecal E. coli in JIA RISK patients. 
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5.2  Background 
5.2.1 The association between HLA-B27 and Crohn’s disease 
Ankylosing spondylitis (AS) is regarded as the prototype of seronegative 
spondyloarthropathies (SpAs), that are a group of chronic inflammatory diseases 
affecting the bowel, joints and the axial skeleton (Rashid et al. 2013). AS is 
predominantly described as chronic inflammation of joints of the spine. Other 
disease entities of SpA include reactive arthritis, psoriatic arthritis and arthritis 
associated with inflammatory bowel disease (IBD), that includes Crohn’s disease 
(CD) (de Vlam et al. 2000). AS and spondylitis associated CD are interlinking 
conditions based on certain genetic, clinical, immunological and microbial features.  
For over 3 decades, human leukocyte antigen B27 (HLA-B27) gene has been 
associated with ankylosing spondylitis (AS) and related spondyloarthropathies 
(Brewerton et al. 1973). HLA-B27 is a cell-surface protein encoded by the B locus 
in the major histocompatibility complex (MHC) that functions in the presentation of 
peptide antigens to T cells (Joel D Taurog 2007).  It’s association with AS is one of 
the strongest known associations between an HLA molecule and disease. 
Approximately 95% of AS patients carry at least one HLA-B27 allele compared 
with <10 % of healthy individuals (Brewerton et al. 1973). The frequency of this 
molecule in the general IBD population is found to be comparable to the healthy 
control population (Figure 5.2)(J et al. 1988, Palm et al. 2002, Peeters 2004). 
However, IBD patients with AS often show a significantly higher association with 
HLA-B27 (25–78% being HLA-B27 positive), suggesting that HLA-B27 is a risk 
factor for the development of AS in these patients (Figure 5.2)(Palm et al. 2002, 
Steer et al. 2003, de Vlam et al. 2000). Furthermore, AS is frequently associated 
with IBD with 5-10% of cases having clinically overt IBD and approximately 70% of 
cases having subclinical bowel inflammation (Thomas and Brown 2010, De Vos et 
al. 1989). Additionally, approximately 30% of CD patients present with axial and 
peripheral arthritis (Hammer et al. 1990, Mielants et al. 2005, Orchard and Holt 
2009). Furthermore, gut changes varying from acute to asymptomatic chronic 
inflammation, are observed in 60% of patients with SpA’s, and disease remission 
is frequently preceded by the disappearance of gut inflammation (Demetter et al. 
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2002). These data indicate a pivotal role for gut inflammation and HLA-B27 for the 
development of SpA’s, especially CD and AS.  
 
 
Figure 5-2: Proportion of phenotypic and genetic subsets in patients with IBD. 
Figure shows approximate frequency of HLA-B27 in each subset of IBD. Figure adapted from 
Rudwaleit et al.(Rudwaleit and Baeten 2006). 
 
5.2.2 HLA-B27 is associated with intestinal inflammation and 
dysbiosis 
The HLA-B27 transgenic rat model represents a unique model to understand the 
role of the HLA-B27 gene in SpAs associated with IBD (Milia et al. 2009). Rats 
transgenic for HLA-B27 spontaneously develop chronic inflammatory disease that 
resembles the human SpA, involving colitis and peripheral arthritis (Hammer et al. 
1990). Several important factors of this model have been established, including it’s 
dependency on bacterial flora and the immune system (Milia et al. 2009). 
Typically, colitis and arthritis does not develop in HLA-B27 transgenic rats that are 
raised in a GF environment, although transfer of rats out of this environment 
causes spontaneous intestinal inflammation to develop (Hammer et al. 1990; 
Taurog et al. 1994). Intestinal inflammation detected in this model involves 
progressive chronic gastrointestinal inflammation (mostly involving the colon) and 
the pro-inflammatory cytokine pattern of HLA-B27 rats corresponds to that 
observed in CD (Faure et al. 2004).  
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Interestingly, increased E. coli and Enterococcus numbers were detected in HLA-
B27 transgenic rats with chronic colitis (Onderdonk et al. 1998). Moreover in this 
model, authors failed to detect the presence of enterotoxin genes in resident E.coli 
populations, indicating an imbalance of commensal E. coli rather than pathogenic 
E. coli species. In other work, severe colitis was induced by reconstitution of germ 
free HLA-B27 transgenic rats with Bacteroides vulgatus and monocolonisation of 
rats with E. coli  induced very mild colonic inflammation (Rath et al. 1999). It is yet 
to be determined if increased E. coli populations associated with HLA-B27 
demonstrate any phenotypic similarity to CD associated AIEC. 
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5.3 Hypothesis and aims 
5.3.1 Hypothesis 
Although dysbiosis and increased levels of AIEC are strongly associated with CD, 
the exact role of the gut microbiota in CD is poorly understood. This is due to the 
inability of previous studies to establish whether alterations to the gut microbiota 
are a consequence of disease and not a primary factor in the development of CD. 
The hypothesis we attempted to test in this work was that JIA patients who are 
HLA-B27 positive and are at increased risk of developing CD, show increased 
levels of AIEC, that precede the development of intestinal inflammation. If this is 
the case then this would strengthen the idea that AIEC is an important primary 
factor in the development of CD.  
 
5.3.2 Aims 
 Isolate E.coli from faecal samples of JIA HLA-B27 (-) (JIA NULL), JIA HLA- 
B27 (+) (JIA RISK) patients and healthy patients using standard cultivation 
techniques.  
 Determine if isolated E. coli demonstrate AIEC associated phenotypes and 
assess if these phenotypes are more frequently detected in E. coli isolated 
from JIA HLA-B27 (+) patients.    
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5.4 Results  
5.4.1  Isolation of E. coli from patient faecal samples  
5.4.1.1 Cultivation of E. coli on Gram-negative selective media 
In order to isolate E. coli from faecal samples, standard cultivation methods on 
Gram-negative selective media were used. Faecal samples were homogenised, 
serially diluted and plated in triplicate on MacConkey agar and incubated overnight 
at 37°C. E. coli colonies (pink; purple) were counted and mean colony counts were 
determined for each patient stool sample. Three to five putative E. coli isolates that 
showed distinct colony morphology, were stocked for each stool sample. All 
isolates were restreaked on EMB agar and E. coli growth was detected by 
appearance of metallic green colouration around colonies (Figure 5.3). The 
majority of patient faecal samples contained very low numbers of viable E. coli. 
Median faecal E. coli counts for JIA RISK, JIA NULL and healthy groups were 
81.20; 8.42 and 13.57 respectively (Figure 5.3). There was no significant 
difference between groups for median E. coli counts (P > 0.05).   
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Figure 5-3: Isolation and selection of faecal E.coli strains. 
A) Faecal samples were plated on Gram-negative selective media, MacConkey agar, and 
incubated overnight at 37°C. Growth of E. coli was shown by growth of pink (i) or purple colonies 
(ii). Isolates were stocked on LB agar and restreaked on eosin methylene blue (EMB) agar that 
indicates for the growth of E. coli by formation of metallic green colonies (iii; iv). B) Colony counts 
of E. coli on MacConkey agar for healthy, JIA NULL and JIA RISK faecal samples. Each point 
represents mean E. coli colony count for one patient stool sample and data represents mean value 
from three independent experiments. Black line shown represents median colony count for each 
group. Differences in bacterial counts between groups were tested by the Mann-Whitney U test. 
There was no significant differences observed between groups for median colony counts (P> 0.05).   
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5.4.1.2 PCR amplification of 16S rRNA of faecal E. coli strains 
In order to select strains for further assessment of the adherent and invasive 
phenotype it was important to confirm species identify as E. coli. This was 
achieved by sequencing of the 16S rRNA gene. As the majority of strains showed 
identical growth phenotype on MacConkey and EMB agar, only half of the isolated 
strains were tested by this method (See Appendix E).  
Extraction of genomic DNA was carried out using a freshly streaked colony on LB 
agar that was lysed as described. Universal primers targeting the V2 and V3 region 
of the 16S rRNA gene sequence, 88F and 91R, were used in a standard PCR 
reaction giving a 300bp fragment for all tested strains of E. coli. Amplicons of 16S 
rRNA gene were sequenced at Source Bioscience using 88F and 91R primers and 
the sequences were analysed using BLAST tool at National Centre for 
Biotechnology Information (NCBI). Sequencing of 16S rRNA showed that all tested 
strains belonged to E. coli species. Strains that were not investigated for PCR 
amplification of 16S rRNA but showed identical phenotypes to surveyed strains 
were also classified as E. coli.  By this method 40 E. coli strains were isolated that 
comprised of 23 strains isolated from healthy patient samples; 12 strains isolated 
from JIA NULL patients and 5 strains from JIA RISK patients (Appendix E). These 
strains were used for all experiments described in the remainder of this chapter. 
 
5.4.2 Investigation of the AIEC phenotype in faecal E. coli strains 
 
5.4.2.1 Invasion of T84 intestinal epithelial cells by faecal E. coli strains 
It has previously been shown that in contrast to most commensal E. coli, AIEC 
have the ability to invade intestinal epithelial cells (Boudeau et al. 1999). In order 
to compare the invasive ability of E. coli strains isolated from JIA RISK, JIA NULL 
and healthy patients, we performed invasion assays using T84 cell monolayers. 
T84 monolayers were infected with E. coli strains (MOI = 10) for 2 h and treated 
with gentamicin or kanamycin for 1 h to kill extracellular bacteria. MICs for 
antibiotics against faecal E. coli strains are shown in Appendix F. Lysed cells were 
then plated on LB agar to determine CFU counts. The ability to invade T84 cells 
was expressed as an invasion index (I_INV) that was calculated as: (number of 
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intracellular bacteria at 2 h / number of bacteria in original inoculum)* 100. As 
reported previously in the literature, to be classified as invasive E. coli strains must 
show I_INV value ≥ 0.1 (Martinez-Medina and Garcia-Gil 2014). The mean I_INV 
of the non- invasive control strain, E. coli F18, was 0.001 ± 0.0025 (Table 5.1). 
AIEC reference strain LF82, included in all of the assays as a positive control, 
showed mean I_INV of 1.25 ± 0.3.  For the E. coli strain group isolated from 
healthy patients, the median I_INV was 0.0040. The median I_INV for the E. coli 
strain group isolated from JIA NULL patients was 0.02567. The median I_INV for 
E. coli strain group isolated from JIA RISK patients was 0.0027 (Figure 5.4). A 
significantly different median I_INV was shown between E. coli groups isolated 
from JIA NULL and JIA RISK patients (P = 0.0392) (Figure 5.4). There was no 
significant difference in the median I_INV values between E. coli groups isolated 
from JIA RISK and healthy patients (P=0.76). For E. coli strains isolated from 
healthy patients (n=23), 3 strains (13%) showed I_INV ≥ 0.1 (Figure 5.4). For E. 
coli strains isolated from JIA NULL patients, 2 (16.6%) strains showed I_INV ≥ 0.1. 
In this work, zero E. coli strains that were isolated from JIA RISK patients 
demonstrated I_INV ≥ 0.1. These data indicate that E. coli isolated from HLA-B27 
positive patients do not show an increased ability to invade intestinal epithelial 
cells compared to E. coli isolated from HLA-B27 negative patients and healthy 
patients. 
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Figure 5-4: Mean invasion index values for faecal E.coli strains isolated from healthy, JIA 
NULL and JIA RISK patients. 
Each data point represents mean I_INV value for one strain. Median is shown by black line. Strains 
that showed invasion index ≥ 0.1 (above or on dashed line) were classified as invasive. Data 
represents mean I_INV value calculated from three independent experiments. For invasion data, 
comparisons of unpaired median I_INVs were performed using the nonparametric Mann–Whitney 
U test. Differences were considered statistically significant at P < 0.05.  
  
5.4.2.2 Intramacrophagic replication 
AIEC bacteria survive and replicate within macrophages without inducing host cell 
death. This is proposed to induce production of pro-inflammatory cytokines 
(Glasser et al. 2001). In order to test bacterial replication within macrophages, 
gentamicin protection assays were performed using the murine macrophage-like 
cell line J774-1. E. coli (MOI=50) were added to confluent J774 cells for 2 h and 
treated with gentamicin or kanamycin to kill extracellular bacteria. Cells were 
plated on LB agar after 1 h and 4 h to determine intramacrophagic proliferation. 
The ability to replicate within macrophages was expressed as the replication index 
(I_REP) that was calculated as: (number of intracellular bacteria at 4 h / number of 
bacteria at 1 h) *100. AIEC associated replication was denoted by I_REP ≥ 100. 
AIEC reference strain LF82 showed a mean I_REP of 159 ± 21. The non-invasive 
commensal strain F18 showed a mean I_REP of 72 (Table 5.1). For E. coli strain 
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group isolated from healthy controls, the median I_REP was 52.87. The median 
I_REP for E. coli strain group isolated from JIA NULL patients was 62.88.  For the 
E. coli group isolated from JIA RISK patients, the median I_REP was 41.67 
(Figure 5.5). There was no significant difference in median I_REP values between 
all groups (P>0.05).  
These data showed that 7 (30.4%) of the E. coli strains isolated from healthy 
controls showed I_REP ≥ 100. It was shown that 5 (41.6%) of the E. coli strains 
isolated from JIA NULL patients showed mean I_REP ≥100 and finally 2 (40%) of 
the E. coli strains isolated from JIA RISK patients, demonstrated mean I_REP ≥ 
100 at 4 h (Figure 5.5).  
Overall, these data indicate that E. coli strains isolated from HLA-B27 positive 
patients do not show an increased ability to proliferate within macrophages and so 
do not resemble AIEC more than E. coli strains isolated from JIA NULL patients 
and healthy controls. Furthermore, these data also demonstrate that E. coli strains 
that demonstrate intramacrophagic proliferation can be found in the colon of 
healthy individuals.  
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Figure 5-5: Mean replication index values for faecal E.coli strains isolated from healthy, JIA 
NULL and JIA RISK patients. 
Each data point represents mean value for one strain. Median is shown by black line. Strains that 
showed replication index ≥ 100 (above or on dashed line) demonstrated AIEC associated 
phenotype of intramacrophagic proliferation. For intramacrophagic replication data, comparisons of 
median I_REPs for groups were performed using the nonparametric Mann–Whitney U test. 
Differences were considered statistically significant at P < 0.05.  
 
5.4.2.3 Intramacrophagic persistence 
In addition to the ability of AIEC to replicate within macrophages, other work has 
demonstrated persistence of AIEC within macrophages at 48 h (Dunne et al. 
2013). In order to test the ability of E. coli strains to persist within macrophages at 
48 h, gentamicin protection assays were performed using J774.1 macrophages. 
The ability of E. coli to persist within macrophages was expressed as a 
persistence index (I_PERS) that was calculated as: (number of intracellular 
bacteria at 48 h/ number of bacteria at 1 h)*100. Intracellular persistence was 
denoted by I_PERS ≥1. AIEC LF82 reference strain showed a mean I_PERS of  
2.3 ± 1.2 at 48 h and commensal E. coli strain F18 showed a mean I_PERS value 
of 0 (Table 5.1). The majority of faecal E. coli strains investigated in this assay 
showed a mean I_PERS of 0 and did not persist in macrophages at 48 h (Figure 
5.6a). E. coli strains that showed I_PERS value of 0 were removed from 
subsequent analysis. For E. coli strains that showed I_PERS > 0: the median 
I_PERS value for E. coli strains isolated from healthy controls was 1.17; the 
median I_PERS value for E. coli strains isolated from JIA NULL patients was 0.23 
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and the median I_PERS value for E. coli group isolated from JIA RISK patients 
was 3.75. Median I_PERS values were not significantly different between JIA 
NULL and healthy control groups (P=0.14). Due to the small sample size shown 
for E. coli group isolated from JIA RISK patients, Mann Whitney U test could not 
be performed to determine statistical significance between JIA RISK vs JIA NULL, 
healthy E. coli groups. These data showed that 5 (21.7%) of the E. coli strains 
isolated from healthy controls showed mean I_PERS ≥1. Two (16.6%) of the E. 
coli strains isolated from JIA NULL patients showed a mean I_PERS ≥ 1.  Two 
(40%) E. coli strains isolated from JIA RISK patients showed a mean I_PERS≥ 1 
(Figure 5.6a).  
 
Data obtained in this work demonstrates that E. coli strains isolated from HLA-B27 
positive patients do not show increased ability to persist within macrophages as 
shown by AIEC, relative to E. coli isolated from HLA-B27 negative patients and 
healthy controls. Additionally, these data demonstrate that the AIEC associated 
phenotype of intracellular persistence is shown by E. coli strains isolated from 
healthy patients.  
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Figure 5-6: Mean persistence index values for faecal E.coli strains isolated from healthy, JIA 
NULL and JIA RISK patients. 
A) Each data point represents mean I_PERS for one E. coli strain. Majority of E. coli strains show 
mean I_PERS of 0. Strains that showed persistence index ≥ 1 (above or on dashed line) were 
classified as intramacrophagic persister strains. B) Persistence index values for strains that 
showed mean I_PERS> 0. Median I_PERS value for each group is shown by black line. 
Comparisons of median I_PERSs for groups were performed using the nonparametric Mann–
Whitney U test. There was no significant differences in median I_PERS values between all groups 
(P> 0.05). 
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A full summary of the mean I_INV, I_REP and I_PERS for all E. coli strains used in this chapter is 
listed in Table 5.1.  
 
Table 5-1: AIEC associated invasive and intracellular survival phenotypes detected in faecal 
E. coli strains. 
Strain Type I_INV  SD (±) I_REP SD (±) I_PERS SD (±) 
F18 Commensal 0.0000 0.0000 72.00 0.00 0.00 0.00 
LF82 AIEC  1.2500 0.0289 159.02 21.19 2.30 1.20 
H2CA1 Healthy 0.0467 0.0115 187.81 146.99 0.00 0.00 
H47AA1 Healthy 0.0400 0.0000 155.17 34.48 3.45 1.19 
44BB2 Healthy 0.0000 0.0000 126.56 17.95 0.06 0.01 
H42CA1 Healthy 0.0002 0.0003 116.54 82.08 0.00 0.00 
H17CA1 Healthy 0.0033 0.0012 113.95 79.80 7.44 1.61 
H51cA1 Healthy 0.4000 0.3464 107.14 0.00 0.00 0.00 
H43CA1 Healthy 0.0013 0.0012 91.09 45.36 0.00 0.00 
H44BA1 Healthy 0.0007 0.0012 85.71 69.99 0.14 0.03 
H13AA1 Healthy 0.0333 0.0115 80.36 96.43 0.00 0.00 
H54bA1 Healthy 0.0013 0.0012 74.35 60.03 3.08 3.08 
H50aA1 Healthy 0.0333 0.0115 52.87 42.00 0.00 0.00 
H14BA1 Healthy 0.0002 0.0000 44.65 7.77 0.00 0.00 
H59cA1 Healthy 7.3333 1.1547 37.50 30.62 0.00 0.00 
H45AA1 Healthy 0.0040 0.0020 34.57 9.55 0.00 0.00 
H15AA1 Healthy 0.0467 0.0115 33.86 39.46 0.44 0.00 
H7dA1 Healthy 0.1600 0.0200 32.50 8.66 0.00 0.00 
H12bB1 Healthy 0.0020 0.0000 30.77 35.53 0.00 0.00 
H11dA1 Healthy 0.0667 0.0306 22.90 26.66 1.24 1.14 
H13AB1 Healthy 0.0067 0.0042 21.15 26.18 1.10 0.08 
H18BA1 Healthy 0.0003 0.0000 20.31 13.86 0.01 0.01 
H53bA1 Healthy 0.0060 0.0040 14.89 17.40 0.00 0.00 
H12bA1 Healthy 0.0027 0.0012 4.84 1.71 0.00 0.00 
JR25aA1 JIA risk 0.0080 0.0053 131.25 94.37 5.00 2.17 
JR39AA2 JIA risk 0.0033 0.0023 28.13 13.01 0.00 0.00 
JR24aA1 JIA risk 0.0027 0.0012 124.03 12.00 2.51 0.40 
JR29bA1 JIA risk 0.0027 0.0012 41.67 14.43 0.00 0.00 
JR40bA1 JIA risk 0.0020 0.0035 37.40 26.97 0.00 0.00 
J22eA1 JIA 0.4667 0.0577 384.62 314.04 0.00 0.00 
J64dA1 JIA 0.1433 0.0321 15.34 11.64 0.00 0.00 
J80cA1 JIA 0.0467 0.0115 42.86 52.49 0.26 0.15 
J23aA1 JIA 0.0403 0.0560 897.22 1625.25 1.06 0.00 
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J83bA1 JIA 0.0400 0.0200 102.63 119.21 0.04 0.03 
J66cA1 JIA 0.0400 0.0000 33.33 27.22 0.00 0.00 
J82aA1 JIA 0.0113 0.0012 25.00 28.87 0.05 0.07 
J35aA1 JIA 0.0093 0.0012 0.13 0.25 0.00 0.00 
J26aA1 JIA 0.0073 0.0012 150.00 101.00 0.00 0.00 
J84dA1 JIA 0.0067 0.0031 42.86 38.97 1.02 0.40 
J36aA1 JIA 0.0027 0.0012 146.15 63.43 0.20 0.18 
J62b3 JIA 0.0000 0.0000 82.90 56.38 0.00 0.00 
                
Ability to invade intestinal cells was expressed as invasion index (I_INV) that was calculated as: 
(number of intracellular bacteria at 2 h/ number of bacteria in original inoculum)*100.  Ability to 
replicate within macrophages was expressed as replication index (I_REP) that was calculated as: 
(number of intracellular bacteria at 4 h / number intracellular of bacteria at 1 h)*100.  Ability to 
persist within macrophages was expressed as persistence index (I_PERS) that was calculated as: 
(number of intracellular bacteria at 48 h/number of intracellular bacteria at 1 h)* 100. Data shown is 
mean index value and SD determined from 3 independent assays.  
5.4.3 Serotyping of E. coli O antigen  
AIEC are clonally diverse and belong to different groups of serotypes (Martinez-
Medina, Mora, et al. 2009). Interestingly, previous work has reported that AIEC 
prototype strains LF82 and NRG857c belong to O83:H1 serotype (Nash et al. 
2010). Other work reported that approximately 40% of surveyed AIEC strains 
belonged to O6 or O22 serogroups (Martinez-Medina, Aldeguer, et al 2009). In 
order to determine serogroups of faecal E. coli isolates from JIA patients and 
healthy controls, serotyping of somatic O antigen was performed at the 
Gastrointestinal Bacteria Reference Unit, Public Health, Colindale. These data 
showed that a high variability in O antigen serotypes was detected in all groups 
(Table 5.2). This work did not report increased prevalence of serogroups O22, O6 
or O83 in E.coli strain group isolated from JIA RISK patients relative to strains 
isolated from JIA NULL or healthy patients.   
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Table 5-2: Serogroups detected in E. coli strain groups isolated from JIA RISK, JIA NULL 
and healthy patients. 
 
O antigen Number of isolates 
 JIA NULL  JIA RISK  Healthy  
O1 0 1 5 
O18 0 1 0 
O2 0 1 0 
O21 0 1 0 
O8 0 1 2 
O6 0 0 2 
O11 0 0 1 
O19A 0 0 1 
O159 0 0 1 
O146 0 0 1 
O55 0 0 1 
O88 1 0 1 
O125c 1 0 0 
O18Ac 1 0 0 
O20 1 0 0 
O25 1 0 0 
O32 1 0 0 
O81 1 0 0 
O9A 1 0 0 
Ond 4 0 8 
Ond; O antigen for E. coli strain was not identified by this method.  
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5.4.4  Detection of AIEC associated virulence genes in E. coli 
faecal isolates 
In this work, our first approach that investigated the prevalence of AIEC associated 
phenotypes in faecal E. coli through measurement of invasion and intracellular 
replication assays failed to show differences in the frequency of AIEC in JIA NULL, 
JIA RISK and healthy E. coli groups. Therefore, we decided to next investigate the 
prevalence of genetic markers associated with AIEC in faecal E. coli strains. AIEC 
have been shown to carry different sets of virulence genes that are characteristic 
of ExPEC strains (Martinez-Medina, Aldeguer, et al. 2009). In this work, two 
virulence genes that have been previously associated AIEC were investigated; 
lpfA and malX (Martinez-Medina, Mora, et al. 2009). PCR products for lpfA and 
malX were approximately 540 bp and 1600 bp respectively (Figure 5.7). Boiled 
and lysed bacterial colonies were utilised for extraction of genomic DNA and 
amplification of lpfA and malX was performed by standard PCR reaction utilising 
primers lpfAF, lpfAR and malXF, malXR. These data showed that 7 (30.4%) 
strains of the E. coli group isolated from healthy controls, 4 (33.3%) strains of the 
E. coli group isolated from JIA NULL patients and one (20%) strain from the E. coli 
group isolated from JIA RISK patients possessed lpfA.  The malX gene was 
detected in 8 (34.7%) strains of the E. coli group isolated from healthy patients.  
Four strains (33.3%) from the E. coli group isolated from JIA NULL patients and 4 
strains (80%) of the JIA RISK E.coli group possessed malX. Overall, these data 
show that AIEC associated virulence genes, malX and lpfA are detected in E. coli 
strains isolated from healthy controls, HLA-B27 positive and HLA-B27 negative 
patients.  
 
 
Figure 5-7: PCR for detection of AIEC associated virulence factor malX. 
PCR product visualised by agarose gel electrophoresis for AIEC LF82. Lane one shows DNA 
ladder. 
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A full summary of the detection of malX and lpfA in all E. coli strains isolated from 
healthy controls and JIA patients is shown in Table 5.3. The table shows that lpfA 
and malX are detected in E. coli strains isolated from JIA RISK, JIA NULL and 
healthy patients.  It is shown Table 5.3 that some E. coli strains possess both lpfA 
and malX. 
 
Table 5-3: AIEC associated virulence genes detected in faecal E. coli strains isolated from 
JIA NULL, JIA RISK and healthy patients. 
Type Strain Serotype 
AIEC genes detected  
(lpfA, malX) 
Healthy H44bB2 OND - 
  H2cA1 O:88 - 
  H7dA1 O:19A lpfa 
  H11dA1 OND lpfA, malX 
  H15aA1 OND lpfa 
  H18Ba1 O11 - 
  H20Da1 O:1 lpfA, malX 
  H42cA1 O:1 malX 
  H43cA1 O:6 malX 
  H45aA1 O:55 - 
  H47cA1 OND lpfa 
  H50aA1 O:1 malX 
  H51cA1 OND - 
  H53cA1 O:8 lpfa 
  H54bA1 O:6 malX 
  H59cA1 OND lpfA 
  H12ba1 OND - 
  H12bB1 OND - 
  H13aa1 O:1 malX 
  H13AB1 O:1 malX 
  H14BA1 O:146 - 
  H17CA1 O:8 - 
  H44bA1 O:139 - 
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JIA NULL J22eA1 OND lpfa 
  J23aA1 OND - 
  J26aA1 O:81 - 
  J35aA1 OND malX 
  J36aA1 O:125C - 
  J64dA1 OND lpfA 
  J66cA1 O:25 malX 
  J80cA1 O:20 - 
  82aA1 O:88 lpfA 
  83bA1 O:32 - 
  J84dA1 O:18AC malX 
  J62B3 O:9A lpfA, malX 
JIA RISK JR24aA1 O:18 malX 
JR25aA1 O:1 malX 
JR29aA1 O:2 lpfA, malX 
JR39aA2 O:21 - 
JR40bA1 O:8 malX 
OND; O antigen was not identified. – shows that neither malX nor lpfA were 
detected in E. coli strain.  
 
5.4.5 Genotypic profile of intramacrophagic E. coli strains 
The data obtained in this chapter did not report increased prevalence of AIEC 
associated phenotypes in E. coli strains isolated from HLA-B27 positive patients. 
However, phenotypes associated with AIEC, including survival in macrophages, 
were detected in E.coli strains isolated from all patient groups, including healthy 
controls. Additionally, AIEC associated virulence genes were detected in E. coli 
strains isolated from healthy patients. This indicates that phenotypes associated 
with pathogenic E. coli, such as AIEC, may also be associated with specific 
commensal strains, therefore undermining the current definition for AIEC.  In order 
to further investigate the existence of pathogenic traits in commensal E. coli, the 
presence of other pathogenic E. coli associated virulence factors was investigated.  
Four E. coli strains isolated from healthy patients (H13aB1; H47aA1) and HLA-B27 
negative patients (J36aA1; J84Da1) were assessed using multiplex PCR that was 
performed for 10 virulence factor gene regions associated with extraintestinal E. 
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coli. Investigated genes were pap, fimH, ibeA, fyuA, iutA, ompT, traT, k1 and uidA, 
a molecular marker for E. coli. Multiplex PCR assays were performed at 
Gastrointestinal Bacteria Reference Unit, Public Health, Colindale (work by Holly 
Ciesielczuk). These data showed that different virulence factors were detected in 
the 4 surveyed commensal E. coli strains. It was shown that J84dA1, isolated from 
HLA-B27 negative JIA patient, and H13aB1, isolated from a healthy patient, 
possessed fyuA and k1 that encode iron siderophore and K1 capsule respectively 
(Table 5.4). J84dA1 also possessed iutA, that encodes the aerobactin siderophore 
and ompT that is involved in serum resistance. H13aB1 possessed pap, that 
encodes pyelonephritis associated pili and traT that is involved in serum 
resistance (Table 5.4). These data also showed that strain J36aA, isolated from 
HLA-B27 negative JIA patient, possessed ibeA, an invasive protein found in APEC 
and low numbers of ExPEC (Germon et al. 2005) (Table 5.4).  These data 
highlight the existence of pathogen associated virulence factors in commensal 
strains that reside in the human gut. 
 
Table 5-4:  Presence of pathogenic E. coli associated virulence factors in commensal E. coli 
strains. 
 
E. coli Strain 
Virulence factor  H13aB1 J36aA1 H47aA1 J84Da1 
pap + - - - 
fimH + + + + 
ibeA - + - - 
fyuA + - - + 
iutA - - - + 
ompT - - + + 
traT + - - - 
k1 + - - + 
uidA + + + + 
Presence of virulence genes was tested by multiplex PCR that was carried out at 
Gastrointestinal Bacteria Reference Unit, Public Health, Colindale. + denotes presence of 
gene, - denotes absence of gene.
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5.5 Discussion 
Over 2000 years ago Hippocrates, referred to as ‘the father of medicine’, stated 
that “all disease begins in the gut”. Much work carried out over the last decade 
now highlights the significance of this observation. In an attempt to draw further 
conclusions on the prevalence of AIEC in gut-associated inflammatory disorders 
and further establish its role in the development of intestinal inflammation, this 
chapter aimed to investigate the frequency of AIEC occurring in gut E. coli 
populations in JIA HLA-B27 (+) patients relative to HLA-B27 (-) patients and 
healthy controls.  Increased prevalence of AIEC in CD patients has been 
demonstrated in a multitude of independent studies (Martin et al. 2004, Martinez-
Medina, Aldeguer, et al. 2009) and recent work has also shown increased AIEC in 
newly diagnosed, paediatric CD patients compared to healthy controls (Conte et 
al. 2014). For the purpose of this pilot study, previously sampled faecal samples 
(Gerasimidis et al. 2012; unpublished data) obtained from healthy, JIA HLA-B27 (-) 
and JIA HLA-B27 (+) patients were used to isolate viable E. coli bacteria by 
traditional cultivation methods. A key limitation of this method was that the majority 
of patient faecal samples contained very low numbers of viable E. coli.  Previous 
work investigating the prevalence of AIEC bacteria in specific patient groups 
frequently utilised fresh biopsy samples for isolation of E. coli bacteria (Martin 
Baumgart et al. 2007, Martin et al. 2004, Martinez-Medina, Aldeguer, et al. 2009). 
This has shown to be extremely effective for the isolation of large numbers of 
clinical E. coli isolates and through extensive washing procedures can be used to 
specifically isolate mucosa-associated E. coli strains, that is a feature of AIEC 
colonisation (Prorok-Hamon et al. 2014).  In order to make valid conclusions on 
the prevalence of AIEC in HLA-B27 (+) patients and indeed other patient groups, 
future work should include fresh biopsy samples obtained from patients for which 
extensive clinical information has been obtained (Guy et al. 2014, Ibekwe and 
Grieve 2003, Kang et al. 2010, Martinez-Medina et al. 2014).  
Overall, this work did not show increased prevalence of AIEC associated 
phenotypes in E. coli strains isolated from HLA-B27 (+) patients relative to HLA-
B27 (-) patients and healthy controls. A key limitation in this chapter was the low 
number of E. coli strains isolated from HLA-B27 positive patients. However, 
invasion of intestinal epithelial cells and survival within macrophages was 
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demonstrated by E. coli strains isolated from healthy patients. Indeed, the ability of 
commensal E. coli strains to invade colonic epithelial cells has been previously 
demonstrated in vitro using SW-480 cells whereby several commensal bacteria 
including E. coli JCM 1649T but not probiotic strains were shown to invade SW-
480 cells (Ohkusa et al. 2009). In this work 13% of the E. coli strains isolated from 
healthy patients were classified as invasive. This indicates that E. coli capable of 
inducing pathology via invasion of intestinal epithelial cells exist in the gut 
microbiota of healthy patients. These particular strains are unlikely to induce 
disease in healthy individuals who possess effective gut barrier functions. 
However, in compromised hosts such as CD patients, where impaired autophagy 
and a leaky intestinal barrier is reported, invasion of intestinal epithelial cells would 
be a far more frequent event (Buhner et al. 2006, Caprilli et al. 2010, Gibson 2004, 
Homer et al. 2010).   
The detection of E. coli strains which show the ability to survive within 
macrophages in healthy patients, also demonstrates the capacity for commensal 
E. coli to induce pathology following disruption of host mucosal immune 
responses. Intramacrophagic survival has been demonstrated for several distinct 
E. coli pathovars including E. coli O157:H7 (Poirier et al. 2008); E. coli K1 
(Sukumaran et al. 2003), uropathogenic E. coli (Bokil et al. 2011) and indeed, 
AIEC (Bringer et al. 2012). Several virulence factors have been implicated in this 
mechanism including the production of shiga toxin that causes downstream effects 
on host cells (E. coli O157:H7); OmpA ( E. coli K1) and expression of specific 
virulence factors utilised for intracellular survival including dtrB and htrA (AIEC 
LF82) (Bringer et al. 2005, Poirier et al. 2008, Sukumaran et al. 2003). 
Furthermore, recent work has demonstrated the ability of commensal E. coli 
strains to adapt genetically to the intramacrophagic environment. Following 
prolonged co-culture with host macrophage cells, commensal E. coli evolved 
virulent clones that were able to evade phagocytosis and showed increased 
pathogenesis in mice in vivo (Miskinyte et al. 2013). This was mediated by 
transposon insertion into promotor region of the E. coli yrfF gene (Miskinyte et al. 
2013).  
These data obtained in this work therefore support a pathobiont role for specific 
commensal E. coli strains, where pathology is induced by host factors or an 
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environmental trigger. This is further supported by the detection of multiple 
virulence factors in commensal E. coli strains surveyed in this work. 
A theory that can derived from this work is that the term ‘AIEC’ can be recognised 
as a catch all title for certain commensal E. coli strains that have the ability to 
induce pathology. In this new working model, AIEC exist as commensal E. coli in 
healthy hosts, however in patients that show impaired bacterial clearance and 
recognition functions, these unique commensal E. coli strains are able to 
proliferate, interact with host cells, induce pathology and become AIEC. It is likely 
that in the healthy host these behaviours are still demonstrated by a small number 
of these AIEC strains but, due to effective mucosal immune responses are not 
inductive of inflammation. Yet, it is possible that AIEC may also exhibit a unique 
and unknown behaviour that may enhance their interaction with host cells 
compared to other commensal strains (Appendix G and H).  Indeed, this unique 
attribute is yet to be identified.  
Pathogenic E. coli pathovars have been widely investigated and their roles in 
human disease confirmed. Commensal E. coli on the other hand are not 
investigated extensively and in much work they are grouped as a single entity. It is 
clear from the results obtained in this work that commensal E. coli strains are a 
diverse group, with specific strains having the capability to induce disease in 
certain individuals. Therefore, rather than invent new E. coli pathovars for strains 
that display seemingly pathogenic behaviours, I recommend that we first 
distinguish unique pathogenic determinants prior to grouping of these strains. This 
work has shown that the in vitro phenotypical traits associated with AIEC are 
detected readily in E. coli isolated from healthy individuals. Therefore, one must 
question the role of the host in the evolution of these novel E. coli pathovars? Are 
alterations in gut barrier function, induced by antibiotic exposure and western diet, 
making our commensal strains pathogenic? Of course, long term and large cohort 
studies are required to confirm the role of AIEC in CD pathogenesis. However, as 
they are currently recognised as a diverse group, it is likely that AIEC strains 
associated with specific CD patients would behave similar to a commensal strain 
when reintroduced into the healthy gut environment.  
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6 Final conclusion and future perspectives 
Crohn’s disease is a highly complex disorder that is associated with distinct 
aetiological agents in different groups of patients. In this work we recognise that 
for a subset of patients, intestinal inflammation is associated with an abnormal 
microbiota profile involving enriched AIEC (Arlette Darfeuille-Michaud 2002, 
Martinez-Medina, Aldeguer, et al. 2009). For this particular subset of patients, E. 
coli-targeted antibiotics such as colicins represent a promising therapy.   
AIEC is a diverse and specialised E. coli pathotype (Arlette Darfeuille-Michaud 
2002) that shows abnormal association with the gut mucosa and can adopt an 
intracellular lifestyle (Bringer et al. 2006, Eaves-Pyles et al. 2008). Additionally, 
multidrug resistance is frequently detected in E. coli isolated from ileal CD patients 
and resistance to macrophage-penetrating antimicrobials, including ciprofloxacin is 
common (Dogan et al. 2013).  Evidently, alternative therapies to traditional 
antibiotics are required that show activity within eukaryotic cells without inducing 
cytotoxicity. 
In this work, we report good in vitro efficacy of colicins against AIEC that was 
adherent to intestinal epithelial cells and growing inside macrophages. As a 
putative E. coli pathotype associated with CD, the most striking phenotypic feature 
of AIEC is its ability to persist within macrophages that is associated with 
granuloma formation (Meconi et al. 2007). Indeed, the development of a 
therapeutic that has the ability to prevent and / or target granuloma formation is 
highly beneficial. Currently, granulomatous CD is managed by the administration 
of anti-inflammatory and immunoregulatory therapies including infliximab and 
mesalamine (Bandzar et al. 2013). However, previous work reporting E. coli DNA 
in 80% of CD granulomas indicates that antimicrobial therapies such as colicins 
would be far more suitable therapies in these subsets of patients. 
The intracellular activity of colicins within eukaryotic cells is promising with regards 
to the use of colicins as a therapeutic for intracellular colon-cancer associated E. 
coli detected in tumours and colon tissue (Swidsinski et al. 1998; Raisch et al. 
2015).  Future work must ascertain the activity of colicins against AIEC growing 
intracellularly within granulomas. A good basis for this work is an investigation of 
colicin penetration into granuloma tissue in vitro.  
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Although, this study did not report good in vivo activity of colicins against AIEC 
growing in the murine intestine, these data alone should not be used to predict 
colicin efficacy in human subjects. For example, we showed that following 
encapsulation within pectin / zein hydrogel beads, colicin showed potent activity 
against AIEC in vitro. This highlights the potential of this method of delivery 
following optimisation of colicin encapsulation efficiency that was calculated as 
1.4% in this work. Furthermore, we show here that prolonged colicin treatment of 
mammalian cells failed to induce production of pro-inflammatory cytokines or 
cytotoxicity. These data support the use of colicins as a clinical therapeutic in CD 
patients however further work investigating colicin immunogenicity in vivo is 
required.  
Based on results on from earlier work in the Walker lab a patent was filed titled  
“Colicins as a treatment for bacterial infections” (WO2014009744 A1) that is 
supported by the promising work described in this thesis. This innovative treatment 
method holds remarkable possibilities for the future as a form of personalised 
medicine.  Personalised medicine has the potential to dramatically alter the way 
we perceive medicine, for example by switching the emphasis on prevention rather 
than reaction (Gurwitz 2013). Screening for Crohn’s-associated E. coli in early 
childhood and hence administration of specific and patient matched colicins could 
function as a preventative measure for CD development. Of course, the success of 
this relies on further investigation into the pathogenic mechanisms of these 
mucosa-associated E. coli in CD.  
An interesting study that will provide additional support for E. coli targeting in CD 
and potentially CRC, is the recently implemented clinical trial at Royal Liverpool 
University Hospital (Royal Liverpool University Hospital 2014). The pilot study will 
investigate the use of ciprofloxacin, doxycycline and dydroxychloroquine with 
budesonide for treatment of AIEC overgrowth and alleviation of inflammatory 
symptoms in CD patients. Hydroxychloroquine in combination with doxycycline 
and ciprofloxacin were selected on the basis of their ability to kill intramacrophagic 
AIEC.  The clinical outcome of this study has the potential to demonstrate the 
pathogenic capability of mucosa-associated E. coli in these intestinal disorders.  
Alongside the development of a narrow spectrum therapeutic for AIEC, this study 
also investigated the prevalence of this E. coli pathotype in other inflammatory 
disorders associated with CD. Increased prevalence of AIEC was not reported in 
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HLA-B27 (+) JIA patients compared to HLA-B27 (-) patients and healthy controls. 
However, the identification of AIEC-associated phenotypes, namely persistence 
within macrophages in E. coli strains isolated from healthy and JIA patients clearly 
highlights that bacteria capable of inducing pathogenesis occur frequently in the 
gut. These data demonstrate the clinical potential for microbiota manipulating 
therapeutics such as the colicin-like bacteriocins, that can be administered 
frequently and throughout life to maintain a ‘healthy microtype’ in the gut of risk 
patients.   
Due to their multifunctional potential as a prophylactic and antimicrobial 
therapeutic, colicin-like bacteriocins deserve extreme merit in the clinical sector.  
Enormous effort must be placed upon the development and utilisation of these 
innovative and targeted antibiotics as a primary treatment method for bacterial 
infection and dysbiosis.  
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A. Alignment of peptide sequences for colicin E9 and 
mutant colicin E9H575A 
Mutant colicin E9H575A was constructed by PCR mutagenesis of pcS4 template 
using primers E9H575AF and E9H575AR. PCR product was sequenced and 
nucleotide sequences were aligned with wild-type colicin E9 protein sequence that 
showed mutation at residue 575, Histidine to Alanine.  
 
 
 
Figure A-1: Peptide sequence alignment of WT colicin E9 and mutant colicin E9H575A 
showing mutation at residue 575. 
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B. Purification of colicin E9 
Figure B-1: Purification of colicin E9 
Purification of colicin E9 by SEC (Superdex S275 26/60 column), post-purification with nickel affinity chromatography. Protein eluted into 50 mM Tris-HCl, 200 mM 
NaCl, pH 7.5. This method gave highly purified colicin E9. Figure shows peak and corresponding SDS-PAGE (12% polyacrylamide) gel of purified colicin E9 (60kDa). 
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C. Purification of colicin E1 
Figure C-1: Purification of colicin E1 
Purification of colicin E1 by SEC (Superdex S200 26/60 column), post anion exchange chromatography. Protein eluted into 50 mM Tris-HCl, 200 mM NaCl, pH 7.5. 
This method gave highly purified colicin E1. Figure shows peak and corresponding SDS-PAGE gel of purified colicin E1 (62kDa). 
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D. Determination of minimum inhibitory concentrations 
of AIEC strains for colicin E1 and E9.  
The MIC profiles of ileal AIEC reference strain LF82 and colonic AIEC strains 
against colicin E1 and E9 were determined in liquid broth.  
 
Table D-1: Minimum inhibitory concentrations (MICs) for AIEC isolates against colicin E1 
and colicin E9. 
       
Strain 
 
 
 
 
MIC (µg ml-1) 
 
Colicin E1 Colicin E9 
    
LF82  ≤ 0.122  ≤ 0.122 
HM95  0.244- 0.48  0.122 - 0.244 
HM154  ≥ 250  ≥ 250  
HM419  0.48 - 0.976 <0.122 
HM580  ≥ 250 250-125 
HM605  ≥ 250  ≥ 250  
HM615  0.122 - 0.244 0.122 - 0.244 
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E. Faecal E. coli strains used for invasion and 
intracellular proliferation assays for determination of 
AIEC phenotype 
Selection of E. coli strains was performed on MacConkey agar and EMB agar. 
Species identify was confirmed by sequencing of 16S rRNA gene. Activity of E. 
coli strains against LF82 indicator strain was investigated by overlay spot plate 
assay. E. coli strains were grown in LB broth and spotted on LB agar containing 
mitomycin C, lysed and then LF82 soft agar lawn was grown on top. Killing was 
shown by zone of inhibition around producer E. coli strain. A wide range of E. coli 
strains were shown to produce antimicrobial compound active against LF82.   
 
Table E-1: Summary of E. coli strains utilised for invasion and intracellular proliferation 
assays. 
Table shows strain name, appearance on selective media and species identity determined by 16S 
rRNA sequencing of V2 and V3 region and activity of strains against LF82 determined by overlay 
spot plate assay. Strains that were not investigated by PCR amplification of 16S rRNA but showed 
identical colony morphology to sequenced strains were classified as E. coli. MAC: MacConkey, 
EMB: Eosin methylene blue agar. NT: Not tested. 
Type Strain no Pink / purple 
on MAC 
Metallic green 
on EMB 
16S rRNA  
sequence 
identity 
Activity 
against 
LF82 
Healthy H2ca1 + + E. coli  
H7da1 + + NT - 
H11da1 + - E. coli + 
H12ba1 + + E. coli - 
H12bb1 +  + E. coli - 
H13aa1 + + E. coli - 
H13ab1 + + E. coli - 
H14ba1 +  + NT - 
H15aa1 + + NT - 
H17ca1 + + E. coli - 
H18ba1 + + NT - 
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H20da1 + + NT - 
H42ca1 +   + NT + 
H43ca1 + + NT - 
H44ba1 + + E. coli + 
H44bb2 + + NT - 
H45aa1 + + NT - 
H47aa1 + + E. coli - 
H50aa1 + + NT + 
H51ca1 + + E. coli - 
H53ba1 + + E. coli - 
H54ba1 +  + NT - 
H59ca1 + + E. coli - 
JIA NULL J22ea1 + + E. coli  
J23aa1 + + E. coli + 
J26aa1 + + NT + 
J26ab3 - + E. coli - 
J35aa1 + + E. coli - 
J36aa1 + + E. coli - 
J62b3 + + E. coli - 
J64da1 + + NT + 
J66ca1 + + NT + 
J80ca1 + + NT - 
J82aa1 + + NT + 
J83ba1 + + E. coli - 
J84da1 - - E. coli - 
JIA RISK JR24aa1 + + NT - 
JR25aa1 + + NT - 
JR29ba1 + + NT + 
JR39aa2 + + E. coli + 
JR40ba1 +  + E. coli - 
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F. MICs of antibiotics against faecal E. coli strains 
isolated from JIA NULL, JIA RISK and healthy patient 
stool samples 
To determine MICs of antibiotics against E. coli strains, MIC assays were 
performed in 96 well plates in LB broth.  
 
Table F-1: MICs for antibiotics against E. coli faecal isolates for antibiotics gentamicin, 
ampicillin and kanamycin. 
Type Strain MIC (µg ml-1) 
AMP GEN KAN 
Healthy H2ca1 1.56- 3.125 50-100 12.5-25 
H7da1 1.56- 3.126 12.5-25 6.25- 12.5 
H11da1 0.39- 0.78 50-100 12.5-25 
H12ba1 0.78- 1.56 25-50 12.5-25 
H12bb1 1.56 - 3.125 25-50 12.5-25 
H13aa1 0.78 - 1.56 ≥200 50-100 
H13ab1 3.125 - 6.25 ≥200 25-50 
H14ba1 1.56 -3.125 25-50 6.25-12.5 
H15aa1 0.78 - 1.56 50-100 6.25-12.5 
H17ca1 1.56-3.125 100-200 25-50 
H18ba1 ≥200 25-50 50-100 
H20da1 ≥200 25-50 50-100 
H42ca1 ≥200 50-100 25-50 
H43ca1 6.25-12.5 25-50 6.25-12.5 
H44ba1 1.562-3.125 12.5-25 Not tested 
H44bb2 50-100 12.5-25 Not tested 
H45aa1 1.562-3.125 50-100 6.25-12.5 
H47aa1 >200 50-100 6.25-12.5 
H50aa1 0.78-1.562 6.25-12.5 3.125-6.25 
H51ca1 ≥200 ≥200 25-50 
H53ba1 3.125-6.25 12.5-25 6.25-12.5 
H54ba1 1.562-3.125 6.25-12.5 6.25-12.6 
H59ca1 ≥200 >200 50-100 
JIA NULL J22ea1 0.78- 1.56 25-50 6.25-12.5 
J23aa1 0.78-1.56 50-100 12.5-25 
J26aa1 1.56-3.125 50-100 12.5-25 
J26ab3 3.125-6.25 50-100 12.5 - 25 
J35aa1 1.56 - 3.126 50-100 25-50 
J36aa1 1.56 - 3.127 12.5-25 25-50 
J62b3 3.125-6.25 50-100 12.5-25 
J64da1 ≥200 ≥200 50-100 
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J66ca1 ≥200 12.5-25 Not tested 
J80ca1 3.125-6.25 3.125-6.25 Not tested 
J82aa1 3.125-6.26 25-50 25-50 
J83ba1 3.125-6.27 6.25-12.5 Not tested 
J84da1 3.125-6.28 6.25-12.5 Not tested 
JIA RISK JR24aa1 ≥200 12.5-25 Not tested 
JR25aa1 1.56-3.125 50-100 12.5-25 
JR29ba1 1.56 - 3.125 12.5-50 Not tested 
JR39aa2 0.78-1.562 50-100 12.5-25 
JR40ba1 1.56-3.125 25-50 12.5 - 25 
          
AMP; ampicillin, GEN; gentamicin; KAN; kanamycin. 
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G. Differential expression of Ag43 by AIEC and 
commensal E. coli strains 
By western blotting it was shown that increased expression of Ag43 α-domain was 
detected in AIEC LF82 compared to commensal E. coli strains K12 and F18 
(Figure G1). Furthermore results also showed increased expression of α-Ag43 in 
AIEC HM95, HM605, HM615, HM154, HM580 compared to E. coli K12 and F18.  
 
Figure G-1: Increased Ag43 production by AIEC bacteria. 
Western blotting, with polyclonal antiserum against the Ag43 passenger domain, of α domains 
liberated from E. coli strains by brief heat treatment. The position of the Ag43 α-subunit protein is 
indicated by arrow.  
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H. Incubation of LF82 with Ag43α increases 
intramacrophagic proliferation. 
Log phase cultures were incubated with 1 mg ml-1 purified α- Ag43 for 3-4 h at 
4°C. Where required anti- α-Ag43 antibody was added to bacterial suspension and 
incubated for 3-4 h at 4°C mixing. Bacteria- Ag43α suspension was then added to 
J774.1 macrophages (MOI= 50) and incubated for 2 h. Macrophages were then 
treated with gentamicin for desired time point to kill extracellular bacteria. Pre-
incubation of LF82 with α-Ag43 significantly increased bacterial survival within 
J774 macrophages at 24 h (P=0.0284). Pre-incubation of LF82 with anti-Ag43α 
antibody prior to macrophage invasion was also shown to reduce intracellular 
survival at 24 h but this was not significant (P=0.064).  Pre-incubation of E. coli 
commensal strain F18 with Ag43α did not significantly increase macrophage 
survival at 24 h (P=0.54).  
 
Figure H-1: Pre-incubation of LF82 with Ag43 protein enhances intracellular macrophage 
survival. 
LF82 was pre-incubated with 1 mg ml-1 Ag43 α-fragment and added to J774-1 macrophages for 4h 
or 24 h. Bacteria were also pre-incubated with antibody against α-Ag43 and used to infect 
macrophages. Intracellular bacteria were determined by CFU counts. E. coli commensal F18 strain 
was used as negative control. Data shown represents mean from two independent experiments. 
Error bars show SEM. Non parametric Mann-Whitney U test used for comparison of bacteria 
CFUs. Significant difference was reported as P <0.05. * denotes signficant difference. 
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